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Resumo 
 
Os Líquidos Iónicos (LIs) possuem algumas propriedades invulgares: pressão de vapor muito 
baixa; alta estabilidade química e térmica e a capacidade de se dissolver numa vasta gama de 
substâncias. Uma nova área de pesquisa está a avaliar a possibilidade de usar biomoléculas 
naturais quirais para a síntese de Líquidos Iónicos Quirais (LIQs). Este importante desafio pode 
abrir novos caminhos de pesquisa para evitar alguns problemas relacionados com a 
biodegradabilidade intrínseca e a toxicidade associada aos LIs convencionais. 
 
O trabalho de pesquisa desenvolvido resultou na síntese de LIQs, com base em unidades 
biológicas utilizadas quer como catiões ou aniões quirais, dependendo da manipulação sintética 
dos derivados. No total, 28 sais orgânicos incluindo alguns LIQs foram sintetizados: 9 baseados 
em derivados de L-cisteína, 12 com base na L-prolina, 3 baseados em nucleosídeos e 4 em 
nucleotídeos. Estes novos LIQs foram completamente caracterizados a fim de avaliar as suas 
propriedades químicas e físicas e potenciais aplicações. Alguns destes LIQs, nomeadamente os 
baseados na L-cisteína e na L-prolina, foram aplicados em processos de discriminação, 
incluindo a síntese assimétrica, em particular como um meio de reação quiral para as reações 
assimétricas de Aldol e de Michael e a resolução de racematos. 
 
Em paralelo, foram estudadas as interações de oligossacarídeos macrocíclicos denominados 
ciclodextrinas (CDs) com vários LIs. Foi possível melhorar a solubilidade das CDs em água e 
soro. A solubilidade dos ácidos gordos e esteróides em água também aumentou quando foram 
utilizados sistemas de LIs-CDs. O desenvolvimento de sistemas LIs-CDs eficientes e seletivos é 
indispensável para ampliar o leque das suas aplicações em interações host-guest, sistemas de 
administração de medicamentos ou reações catalíticas. 
 
Novos sais derivados de nucleobases foram utilizados em estudos que visavam promover o 
aumento da fluorescência em meios aquosos. 
 
Adicionalmente, foram realizados estudos preliminares para avaliar se o lactato de etilo poderia 
ser um solvente alternativo na organocatálise assimétrica. 
 
 
PALAVRAS-CHAVE: Líquidos Iónicos, Moléculas Biológicas, Quiralidade, Catálise 
Assimétrica. 
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Abstract 
 
Ionic Liquids (ILs) belong to a class of compounds with unusual properties: very low vapour 
pressure; high chemical and thermal stability and the ability to dissolve a wide range of 
substances. A new field in research is evaluating the possibility to use natural chiral 
biomolecules for the preparation of chiral ionic liquids (CILs). This important challenge in 
synthetic chemistry can open new avenues of research in order to avoid some problems related 
with the intrinsic biodegradability and toxicity associated to conventional ILs. 
 
The research work developed aimed for the synthesis of CILs, their characterization and 
possible applications, based on biological moieties used either as chiral cations or anions, 
depending on the synthetic manipulation of the derivatives. Overall, a total of 28 organic salts, 
including CILs were synthesized: 9 based on L-cysteine derivatives, 12 based on L-proline, 3 
based on nucleosides and 4 based on nucleotides. All these new CILs were completely 
characterized and their chemical and physical properties were evaluated. Some CILs based on 
L-cysteine have been applied for discrimination processes, including resolution of racemates 
and as a chiral catalyst for asymmetric Aldol condensation. L-proline derived CILs were also 
studied as chiral catalysts for Michael reaction. 
 
In parallel, the interactions of macrocyclic oligosugars called cyclodextrins (CDs) with several 
ILs were studied. It was possible to improve the solubility of CDs in water and serum. 
Additionally, fatty acids and steroids showed an increase in water solubility when ILs-CDs 
systems were used. The development of efficient and selective ILs-CDs systems is 
indispensable to expand the range of their applications in host-guest interactions, drug delivery 
systems or catalytic reactions. 
 
Novel salts derived from nucleobases were used in order to enhance the fluorescence in aqueous 
solution. 
 
Additionally, preliminary studies regarding ethyl lactate as an alternative solvent for 
asymmetric organocatalysis were performed. 
 
 
 
KEYWORDS: Ionic Liquids, Biological Molecules, Chirality, Asymmetric Catalysis. 
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Abbreviation List 
 
[AcO] acetate 
[AOT] docusate, (dioctyl sulfosuccinate) 
[Bmim] 1-butyl-3-methylimidazolium 
[Boc] N-(tert-butoxycarbonyl) 
[Bvim] 1-butyl-3-vinylimidazolium  
[Bz] benzyl 
[C2mim] 1-ethyl-3-methyl-imidazolium 
[C2OHDmim] 1-(2-hydroxyethyl)-2,3-dimethylimidazolium  
[C2OHmim] 1-(2-hydroxyethyl)-3-methylimidazolium 
[C3Omim]  1-(2-methoxyethyl)-3-methylimidazolium 
[C4mim] 1-butyl-3-methyl-imidazolium 
[DCA] dicyanamide 
[Emim] 1-ethyl-3-methylimidazolium  
[i-Pr] iso-propyl 
[n-Bu] n-buthyl 
[n-Pr] n-propyl 
[NTf2] bis(trifluoromethylsulfonyl)imide 
[Omim] 1-octyl-3-methylimidazolium 
[P6,6,6,14] trihexyltetradecylphosphonium 
[SAC] saccharinate 
[TfO] trifluoromethanesulfonate 
[TsO] p-toluenosulfonate 
AAs Amino Acids 
AD Asymmetric Dihydroxylation 
AMP adenosine 5´-monophosphoric acid  
AO Acridine Orange 
APIS Active Pharmaceutical Ingredients 
ATP adenosine 5´-triphosphate 
Bio-Ils Bioinspired Ionic Liquids 
BDM dimethylated-β-cyclodextrin 
BPM permethylated-β-cyclodextrin 
CD-CSPs Cyclodextrin Chiral Stationary Phases 
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CDs  cyclodextrins 
CE Capillary Electrophoresis 
CILs Chiral Ionic Liquids 
CMC Critical Micellar Concentration 
Cys cysteine 
DBU 1,8 – diazabicyclo[5.4.0]undec-7-ene 
DCM dichloromethane 
DLS Dynamic Light Scattering 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DSC Differential Scanning Calorimetry  
Ea Activation Energy 
Ee Enantiomeric Excess 
EL ethyl lactate 
EPA Enviromental Protection Agency 
Et2O diethyl ether  
EWG Electron Withdrawing Group 
FTIR Fourier Transform Infrared Spectroscopy 
GC Gas Chromatography 
HB Hydrogen Bonds 
HPLC High Performance Liquid Chromatography 
Ils Ionic Liquids 
K Inclusion Complex Stability Constant 
MB Methylene Blue 
MTBE methyl tert-butyl ether  
13
C NMR Carbon Nuclear Magnetic Resonance Spectroscopy 
19
F NMR Fluor Nuclear Magnetic Resonance Spectroscopy 
1
H NMR Proton Nuclear Magnetic Resonance Spectroscopy 
2D NMR Two-Dimensional Nuclear Magnetic Resonance Spectroscopy 
ppm parts per million 
PRO proline 
RNA ribonucleic acid 
RT Room Temperature 
RTILs Room Temperature Ionic Iiquids 
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scCO2 supercritical carbon dioxide 
S-MeCys S-methyl-L-cysteine 
S-MeCysCO2 deprotonated S-methyl-L-cysteine 
S-MeCysNH3 protonated S-methyl-L-cysteine 
SNAP Significant New Alternatives Policy 
Tdec Decomposition temperature 
Tg  Glass Transition Temperature 
TGA Thermogravimetric Analysis 
THF tetrahydrofuran 
Tm melting temperature 
TMG tetramethylguanidine 
TMS tetramethylsilane 
TS Transition State 
VOC Volatile Organic Compounds 
αD optical rotation 
η viscosity 
ᴧ conductance 
ρ density 
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I. Introduction 
 
For economic and environmental reasons the chemistry society is confronted with the 
obligation to optimize their synthetic processes. Nowadays the organic solvents comprise 70% 
of all industrial emissions and 30% of overall volatile organic compounds (VOC) emissions 
nationwide
1,2
. 
 
One of the most important challenges of synthetic chemistry is related with the combination of 
efficiency, reduced costs and environmental impact in the production of relevant molecules, 
particularly in the preparation of chiral compounds. The creation of chiral centers can be 
achieved by several methodologies such as using chiral auxiliaries, readily obtained by chemical 
manipulation of chiral natural and non-natural compounds as well as by application of 
asymmetric catalysis including biocatalysis processes. 
 
Recently, Ionic Liquids (ILs) have emerged as a possible environmentally benign alternative to 
common organic solvents, since they are typically liquids below 100 ºC associated with their 
high thermal stability over a very wide temperature range
1
. Since the first room temperature 
ionic liquid (RTIL), ethylammonium nitrate ever appeared, in 1914
3
, the field of ILs has 
undergone a rapid development mainly in last three decades. It is known that different RTILs 
can be synthesized from the combination of organic cations and relatively large, often poorly 
coordinating organic or inorganic anions
4
. Typically, a quaternary or protonated ammonium, 
phosphonium, pyridinium, pyrrolidinium, guanidinium, sulfonium or various N, N´- 
disubstituted imidazolium ions are distinguished as the cationic part of ILs (as shown in Figure 
I.1) and anions such as [AlX4], [BF4], [PF6], docusate (dioctyl sulfosuccinate) [AOT], 
trifluoromethanesulfonate [TfO], bis(trifluoromethylsulfonyl)imide [NTf2], dicyanamide [DCA] 
or halides represent some examples of the anionic part of ILs. 
 
The interest of current research on ILs is mainly related with their almost negligible vapour 
pressure, high ionic conductivity, large electrochemical window, high chemical and thermal 
stability, peculiar interaction with supercritical CO2 (ILs are insoluble in scCO2 but this 
supercritical gas is soluble in ILs) as well as their ability to dissolve a large range of organic 
molecules and transition metal complexes
5
. The physical and structural properties of the ILs are 
generally dependent on adequate selection of cation/anion combinations. The applications of 
ILs include their use as recyclable media for chemical processes, including non-catalytic and 
(bio)-catalytic reactions, CO2 capture, biphasic extraction, gas chromatography, selective 
transport using supported liquid membranes, pervaporation, dissolution of cellulose, in fuel 
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cells, and their potential use as a matrix for mass spectrometry or as solvent in nuclear electrical 
power plants, amongst others
6,7,8,9
. 
 
According to their properties and characteristics, ILs can be divided into three generations
10
. 
The first generation considers ILs as alternative solvents based on their peculiar physical 
properties (e.g. very low vapor pressure and high thermal stability) (1
st
 Generation). The 
second-generation includes ILs with physical and chemical features that can act as advanced 
materials, such as lubricants, energetic materials and metal ion complexing agents (2
nd
 
Generation). Recently, the third generation of ILs (3
rd 
Generation) has been described using 
active pharmaceutical ingredients (APIs) in order to design a wide range of new ILs with 
tunable biological activity, as well as the well known physical and chemical properties. This 3
rd 
generation of ILs can contribute for a considerable improve in solubility, stability, 
bioavailability or bioactivity of pharmaceutical drugs as well as the elimination of drug 
polymorphism. 
 
 
Figure I.1 - Main families of Ionic Liquids cations
11
. 
 
I.1. Chiral Ionic Liquids 
 
The aim of this subsection is to introduce Chiral Ionic Liquids (CILs), starting with a historical 
background, reviewing the literature and proceeding with the discussion of most promising 
applications as well as future perspectives of their industrial use. 
 
 
Development of novel ionic liquids based on biological molecules 
 
In
tr
o
d
u
ct
io
n
 
5 
In
tr
o
d
u
ct
io
n
 
5 
I.1.1. Chiral Ionic Liquids-historical background and applications 
 
In 1975 Seebach described the first use of a chiral solvent in asymmetric synthesis
12
. Using a 
chiral amino ether as solvent, modest enantioselectivities were obtained in the electrochemical 
reduction of ketones. In the case of ILs related with their high degree of organization, a transfer 
of chirality in these chiral media should be expected. It has been proved that many ILs possess a 
polymeric behavior and they are highly ordered H-bonded liquids, meaning ´three dimensional 
networks of anions and cations linked together by hydrogen bonds`
13
. These characteristics 
allow CILs to be tested as chiral reaction media for asymmetric processes. However, only few 
success reports appeared according the difficult syntheses of some CILs and their high cost. In 
1999 Seddon and co-workers described the first example of CILs, 1-n-butyl-3-
methylimidazolium l-lactate ([Bmim][lactate]), simply synthesized by anion exchange between 
commercially available sodium (S)-2-hydroxypropionate and [Bmim]Cl in acetone (as shown in 
Scheme I.1)
14
. After the removal of NaCl by filtration and evaporation of acetone, it was 
possible to obtain the desired CIL.  
 
 
Scheme I.1 - Synthesis of the first CIL ([Bmim][lactate]) by Seddon and coworkers. 
 
Following the initial work on the preparation and application of CIL ([Bmim][lactate] by 
Seddon and coworkers), a number of new chiral ionic liquids have been synthesized and 
employed as chiral reaction media or additives, in order to induce moderate to high 
enantioselectivities in several reactions such as asymmetric Diels-Alder
15
, Aldol Reaction
16
, 
Michael Addition
17
, Sharpless Dihydroxylation (AD)
18,19
.  
 
One of the most significant examples is related with the Sharpless Osmium-catalyzed 
asymmetric dihydroxylation (AD) of olefins, one of the most reliable methods for the 
preparation of chiral vicinal diols, which act as intermediaries in the syntheses of many 
biologically active substances. The obstacles to its large-scale industrial application remain the 
osmium catalyst's high cost, toxicity, and potential product contamination. CILs based on 
guanidinium cations combined with quinic acid and mandelate as chiral anions were efficiently 
used as unique reaction and chirality-inducing media for asymmetric dihydroxylation of 
olefins
18
. For many cases the yields and enantiomeric excesses (e.e.´s) were comparable or 
higher than the conventional systems (using Sharpless alkaloid chiral ligands). The possibility 
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to recycle and recover the CILs and osmium catalyst by efficient extraction with scCO2 was 
presented as another advantage for the reaction processes. 
 
CILs have been described as having potential application for chiral discrimination, which is one 
of the primary concerns in industry and academia. Despite the high number of applications of 
CILs in asymmetric reactions, other examples of applications have been reported (Figure I.2). 
Different CILs have been tested for chiral recognition as well as chiral separation processes. 
Also, the applications of CILs as chiral media for NMR
20
, gas chromatography
21
, HPLC or mass 
spectra have been tested. 
 
 
Figure I.2 - Chiral Ionic Liquids general synthesis and application. 
 
I.1.2. Chiral Ionic Liquids- design and synthesis 
 
As mentioned previously, the research for synthesis, design and use of CILs is in its infancy. 
Nowadays, investigators try to develop more simple, economic and efficient methods in order to 
prepare alternative chiral RTILs. Therefore, natural materials are used as precursors derived 
from the „chiral pool‟ for the generation of the CILs cation, anion or both. For this reason, CILs 
are described as mainly having a central chirality (nevertheless, some new CILs containing an 
axial or a planar chirality have been reported). 
 
I.1.3. CILs of chiral cation 
 
A larger number of known CILs obtain their chirality from the cationic moiety. The 
imidazolium cation is frequently used in ILs synthesis because it is known to produce salts with 
attractive properties, in particular lower melting points, tunable viscosities as well as high 
thermal and chemical stabilities. 
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I.1.4. Imidazolium derivatives 
 
Herrmann et al. described the first CIL based on chiral imidazolium chloride obtained as an 
intermediate of the synthesis of N-heterocyclic imidazole carbenes
22
. In 2005, Headley and co-
workers reported the attachment of a chiral group to C-2 position of the imidazolium ring. 
Commercially available chiral amino alcohols and 1-methyl-2-imidazol-carboxaldehyde have 
been tested by alkylation followed by anion exchange reactions (Scheme I.2)
23
. 
 
 
Scheme I.2 - Series of CILs synthesized from amino alcohols. 
 
Other examples have included the incorporation of chiral amine (R)-(+)- methylbenzylamine in 
imidazolium unit by three synthetic steps: condensation of the chiral amine with ammonia, 
formaldehyde and glyoxal; alkylation with bromoethane in trichloromethane and then anion 
exchange using NaBF4 in acetone
24
. A similar strategy allowed the introduction of two chiral 
centers, each bonded to nitrogen atoms of the imidazolium ring using two equivalents of 
methylbenzylamine. 
 
Génisson et al. described the development of several novel chiral imidazolium ILs using (R)-
(+)-methylbenzylamine as starting material
25
. Chiral 1,2- diamines were prepared from the 
alkylation of the starting material with chloroethylamine. These chiral 1,2- diamines were 
subjected to a ring-closing reaction with an appropriate ortho ester electrophile in order to 
obtain 4,5-dihydroimidazoles. Overall schematic of the synthesis is described in Scheme I.3. 
The final salts based on BF4 and [NTf2] anions were obtained in relatively high yields, as water 
immiscible room temperature CILs. 
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SchemeI.3 - Génisson´s preparation of the imidazolium chiral RTILs. 
 
Different chiral alcohols have been used for the preparation of novel imidazolium CILs
26
. 
Interesting results were obtained in the case of (S)-2-hexanol, (1S, 2S, 5S)-(-)-myrtanol
27
 and 
(3R)-citronellol as chiral starting materials for the synthesis of chiral imidazolium ILs
28
. 
 
Jodry and Mikami reported the synthesis of hydrophobic chiral imidazolium ILs based on cheap 
and biodegradable L-ethyl lactate, which was firstly converted into a triflate derivative, 
followed by an alkylation and then an anion exchange reaction in order to give the desired 
imidazolium salt (Scheme I.4)
29
.  
 
 
Scheme I.4 - Synthesis of hydrophobic CILs using (L)-ethyl lactate. 
 
 
Independent research groups of Bao
30
and Kubisa
31
 described the use of lactate as a starting 
material to incorporate into imidazolium units. Also, ethyl tartrate was employed as a chiral unit 
for dicationic CILs. Chiral tartrate bis(imidazolium) tetrafluoroborate and hexafluorophosphate 
were prepared as ILs with melting points lower than 90 ºC. 
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In 2006, Ni et al. explored another class of imidazolium CILs with urea functionality
32
. Urea 
derivatives, that contain effective hydrogen bonds formed by their amide hydrogens, are known 
as useful Lewis acid catalysts for organic reactions. Headley and coworkers published that the 
chirality comes from an amino acid ester derived isocyanate which reacts with 1-(3-
aminopropyl)imidazole to yield the final urea derivatives. Many of them were obtained as 
viscous oils at room temperature. 
 
I.1.5. Aminoacids derivatives 
 
The natural chiral molecules such as Amino Acids (AAs) are considered the building blocks of 
life. It is possible to obtain pure AAs in big quantities at low cost, which is their great 
advantage, but there are further advantages, including biodegradability and biological activity. 
Currently, these biocompatible, small, natural molecules are receiving increasing attention due 
to their role as the most frequently employed chiral precursors for novel CILs
33
. Since the AA 
contains both an amino and carboxylic acid group in a single molecule, with various side groups 
and a chiral carbon atom, they can be used as anions or cations for the design of various CILs 
(Figure I.3). 
 
In the last years, the new synthesized CILs (from ´chiral pools´) have enjoyed widespread 
attention and they are being used in the asymmetric synthesis, including direct aldol reaction, 
Michael Addition, Diels-Alder reaction, Baylis–Hillman, amongst others. It was been proved 
that they can be a great substitute for common asymmetric catalysts, presenting unprecedented 
opportunities to address some limitations in asymmetric catalysis. 
 
 
 
Figure I.3 - General design of CILs from naturally occurring amino acids
33
. 
 
In this context, the group of Bao reported the first synthesis of chiral imidazolium ILs from 
natural AAs, in particular using L-alanine, L-leucine and L-valine as chiral starting materials
24
. 
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The imidazole ring was formed by condensation of the amino functionality of the amino acid 
with glyoxal, formaldehyde and aqueous ammonia under basic conditions. Different water 
miscible CILs with low melting points (5-16ºC) were obtained using this synthetic methodology 
presented in Scheme I.5. 
 
 
Scheme I.5 - First synthesis of CILs from natural amino acids. 
 
In the same line, Xu and his coworkers developed novel chiral amine-functionalized ILs derived 
from L-alanine, L-valine, L-leucine, L-isoleucine and L-proline in four steps
34
. All novel CILs 
possesed thermal stability up to 210 °C with higher solubility in polar solvents than less 
nonpolar solvents, when compared with the related unfunctionalized imidazolium-type ILs. 
 
Amino acid derivatives in the form of amino alcohols are also good precursors for the 
development of CILs. Recently, chiral amino alcohols such as D or L-leucinol and L-3-phenyl-
2-aminopropanol, amongst others, were used for the condensation with 1-methyl-2-
imidazolecarboxaldehyde and after reduction in situ using NaBH4, gave the desired chiral 
imidazole derivatives
35,36
. The subsequent N-alkylation was performed by heating imidazoles 
with 1-bromobutane (1 equivalent) in toluene. The novel CILs based on chiral amino alcohols 
and BF4 or [NTf2] as anions, were obtained in moderate to high yields as colorless viscous oils 
at room temperature. Some variations of this synthetic method were also described by Ou et 
al.
37
 
 
Proline is a versatile and inexpensive chiral starting material which has been used for synthesis 
of CILs. Examples of CILs based on L-proline have been firstly described by Luo et al.
38
 (series 
of pyrrolidine-containing chiral imidazolium ILs) and Miao and Chan
39
 (using commercial 
available Boc-Pro-OH incorporated with imidazolium cation), as shown in Figure I.4. 
Development of novel ionic liquids based on biological molecules 
 
In
tr
o
d
u
ct
io
n
 
11 
In
tr
o
d
u
ct
io
n
 
11 
 
Figure I.4 - Novel CILs based on L-proline developed by Luo (A) and Miao groups (B). 
 
Also, histidine as alternative amino acid was explored in order to attach imidazolium cations. 
Hannig et al. showed the two synthetic steps for the preparation of novel L-histidine CILs as 
water soluble salts with relatively lower melting points (39 to 55 ºC), as shown in Figure I.5 
(A)
40
. One year later, Guillen et al. reported other O- and N-protected histidinium salts (Figure 
I.5 (B)
41
). In this case, the protection of histidine methyl ester via cyclic urea is followed by 
alkylation with iodomethane and the opening of the cyclic urea gave the desired histidine 
derivatives. Final alkylation with bromobutane allowed the formation of chiral imidazolium 
bromide salts.  
 
 
 
Figure I.5 - Novel CILs based on L-histidine developed by Erker (A) and Guillen groups (B). 
 
 
Cyclophane-type imidazolium salts were developed by Saigo´s group as first examples of 
planar-chiral ILs
42
. The introduction of a substituent in position 4 of the imidazolium ring can 
induce a planar chirality and dramatically reduce their melting points. The racemization of these 
planar chiral cyclophanes can be suppressed by the presence of a substituent at C-2 position. A 
similar approach was followed in the case of planar-chiral imidazolium chloride with 
tris(oxoethylene) bridge. At the same time, examples of CILs containing a fused and a spiro 
skeleton were reported in the literature by Headley
43
and Sasai
44
 respectively.  
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I.1.6. Pyridinium derivatives 
 
The use of pyridinium ion as the cationic moiety in order to create CILs is not as dominant as 
the use of imidazolium. However, due to its surface-active and antibacterial properties, 
pyridinium-based cations CILs remain an important class of compounds to be investigated.  
 
In 2006, Headley and coworkers, already mentioned in the imidazolium subsection (I.1.4.), 
described pyridinium chiral ILs with urea functionality (Figure I.6)
45
 as well. These class of 
CILs were synthetized starting from 2-(aminomethyl)pyridine and amino acid ester derived 
isocyanates. The use of pyridinium cation instead of imidazolium units can avoid the acidic 
hydrogen in the C-2 position of the imidazolium ring, which produces unwanted byproducts 
under basic conditions. In parallel, the same authors described pyridinium CILs with an 
appropriate pyrrolidine moiety
46
. These CILs were prepared using commercially available (S)-2-
aminomethyl-1-N-Boc-pyrrolidine and 1-(2,4-dinitrophenyl)pyridin-1-ium chloride (Zincke´s 
salt). De Viguerie and coworkers also tested Zincke´s salt as a precursor for pyridinium CILs by 
using Marazano´s reaction based on the original work of Zincke
47
. In this context, they 
synthetized an organometallic CIL (R) and (S)-bis-(1-phenylethylpyridinium) 
tetrachloropalladate, using enantiopure (R) and (S)-1-phenylethylamine as starting precursors.  
Pernak et al. reported a series of pyridinium CILs containing (1R, 2S, 5R)-(-)-menthyl unit using 
a similar synthetic approach already published for imidazolium CILs
48
. 
 
 
Figure I.6 - Pyridinium CILs with urea functionality
45, 49
. 
 
I.1.7. Ammonium derivatives 
 
Two chiral hydroxyammonium salts were prepared in large scale from (-)-ephedrine and (R)-2-
aminobutan-1-ol, as shown in Scheme I.6
50
. The amino alcohols were converted in three steps 
into the desired CILs in moderate to high yields. Ephedrinium salt (based on NTf2 anion) 
presented a low melting point (54 ºC) and water immiscibility while (R)-2-aminobutanol salt 
(based on NTf2 anion) is a room temperature CIL with low viscosity behavior.  
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Scheme I.6 - Ammonium based CILs. 
 
Other ephedrinium salts have been described according to variable alkyl chain lengths on the 
nitrogen group
51
. In these cases, (1R, 2S)-N-methylephedrine was used as a starting material 
previously prepared by reductive amination of ephedrine. Then, alkylation reaction and anion 
metathesis gave the desired CILs in good yields and in most of the cases as viscous oils at room 
temperature. More recent examples of CILs were described by simply one-step acidification of 
natural α-amino acids and α-amino acid ester salts
52
. Due to the strong hydrogen bonds 
involving the carboxylic acid functionality, most of the salts derived from α-amino acid 
derivatives, showed higher melting points than correspondent esters salts (viscous oils at room 
temperature).  
 
I.1.8. Oxazolinium and Thiazolinium derivatives 
 
Wasserscheid and his group reported the first example of CILs based on oxazolinium cation, 
which were prepared in four steps starting from L-valine
50
. The first step was the reduction of 
L-valine methyl ester, followed by the formation of aminoalcohols by Masamune´s protocol 
(NaBH4-H2SO4 in THF). Then, the cyclization step into oxazoline using propionic acid was 
performed and the final step related with alkylation of oxazoline using bromoalkanes gave the 
corresponding salts (Figure I.7). CILs based on oxazoline cation when combined with PF6 as 
anion, showed melting points in the range of 63 to 79 ºC. 
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Figure I.7- CILs based on oxazolinium cation. 
 
The group of Gaumont published a novel class of CILs based on thiazolinium salts, which are 
obtained in four steps using L-phenylalaninol or D-2-aminobutanol with relatively moderate 
yields (68% yield)
53
. The first reaction was between dithioester and the aminoalcohol, followed 
by cyclisation of the intermediate thioamide in the presence of mesyl chloride and trietylamine. 
After the alkylation of the chiral thiazoline with an alkyl halides and further anion exchange 
using Li [NTf2], HPF6 or HBF4, it was possible to obtain the corresponding CILs. Thiazolium 
ILs present good thermal and chemical stabilities (stable under basic and acidic conditions 
unlike their oxygen counterparts the oxazolinium salts). 
 
I.1.9. Other derivatives  
 
Several examples of CILs derived from chiral cations have been developed in the last years. The 
first sugar (fructose-based) IL was described in 2003 by Handy et al. and later the commercial 
available methyl-D-glucopyranoside served to develop a series of CILs
54,55,56
. In this last case, 
novel CILs can act as chiral solvents in organic reactions showing appreciable stability. 
Therefore, the reactivity of hydroxyls was significantly lower by protection as methyl ethers, 
and the labile anomeric acetal was reduced to an inert methylene group. 
 
Similar synthetic approaches were reported for the preparation of novel familes of CILs based 
on isosorbide (derived from dehydration of inexpensive D-sorbitol) and isomannide (prepared 
by acid-catalyzed double dehydration of manitol)
57, 58
. In 2008, Singh and coworkers described 
CILs based on D-arabinofuranose, D-ribofuranose and X-xylofuranose
59
. 
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Figure I.8 - Structures of glucose (a), isosorbide (b) and isomannide (c) based CILs. 
 
I.1.10. CILs based on chiral anion 
 
The first example of chiral ILs based on chiral anions was at the same time the first example of 
CILs, described by Seddon in 1999, as it was mentioned in the historical background 
subchapter
14
 (I.1.1). Lactate anion was used as the source of chirality, combined with 1-butyl-3-
methylimidazolium ([Bmim]) cation by simply anion exchange reaction. Then, Ohno and 
coworkers described the preparation of a series of 19 CILs based on natural amino acids as 
chiral anions
60
. The synthesis involved two steps: first the conversion of 1-ethyl-3-
methylimidazolium bromide ([Emim]Br) into hydroxide ([Emim]OH) using an anion-exchange 
resin method (Amberlite), followed by a neutralization reaction with the selected natural 
aminoacid. All CILs based on aminoacids were reported as almost colorless liquids at room 
temperature, as well as miscible in a variety of organic solvents such as alcohols, acetonitrile 
and chloroform. The authors observed that the increase of the alkyl chain of aminoacid leads to 
a small increase of the glass transition temperatures (Tg), while the presence of aromatic side 
chains induce a larger increase of Tg, probably due their -stacking interactions. The same 
larger increase of Tg values were observed by introduction of very polar units such as carboxyl 
or amide groups. 
 
Several examples of CILs incorporating aminocids have been described mainly because of their 
low cost, good enantiomeric purity, commercial availability and bio renewability. Fukumoto 
and Ohno reported the preparation of other class of CILs containing aminoacid derivatives as 
chiral anions
33
. Previously the conversion of aminoacids into their methyl esters was carried out 
with thionyl chloride in methanol, followed by a treatment with trifluoromethanesulfonic 
anhydride and triethylamine in dichloromethane in order to give the desired methyl esters of N-
trifluoromethanesulfonylamino acids. Final CILs were achieved by the anion exchange reaction 
between the correspondent esters and [Bmim]OH
60
. 
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A similar synthetic approach was described in the case of the preparation of CILs containing 
tetrabutylphosphonium cation combined with deprotonated amino acid anions
61
. Also, Allen et 
al. reported a series of CILs based on tetrabutylammonium cation containing aminoacid 
anions
62
.  
 
Other available natural molecules have been tested as starting materials for the synthesis of 
CILs, containing chirality in the anionic moiety. Branco et al. reported the combination of 
tetrahexyldimethylguanidinium cations with a variety of chiral carboxylic acids and protected 
amino acids such as quinic, camphorsulfonate, mandelic, lactic, Boc-hydroxyproline, Boc-
alanine and acetyl-hydroxyproline
63
. All of them are examples of room temperature CILs with 
high thermal stability and tunable viscosity as well as solubility profile according to the selected 
anion. 
 
Machado and Dorta prepared multigram chiral ILs based on the combination of [bmim] cation 
and (S)-10-camphorsulfonate (viscous oil) and (R)-1,1´-binaphtyl-2,2´diylphosphate (mp. 80ºC) 
as anions 
64
. 
 
Recently, Weiss and coworkers reported reversible room temperature amidinium carbamate ILs, 
obtained by bubbling CO2 gas through a equimolar mixture of an amidine (N´-alkyl-N, N-
dimethylacetamidine) and an amino acid ester or amino alcohol (40 examples)
65, 66
. All CILs 
were stable under CO2 atmosphere up to 50 ºC and can be reconverted to the starting materials 
by purging with nitrogen gas. This reversibility concept has been explored as a CO2 scavenging 
method or delivery system process. 
 
In the last year, new reversible organic salts based on amino acids in the presence of organic 
superbases [1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and tetramethylguanidine (TMG)] have 
been reported
67
. Novel protic amino acid salts with improved water-solubility profiles and 
unexpected phase behaviour were synthesized using an optimized acid–base reaction. It was 
proved that a phase separation between water and the amino acid salt occurs and that the 
process is reversible, depending on the temperature and the selected organic superbase. The 
work presented could show potencial for tuning miscibility and ionicity of organic salts and the 
design of reversible protic CILs or molten salts. 
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Figure I.9 - Structures of CILs based on chiral anion (a)
60
, (b)
62
, (c)
63
, (d)
65
 and (e)
67
. 
 
I.2. Cyclodextrins (CDs) 
 
The aim of this subchapter is to present a family of biological molecules called Cyclodextrins 
(CDs), which have enjoyed widespread attention and use in recent years. A relevant focus of 
current research is related with the chemistry of biomolecules and their crucial role in new 
fields. These useful functional excipients have gained most attention in the pharmaceutical area 
and drug delivery, by improving solubility and/or stability of several drug molecules. Within the 
field of supramolecular chemistry there is an increasing interest focused on the potential 
applications of cyclodextrin-based systems. 
 
I.2.1. Cyclodextrins (CDs)-Introduction, structure, applications  
 
Cyclodextrins (CDs) were first isolated by a French scientist, A. Villiers in 1891, who described 
them as a bacterial digest isolated from starch
68,
 
69
. Experimental results proved that the 
substance was a dextrin and Villiers called it “cellulosine”. Later an Austrian microbiologist, 
Franz Schardinger, reported two crystalline compounds α-dextrin and β-dextrin which he had 
isolated from a bacterial digest of potato starch. Schardinger considered β-dextrin as Villiers' 
“cellulosine”
70,71
. CDs, also known as cycloamyloses, cyclomaltoses and Schardinger dextrins, 
are cyclic oligosaccharides composed of six to eight α-D-glucose monomers linked by α-1,4 
glycosidic bonds (α-, β-, γ- CD respectively, Figure I.10, Table I.1)
72
. They are produced as a 
result of enzymatic degradation of starch. 
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Figure I.10 - Structural representations of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin. 
 
Table I.1 – Some properties of α-, β- and γ- cyclodextrin
72
.
 
Parameters α-CD β-CD γ-CD 
Number of glucose units 6 7 8 
MW [g.mol
-1
] 972 1135 1297 
Water solubility at room temperature [g.100ml
-1
] 14.5 1.85 23.2 
Outer diameter [nm] 1.52 1.66 1.77 
Cavity diameter [nm] inner rim/outer rim 0.45/ 0.53 0.60/ 0.65 0.75/ 0.85 
Cavity volume [ml.g
-1
] 0.10 0.14 0.20 
[α]D at 25 ºC 150±0.5 162.5±0.5 177.4±0.5 
Melting temperature range [ºC] 255-260 255-265 240-245 
 
Among this class of host molecules, the β- CD is the most abundant natural oligomer because of 
its odd number of units and lower price. Owing to their unique structure, hydrophobic internal 
cavity and hydrophilic external surface, CDs have the property of forming inclusion complex 
with various guest molecules. The hydrophobic cavity provides relative good water solubility 
for the cyclodextrins and the hydrophilic surface causes a favourable environment for the 
hydrophobic parts of a guest molecule to be held in. This inclusion isolates the guest molecules 
from the aqueous media and can increase the guest's water solubility and/or stability. The 
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molecules from inclusion complex are only in contact by physical forces and without covalent 
binding
73
. Furthermore, the dissociation-association equilibrium is one the most characteristic 
features of the host-guest processes. 
 
The equilibrium between the guest and cyclodextrin is crucial in the measurement of the 
inclusion complex stability constant. The general equation can be defined as: 
 
                             Eq. I.1 
 
where n and m are the number of mole for the guest molecule and cyclodextrin, respectively. 
The equilibrium constant K or inclusion complex stability constant for the process can be 
defined as:  
 
                             Eq. I.2 
 
where n and m are the number of mole for the guest molecule and cyclodextrin, respectively. 
The simplest formation of a complex between the cyclodextrin and a guest molecule is a 
stoichiometric proportion of 1:1
73
. Several techniques such as pH measurements, potentiometry, 
calorimetry, conductivity, absorption or fluorescence spectroscopy and capillary electrophoresis 
are used to determine their stoichiometry and stability. 
 
The formation of host/guest complexes has been used in different areas, ranging from 
pharmaceutical and food industry to cosmetic, agrochemical and environmental 
applications
74,75,76
. Generally these carbohydrates are used to enhance the solubility, stability, 
and bioavailability of drugs
77
. They can also prevent drug-drug or drug additive interactions and 
reduce gastrointestinal or ocular irritation. At the same time, cyclodextrin complexations give 
rise to flavors, showed potential in asymmetric reactions, enantiomeric separations, self-
assembled monolayers and enzyme mimics
77
. The only limitation of those chiral biomolecules 
is related with their low solubility in water and many common organic solvents
78
. Therefore, it 
is challenging to search for alternative solvents in order to enhance CDs applications
79
. 
 
I.2.2. Interactions between ILs and CDs 
 
In the last years, wide attention has been focused on interactions between CDs and ILs. 
Formation of inclusion complexes of β- CD and ionic liquid surfactant was described by Gao et 
al
80
. They concluded that β- CD and 1-butyl-3-methylimidazolium hexafluorophosphate 
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([Bmim] PF6) could form 1:1 inclusion complexes in water with the whole imidazolium cation 
entering the cavity of β- CD. The group of Tran investigated the binding constants of CDs in 1-
butylmethylimidazolium chloride ([Bmim]Cl) using the near-infrared spectrometry
81
.  
 
According to the application of CDs in polymer chemistry, the group of Ritter studied the 
interactions between β- CD and 1-butyl-3-vinylimidazolium bis(trifluoromethylsulfonyl)imide 
([Bvim][NTf2]) in order to increase the solubility in water. The complexation between the CD 
and the bis(trifluoromethylsulfonyl)imide anion was proved using conductivity measurements, 
NMR and microcalorimetry
82
. 
 
Besides β- CD, α- and γ- CD gain more attention and recently some work has been reported. 
Vranic and Uzunovic reported dissolution studies of indomethacin with α- and γ- CD resulting 
in an increase of solubility of non-steroidal anti-inflammatory drug (NSAID)
83
. 
 
In 2010, the group of Li reported the interaction between α-, β-, γ- CDs and two surfactant ILs 
1-butyl-3-methylimidazolium tetrafluoroborate ([Bmim]BF4) and 1-octyl-3-methylimidazolium 
tetrafluoroborate ([Omim]BF4)
84
. The measurements based on titration microcalorimetry, UV 
and NMR spectra, which were analyzed in terms of hydrophobic interactions between CD 
cavity with alkyl chain of IL cationic unit. The calorimetric studies confirmed that the 
stoichiometry of CDs and the two ILs was 1:1 and 1:2 except that α- CDs with [Omim]BF4, 
which was only 1:1. 
1
H NMR spectra showed the chemical shift data of all the CDs protons, 
proving the formation of inclusion complexes. 
 
As it was mentioned before, CDs have been successfully applied for different chromatographic 
methods such as High Performance Liquid Chromatography (HPLC), Gas Chromatography 
(GC) and Capillary Electrophoresis (CE) for enantioseparation of racemic compounds
85,86
. 
Modified CDs represent the leading type of chiral selectors for gas chromatography. They can 
be layered either as neat chiral stationary phases (CSPs), if they are viscous liquids at ambient 
temperatures, or as cyclodextrin-solvent mixtures if they have higher melting points and exist as 
solids at room temperatures. 
 
On the other hand, ILs have been developed as a significant new class of GC stationary phase 
materials over the last few years
87, 88
. In 2001 Armstrong and coworkers reported the use of 
achiral ionic liquids as stationary phase solvents for derivatized cyclodextrins
89
. More recently, 
a study on ionic cyclodextrins in ionic liquid matrices as chiral stationary phases for gas 
chromatography (GC) resulted in a new ionic liquid-based stationary phase with broader 
enantioselectivities and higher thermal stabilities
90
. This work was also presented by Armstrong 
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group that developed the first synthetic protocols for new class of ultra-high stability ILs
91
. In 
this paper, the authors used permethylated-β-cyclodextrins (BPM) and dimethylated-β-
cyclodextrins (BDM) dissolved in 1-butyl-3-methylimidazolium chloride ([Bmim]Cl) and the 
column performances were evaluated against those of analogous polysiloxane-based 
commercial columns (Chiraldex BPM and Chiraldex BDM). It was proved that the IL-based 
column efficiencies were up to 10 times higher than the commercial columns. 
 
Pereira and coworkers also developed the first room temperature ionic liquids (RTILs) derived 
from α- and β- CDs, the permethylated mono-6-deoxy-6-piridin-1-ium and mono-6-deoxy-6(1-
vinyl-1-H-imidazol-3-ium) α- and β- CDs trifluoromethanesulfonates at room temperature 
under solvent free conditions in low to moderate yields (34-71%)
92
. These new ILs were studied 
as stationary phases in capillary GC columns towards chiral discrimination in enantio-GC-
analysis of racemic mixtures. This method resulted in good enantiomeric separation of some 
racemic lactones, esters and epoxides which were not achieved by using a common CD column 
(Figure I.12). 
 
With the high number of ILs and variety of ionic cyclodextrin structures available nowadays, 
these types of Cyclodextrin Chiral Stationary Phases (CD-CSPs) offer a new avenue of 
potentially functional and interesting research and development. 
 
 
Figure I.11 - The first RTILs derived fom α- and β- CDs, the permethylated mono-6-deoxy-6-
piridin-1-ium and mono-6-deoxy-6(1-vinyl-1-H-imidazol-3-ium) α- and β- CDs 
trifluoromethanesulfonates. 
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Figure I.12 - Separation of the four enantiomers of whiskey lactone in a sample solution using novel 
RTILs derived from CDs
92
. 
I.3. Nucleobases  
 
I.3.1. Nucleobases-Introduction, structure, properties 
 
It was just 70 years ago discovered that DNA was the genetic material – the master draft of 
life
93
. Since that time, nucleoside chemistry is a dynamic area of research both in industry and 
academia. Consequently, the nucleic acids DNA and RNA, which play an important role in 
storing genetic information and in protein biosynthesis, have been precisely studied and their 
properties are now a key factor in the education of both biologists and chemists
94
. In fact, the 
double helical structure of DNA has grown to be a symbol of our time, appearing widely not 
only in the scientific literature, but also in the well-liked press and most recently as jewelry. 
Nucleoside derivatives have found wide-ranging application in agrochemistry (herbicides, 
fungicides, insecticides), biotechnology (e.g. DNA sequencing) and biology
93
. Their chemistry 
defines a significant area of research for drug discovery related with cancer and viral 
chemotherapy, such as human immunodeficiency (HIV), herpes simplex virus (HSV) and 
hepatitis B virus (HBV)
95,96,97
. According to this, the aim of this subchapter is to highlight the 
nucleosides chemistry that influences different pathways and ordered the structure and 
properties for living cells and organisms.  
 
Nucleobases are the parts of Nucleic Acids (DNA, deoxyribonucleic acid and RNA, ribonucleic 
acid) that are involved in pairing, according to the Watson-Crick model
98
.  
 
Nucleoside is defined as the system of a base covalently bound to the 1‟ carbon of a ribose or 
deoxyribose and a nucleoside with one or more phosphate groups attached at the 5‟ carbon is 
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called a nucleotide
93
. They involve the structural units of RNA and DNA. The structural 
elements of the most common nucleotides are presented in the Figure I.13. 
 
 
 
Figure I.13 - Structural unit of common nucleotides. 
 
All nucleotides are made from three elements: a nitrogen heterocyclic base, a pentose sugar and 
a phosphate residue. The main bases are monocyclic pyrimidines or bicyclic purines. The major 
purines are adenine (A) and guanine (G) and are found in both DNA and RNA. Those bases and 
their corresponding nucleosides are described in Table I.2. The major pyrimidines are cytosine 
(C), thymine (T) and uracil (U). The simplest nucleotides, being the phosphate esters of 
nucleosides, have one of the hydroxyl groups of the pentose esterified by a single phosphate 
monoester function. Adenosine 5´-phosphate is a 5´-ribonucleotide, also called adenylic acid 
and abbreviated to AMP (Figure I.14). Nucleotides containing two phosphate monoesters on the 
same sugar are called nucleoside bisphosphates while nucleoside monoesters of pyrophosphoric 
acid are known as nucleoside diphosphates. Furthermore, nucleoside esters of tripolyphosphoric 
acid are nucleoside triphosphates with the classic example of adenosine 5´-triphosphate (ATP). 
 
Table I.2 - Bases and their corresponding nucleosides. 
Abbr. Base Nucleoside Nucleic Acid 
A Adenine deoxyadenosine DNA 
adenosine RNA 
G Guanine deoxyguanosine DNA 
guanosine RNA 
C Cytosine deoxycytidine DNA 
cytidine RNA 
T Thymine deoxythymidine (thymidine) DNA 
U Uracil uridine RNA 
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Figure I.14 - Structure of adenosine 5´-phosphate (AMP) sodium salt in the state of ionization 
observed at neutral pH. 
 
Nucleic acids are soluble in water up to about 1% w/v according to size and they are 
precipitated by the addition of alcohol, due to their polyionic character. One of the most 
important physical characteristic of a nucleotide is its acid–base behavior. It keeps a tautomeric 
structure, its charge, and thus its ability to donate and accept hydrogen bonds. Apparently, all of 
the bases are uncharged in the physiological range 5 < pH < 9. The same applies for the 
pentoses, where the ribose 2´, 3´- diol loses a proton above pH 12. The nucleotide phosphates 
lose one proton at pH 1 and a second proton (in the case of monoesters) at pH 7. This model of 
proton equilibria is shown for AMP across the whole pH range (Figure I.15). 
 
 
 
Figure I.15 - Protonation of adenosine 5´-phosphate (AMP) from strongly acidic solution (left) to 
strongly alkaline (right). 
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I.3.2. Interactions between ILs and nucleobases  
 
Nucleosides are undeniably essential building blocks of biological systems with numerous 
applications. The widespread attention in nucleosides chemistry has motivated investigators to 
design efficient and practical synthetic routes for the development of nucleosides analogues. 
However, the development of new modified nucleosides presents a major drawback, which is 
related with their poor solubility in common organic solvents
99
. Most of the common available 
methods use toxic high boiling solvents such as pyrimidine, N,N-dimethylformamide and N-
methylpyrrolidone
99
. Therefore, it is important to improve those methods using more 
environmentally benign media that could replace the harmful solvents and provide sufficient 
solubilization of nucleosides. 
 
Previously discussed ILs, with the unique combination of their properties, are revolutionizing 
the world of solvents. Their tunable nature in the solubility of various compounds, including 
molecules of pharmaceutical and biological interest and its well known status of “green” 
alternatives for common solvent, confirmed that some not toxic ILs are excellent for dissolution 
of nucleobases (nucleic acids bases that from the structural units of DNA, RNA, nucleotides, 
and nucleosides). 
 
Rebelo and coworkers investigated the dissolution mechanism of uracil, thymine, and adenine, 
in 1-ethyl-3-methylimidazolium ([C2mim][AcO]) and 1-butyl-3-methylimidazolium acetate 
([C4mim][AcO]) ILs using NMR spectroscopy
100
. The results proved that hydrogen bonds (HB) 
ruled the dissolution mechanism and that both cations and anions participate in the solvation 
process. The acetate anion influences the dissolution of nucleic acid bases into 1,3-
dialkylimidazolium acetate ILs. Nevertheless, hydrogen bonding between nucleobases and the 
imidazolium cation also participated in the solubility process. The authors concluded that the 
ionic liquid must be a good hydrogen bond acceptor and a moderate hydrogen bond donor with 
a dissociation degree sufficiently high to dissolve the bases. 
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Figure I.16 - Studies on the dissolution mechanism of nucleobases in ILs
100
. 
 
It has been already reported in the literature that nucleobases, nucleosides, and nucleotides in 
biological fluids and herbal medicines can be separated and determined by inumerous analytical 
methods, including immunoassays
101
, TLC
102
, HPLC
103
, MEEKC
104
 and many more. MEEKC is 
a powerful electrodriven separation technique with many applications in different disciplines, 
including environmental analysis, food analysis, pharmaceuticals analysis, partition coefficients 
study, bioanalysis and natural products analysis, due to its unique properties of 
microemulsion
105
. According to this, in 2013, Li and coworkers simultaneously determined 
nucleobases, nucleosides and nucleotides using MEEKC method in the presence of IL 1-butyl-
3-methylimidazolium hexafluorophosphate ([Bmim]PF6) as oil phase
106
. This particular IL has 
commonly been used as oil phase because of its strong hydrophobicity, which is related with the 
very chaotropic (able to interfere with the HB or van der Waals forces) counter-ion PF6. The 
established method was successfully applied to obtain the contents of investigated compounds 
in three different widely used traditional Chinese medicines (cultured Cordyceps sinensis, Radix 
Astragali, and Radix Isatidis). Hence, the development of a MEEKC method with [Bmim]PF6 
as oil phase for simultaneous determination of nucleotides, nucleosides, and nucleobases should 
be the key for green analytical science, pharmaceutical analysis, and disease diagnosis. 
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II. Chiral Ionic Liquis based on cysteine derivatives 
 
II.1. Background 
 
The understanding of chiral biological molecules chemistry is a crucial role in new research 
fields
5
. Taking advantage of the relevance and natural chirality of these compounds, there is the 
possibility to use them for the preparation of bioinspired CILs
107
. Applications of ILs include 
their use as chiral reaction media in many catalytic and non-catalytic synthetic methodologies 
and separation processes
108
, including extractions with scCO2
18
 and their use as supporting 
liquid membranes
109
. A transfer of chirality in these solvents should be expected, however only 
few CILs have been reported to date
110
. If in the past years the preparation of ILs was 
concentrated on obtaining unique physical-chemical properties (1
th
 Generation), such as the 
absence of volatility or a high thermal stability, or a specific targeted behaviour (2
nd
 
Generation), now one of the main goal is the achieving of specific desirable biological features 
(3
th
 Generation). 
 
Many investigators have described the development of CILs mainly based on amino acids 
(AAs) and by the incorporation of chirality on cation, anion, or both units. 
 
In this context, L-cysteine and its derivatives are interesting biological molecules with attractive 
properties for academia and industrial applications. In general, cysteine (Cys), mainly the L-
enantiomer, is essential because of its prominent tasks in the food, pharmaceutical, and personal 
care industries
111
. One of the biggest applications is related with the production of flavours. It is 
known that the reaction of cysteine with sugars in a Maillard reaction yields meat flavours
112
. L-
cysteine is also used as a processing aid for baking
113
. Cysteine derivatives are considered 
popular targets for site-directed labeling experiments to investigate biomolecular structure and 
dynamics. 
 
In this context, we decided to develop novel CILs based on L-cysteine derivatives as cation or 
anion units, combined with appropriate counter-ions as described in Figure II.1. The 
development of efficient CILs is essential to expand the range of their applications. 
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Figure II.1 - Structures of synthesized S-methyl-L-cysteine based CILs. 
 
II.2. Synthesis of novel CILs based on S-methyl-L-cysteine 
 
This work intended to develop an efficient and simple synthetic methodology for preparing 
CILs from natural amino acid derivatives. According to two different synthetic approaches, as 
described in Scheme II.1, novel S-methyl-L-cysteine based chiral ILs have been synthesized. 
The protonation of primary amine (NH2) from S-methyl-L-cysteine scaffold was performed 
using hydrochloride acid in methanol solution. This correspondent chloride anion was then 
exchanged to more appropriate organic anions such as docusate ([AOT]) and 
bis(trifluoromethanesulfonyl)imide ([NTf2]), in order to obtain room temperature CILs. 
Furthermore, the deprotonation of carboxylic acid from S-methyl-L-cysteine scaffold was 
carried out using sodium hydroxide in methanol solution. The resulting sodium salt was then 
exchanged to organic cations such as choline ([Choline]), 1-ethyl-3-methylimidazolium 
([Emim]) and trihexyltetradecylphosphonium ([P6,6,6,14]) structures, in order to obtain the desired 
CILs. 
 
After optimizing the synthetic approach, CILs based on S-methyl-L-cysteine were obtained in 
moderate to high yields (69-92%) as well as high purities. For purity evaluation, the final water 
and halogen content was checked for each prepared CIL. For both parameters, it was considered 
a minimal quantity of 250 and 100 ppm, respectively.  
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Scheme II.1 - General strategies for the synthesis of CILs starting from S-methyl-L-cysteine. 
 
All novel chiral ILs based on S-methyl-L-cysteine were completely characterized by 
1
H, 
13
C and 
19
F (in the case of NTf2 anion) NMR and elemental analysis (C, N, H), in order to check their 
structure, purity and chemical stability. The correct cation: anion (1:1) proportion could be also 
verified by 
1
H NMR except in the case of CIL with NTf2 anion. Figure II.2 and II.3 present the 
1
H NMR spectrum of 1-ethyl-3-methyl-1H-imidazol-3-ium (S)-2-amino-3-
(methylthio)propanoate (3c) and (S)-1-carboxy-2-(methylthio)ethanaminium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (2b). The spectra clearly indicate the high purity 
for protons detection (99%) and the correct proportion cation: anion (1:1.03) for both 
compounds respectively. 
 
Figure II.2- 
1
H NMR spectrum of (S)-1-carboxy-2-(methylthio)ethanaminium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (2b) performed in CD3OD. 
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Figure II.3- 
1
H NMR spectrum of -ethyl-3-methyl-1H-imidazol-3-ium (S)-2-amino-3-
(methylthio)propanoate (3c) performed in CD3OD. 
 
Table II.1 summarizes the prepared CILs based on S-methyl-L-cysteine and some of their 
properties, such as optical rotation (αD), solubility behaviour in water and common organic 
solvents, glass transition temperatures (Tg) and density (ρ) values. All CILs derived from S-
methyl-L-cysteine were obtained as coloured viscous Room Temperature Ionic Liquids 
(RTILs). The colour of CILs changed according to the use of S-methyl-L-cysteine as a cation or 
anion and the type of counter-ions, between yellow, orange and brown viscous liquids (Figure 
II.4). The cation/anion interaction can justify the colour variation, when comparing with the 
initial white powder salts in the hydrochloride and sodium forms. 
 
 
 
Figure II.4 - Photos of starting material S-methyl-L-cysteine and samples of synthesized ILs with 
the amino acid derivative either as cation (2a) or anion (3a). 
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Table II.1 Physical state, density, optical rotation, solubility and thermal properties of prepared S-
methyl-L-cysteine based CILs. 
      CIL
 
 
Physical 
state 
 
Tg 
[
0
C]
[a]
 
 
Density
[b]
 
[g cm
-3
] 
 
αD
[c] 
[cm
2
 g
-1
] 
Solubility
[d] 
Miscible Immiscible 
  1 white 
powder 
>240 
(dec.) 
    --- +4.8±2° H2O,  
i-PrOH 
ACN, Ac, DCM, 
hex, AcOEt, Et2O 
  2a 
 
 
orange 
liquid 
-74.63    1.67 +3.0±2° i-PrOH, ACN, Ac, 
DCM, AcOEt 
H2O, hex, Et2O 
  2b brown 
liquid 
  --
[e] 
   1.32 +6.0±2° i-PrOH, ACN, Ac, 
DCM, AcOEt, 
Et2O (pm) 
H2O, hex 
  3a yellow 
liquid 
-107.12   0.93 +6.0±2° i-PrOH, ACN, Ac, 
DCM, AcOEt, 
Et2O (pm) 
H2O, hex 
  3b brown 
liquid 
-56.11  0.98 +14.0±2° H2O, i-PrOH, 
ACN, Ac, DCM, 
AcOEt, Et2O (pm) 
hex 
  3c brown 
liquid 
-73.06  1.22 +12.0±2° i-PrOH, ACN, Ac, 
DCM, AcOEt 
H2O, hex, Et2O 
[a]
 Glass transition temperature (Tg) was determined by DSC measurements at a heating/cooling rate of 10 ºC.min
-1
 for all 
ILs.
 [b] 
Density was measured by pycnometer at room temperature.
 [c] 
Optical rotation values measured in ACN (1 
mg/mL) by polarimetry at 20 ºC. 
[d]
 Observed complete solubilization (miscible), partial solubilization (pm) or non-
solubilization (immiscible) by adding solvent to a small amount of ionic liquid, i-PrOH (i-propanol), Ac (acetone), ACN 
(acetonitrile), hex (n-hexane), Et2O (diethyl ether), DCM (dichloromethane) and AcOEt (ethyl acetate).
 [e]
 Not observed 
by DSC studies. 
 
II.3. Thermal properties of novel CILs based on S-methyl-L-cysteine 
 
All different CILs were studied by DSC measurements at heating/cooling rate of 10 ºC.min
-1
, in 
order to evaluate their thermal properties, in particular the characteristic glass transition 
temperature (Tg) values. Commercial S-methyl-L-cysteine, 1, as a crystalline solid with higher 
melting point (Tm= 240 ºC, decomposes), can be transformed in amorphous salts by a simple 
combination with appropriate counter-ions. Generally, the melting point of amino acids, 
including L-cysteine derivatives, is also their decomposition temperatures. In the case of novel 
CILs based on L-cysteine derivatives, it is possible to avoid the characteristic crystallization as 
well as take advantage of their room temperature liquid states. Glass transition temperatures 
were observed for all examples except in the case of [S-Me(Cys)NH3][AOT], 2b. The influence 
of the selected counter-ion in the Tg values is clearly observed for the examples where cysteine 
is combined as anion. [P6,6,6,14], 3a, cation decreases significantly the Tg value when compared 
with [choline], 3b, or [Emim], 3c, cations. [Emim][S-Me(Cys)CO2], 3c, and [S-
Me(Cys)NH3][NTf2], 2a showed similar Tg values, comparable with some values already 
reported in the literature. The detailed DSC spectra are attached in annex. 
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II.4. Physical properties of novel CILs based on S-methyl-L-cysteine 
 
Optical rotation values in acetonitrile solution for all CILs and neutral S-methyl-L-cysteine 
were measured (1 mg.mL
-1
) by polarimetry at 20 ºC. In the case of CILs 2a, 2b and 3a, similar 
optical rotations to 1 were obtained. In contrast, a significant increase in the optical rotations for 
CILs 3b and 3c were observed. This difference can be explained by a stronger interaction 
between [Choline] and [Emim] cations with S-methyl-L-cysteine anion. In particular, the 
hydrogen bonding formation between OH group of choline cation, or H-2 acidic proton of 
imidazolium cation, with carboxylic group from cysteine derivative anion, is expected. 
 
Density measurements were performed with the use of pycnometer at room temperature (25 ºC). 
The higher density values were obtained for CILs 2a, 2b and 3c due to the presence of [NTf2] or 
[AOT] anion and imidazolium cation respectively. As expected, the presence of ammonium or 
phosphonium cation contributed to density values lower than 1 g.cm
-3
. 
 
Solubility profiles of novel CILs were studied in water and different classes of common organic 
solvents, such as alcohols (methanol, ethanol and i-propanol); alkane (n-hexane); ether (diethyl 
ether); ketone (acetone); ester (ethyl acetate); dichloromethane and acetonitrile. Three novel 
CILs showed water immiscible behaviour, when compared with the initial water miscible S-
methyl-L-cysteine, 1. The combination of cysteine derivative with more hydrophobic counter-
ions changes significantly the final water solubility profile. In general, all novel CILs are 
completely soluble in alcohols, acetone, acetonitrile and ethyl acetate but insoluble in n-hexane 
and diethyl ether. In the case of CILs 2b, 3a and 3b, a partial miscibility in diethyl ether was 
observed. 
 
According with the interest, it is possible to improve the initial cysteine derivative solubility 
(water and alcohols) by a simple combination with appropriate counter-ions. The possibility to 
tune the final solubility of cysteine derivative salts can be relevant for applications in 
asymmetric catalysis or chiral resolution. 
 
II.5. NMR interaction study 
 
Many studies have been performed to examine the structure and interactions of ILs, by using 
different approaches
114
. ILs are rather unique in the sense that in addition to the interactions 
existing in common organic solvents (hydrogen bonding, dipole–dipole and van der Waals 
interactions) ILs have other interactions, such as strong electrostatic interactions. ILs are 
Development of novel ionic liquids based on biological molecules 
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constituted only by ions and thus experience strong cation-anion interactions that yield long- 
lived association of ions
115
. Some authors suggested that cations and anions are hold together 
through hydrogen bonding and others consider its relevance minor compared with the role of 
electrostatic interactions.  
 
The nature of the forces in different ILs may differ from another and mainly control their 
physical and chemical properties. As it was mentioned before, all CILs based on crystalline S-
methyl-L-cysteine were obtained as coloured viscous RTILs. This change of colour obviously 
indicates different interactions between the ions. NMR data allows extracting information on 
existence and strength of H-bondings present between cation and anion in ILs. Therefore, 
1
H 
NMR spectroscopy has been used to determine the degree of cation-anion interactions of S-
methyl-L-cysteine based ionic liquids. In particular, the [S-Me(Cys)NH3][AOT] scaffold, 2b, is 
presented in this subsection. Figure II.5 shows 
1
H NMR spectra of 2b, with variation of 
temperature (in DMSO as deuterated solvent due to its high boiling point). The CH2 peaks close 
to the ion charge, both from the cationic cysteine moiety (3, 3´) and the docusate anion (h, h´) 
increase in higher temperature (facilitate the rotation of molecules). It seems that increase of 
temperature from 25 ºC up to 70
 
ºC (hence decrease of viscosity), facilitates the cation-anion 
interaction near the ion charge. These observations could be confirmed by using two-
dimensional nuclear magnetic resonance spectroscopy (2D NMR). 
1
H and 
13
C NMR of [S-
Me(Cys)NH3][AOT] spectra are included in the annex chapter (Figure VII.1). 
 
 
Figure II.5 - 
1
H NMR specra of [S-Me-Cys][AOT] performed in different temperatures.  
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In summary, cation- anion interactions have been studied to obtain a further understanding of 
the behavior of ILs that could expand their future applications such as chiral recognition. Many 
experimental and theoretical works from literature indicate strong cation- anion interactions 
through the interplay of hydrogen bond and Coulombic forces. Nevertheless, the relative 
importance of hydrogen bond and Coulombic forces in cation-anion interactions is still under 
discussion. 
 
II.6. Application of S-Me-L-cysteine based ILs for enantiomeric 
resolution 
 
Chiral analysis continues to play a crucial role in science and engineering. There are many 
compounds which have enantiomeric forms with different physiological and therapeutic 
effects
50
. Generally, one enantiomer is pharmacologically active, while the other may be 
inactive or limit the effect of the desired form and/or be highly toxic. Single enantiomers of 
chiral drugs are continuously receiving more attention in the pharmaceutical industry. 
Therefore, the optimization of purification processes of enantiomeric pairs has become highly 
desirable. Many different chiral shift reagents (e.g. cyclodextrins, antibodies, antibiotics, crown 
ethers) have been proposed for enantiomeric recognition. More recently, the potential of CILs to 
be applied as NMR chiral shift reagents in spectroscopy has enjoyed considerable 
attentionError! Bookmark not defined.. In contrast to most of the chiral selectors, relatively 
simple to prepare, CILs show discrimination through the solvating power of ionic liquids
116
. 
Thus, the multiple solvation interactions may minimize solubility problems. In addition, CILs 
don´t have the need to include the analyte into the selector‟s cavity to provide discrimination, 
thus adding to their universality.  
 
The first example of the application of CILs in NMR spectroscopy was described in 2002 by 
Wasserscheid and his coworkers, who studied the interionic diastereomeric interactions between 
the enantiopure CIL and a racemic substrate monitoring the 
19
F NMR spectroscopyError! 
Bookmark not defined.. 
 
In 2006, Jurcik et al. observed the diastereomeric interactions between a bis-imidazolinium salt 
containing an aromatic substituent at the C-2 position of the imidazolinic group and PF6 counter 
anions with Mosher‟s carboxylate
15
. The splitting of both proton and fluorine signals of 
Mosher‟s carboxylate has been shown. In addition, while using a borate anion B[C6H3(CF3)2]4 
instead of PF6, no 
1
H NMR splitting and smaller chemical shift difference of fluorine signals in 
the 
19
F NMR were detected.  
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Malhotra and co-workers studied the use of a series of isomannide-based CILs for chiral 
discrimination in NMR
117
. Lindeman and coworkers showed the enantiomeric recognition using 
CILs based on chiral anions
118
. It was found that stronger chiral discrimination was given for 
anions with a relatively larger substituent group (e.g., phenylmethyl group, that led to better 
recognition compared to that with a phenyl group or the weakest isobutyl group). Their studies 
were performed by analyzing NMR spectra of CILs composed of chiral anions and a racemic 1-
methyl-3-(2-methyl-butyl)imidazolium cation. In 2011, De Rooy et al. studied the interionic 
diastereomeric interactions between the enantiopure CIL and a racemic substrate monitoring the 
19
F NMR spectroscopy in the presence of crown ether
119
. A CIL based on ephedrine and 
racemic Mosher‟s acid sodium salt in deuterated CDCl3, provide splitting of the CF3-fluorine 
signal in 
19
F NMR as indicated in Figure II.6. All these efforts showed that these CILs may be 
attractive candidates for many applications in chemical synthesis and separation science. 
 
 
Figure II.6 - 
19
F-NMR (CDCl3) spectra of potassium Mosher’s salt (A), potassium Mosher’s salt 
with (1S,2R)-NorHEph[NTf2] as chiral selector (B), potassium Mosher’s salt with (1S,2R)-
HEphNTf2as chiral selector (C), and potassium Mosher’s salt with (1S,2R)-MeHEph [NTf2] as 
chiral selector (D)
119
. 
 
In order to estimate the potential of our CILs based on S-methyl-L-cysteine, as chiral shift 
reagents for enantiomeric resolution, we studied the influence of the addition of CILs 3b and 3c 
(10 mol%) to racemic Mosher‟s acid sodium salt in deuterated DMSO. For both cases a splitting 
of the CF3-fluorine signal in 
19
F NMR spectra was observed as indicated in Figure II.7 (for the 
case of CIL [Choline][S-Me(Cys)NH3], 3b). No influence in the case of original S-methyl-L-
cysteine, 1, addition was observed. In the case of other CILs no significant influence was also 
observed. It should be stated that no additional crown ether was needed in our studies. 
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In general, the chemical shift difference of fluorine signals in the 
19
F NMR spectra, as well as an 
effective enantiomeric resolution of racemic Mosher salt, was achieved by the simple addition 
of a small quantity of selected CILs. The chiral separation was 4 Hz using 10 mol% of CILs. 
According to the quantity of CILs an improvement of this value is expected. 
 
 
 
Figure II.7 - 
19
F NMR (DMSO) spectra of initial Mosher´s sodium salt (A), Mosher´s sodium salt 
with S-methyl-L-cysteine as chiral selector (B) and [Choline][S-MeCysCO2] as chiral selector (C). 
 
II.7. Application of S-Me-L-cysteine based ILs for asymmetric aldol 
reaction  
 
Asymmetric aldol reaction is largely studied in formation of C-C bonds as well as introducing 
chirality in organic synthesis
120
. The discovery of novel catalysts which exhibit high activity and 
discriminating selectivity is a major focus of current research in the field of asymmetric 
synthesis. The use of CILs instead of common metallic organocatalysts led to overcome the 
complications related with the price, quantities and often toxicity of metals and the use of highly 
polar solvents like DMSO which make the reaction work-up and the recycling of catalyst 
impossible. In this context, the use of organocatalysis based on chiral small organic molecules 
has become a highly active area of research, with many opportunities to discover new reactions 
and their application in asymmetric synthesis. The aldol reaction is one of the most relevant 
carbon-carbon bond forming reactions for the preparation of small optically-active molecules 
(Scheme II.2).  
Initial racemic 
mixture 
Addition of S-
methyl-L-cysteine 
(10 mol%) 
Addition of 
[Choline][S-
MeCysCO2  
(10 mol%) 
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Scheme II.2 - General asymmetric aldol reaction between aldehydes and ketones. 
 
Hajos and Parrish first described the use of L-proline as the organocatalyst for aldol reaction
121
. 
Then, several examples involving proline and its derivatives confirmed their efficiency as 
catalysts for stereoselective organic reactions. Nevertheless, these approaches show some 
limitations such as the use of environmentally unfriendly solvents as DMF or DMSO as well as 
the difficulties of recycling large quantities of catalysts. In the last years, several groups studied 
the direct asymmetric aldol reaction catalyzed by hydrophobic proline derivatives in the 
presence of water. 
 
The original proposed mechanism for the proline-catalyzed intermolecular aldol reaction was 
based on the launched class I aldolase-mechanism that includes carbinolamine, imine or 
iminium, and enamine intermediates
122
. The catalytically active functional groups in class-I 
aldolases, are an  - amino group of a lysine residue and depending on the enzyme subtype, a set 
of Brønsted cocatalysts needed for the various proton-transfers of the multi-step reaction 
mechanism. In the proline-catalyzed case, the catalytic amine is proline´s pyrrolidine. The 
carboxylate could function as multi-purpose Brønsted cocatalysts for the proton transfer 
(Scheme II.3)
123
. The enantioselectivity was explained with a transition state (TS)- (A) that can 
be described as a metal free version of the common Zimmermann-Traxler model (B)
124
, which 
justifies the stereoselectivity of metal enolate aldol reaction. Despite this, it is known that an N- 
H hydrogen bond does not lower the energy of a TS and model A has been advanced to model 
C
123
, which is suitable with the calculated TS of the proline-catalyzed intermolecular aldol 
reaction. 
 
Figure II.8 - Transition states (TS)
123
. 
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Scheme II.3 - The original proposed mechanism of proline-catalyzed intermolecular aldol reaction. 
Proline acts through enamine catalysis. Enamine is formed from the pyrrolidine nitrogen and the 
carbonyl donor. Iminium ion, created by attack of the enamine on the re-face of the aldehyde, is 
then hydrolyzed to give chiral β-hydroxyketone
123
. 
 
Miao and Chan reported the development of IL-anchored L-proline as an efficient and reusable 
catalyst for direct asymmetric aldol reaction
39
. The prepared ILs combined with the chiral 
precursor in neat ketone reaction systems, showed higher catalytic activities than proline itself 
and made it possible to avoid the use of DMSO or DMF as a solvent for the reaction. In the 
same line, some L-proline and pyrrolidinium derivatives based CILs have been presented
125
. 
 
Yang et al. concluded that other amino acids such as threonine and serine derivatives are highly 
efficient organocatalysts for the asymmetric aldol reactions in aqueous media
126
. The same 
authors described some novel cysteine, serine, and threonine based organocatalysts with the 
intention of creating a practical large scale process for asymmetric aldol reactions. The 
performed experiments showed that natural cysteine, serine and threonine are ineffective 
organocatalysts in water, but at the same time all new synthesized CILs derived from these 
amino acids, catalyzed the asymmetric direct aldol reaction of 4-nitrobenzaldehyde and 
cyclohexanone to give the desired product in good yields and enantiomeric excesses
127
.  
 
As it was presented in the previous paragraphs, the state of research concerning asymmetric 
aldol reactions with CILs based on small natural molecules as catalysts has been growing. 
Inspired by the work described in the literature, we studied the application of S-methyl-L-
cysteine CILs previously synthetized and characterized, as chiral organocatalysts for 
asymmetric aldol reaction.  
 
The model reaction was carried out in neat ketone reaction system using acetone or in water 
using cyclohexanone as ketones with 2- or 4-nitrobenzaldehyde in the presence of 10 to 20 
mol% of catalyst, to find the optimum reaction conditions. Table II.2 summarizes the different 
yields and enantiomeric excesses of tested asymmetric aldol reactions. The initial investigation 
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confirmed that L-proline is an effective organocatalyst for asymmetric aldol reactions (Table 
II.2, Entries 1 and 2). However, novel chiral RTILs, essentially [S-MeCysNH3][NTf2], 2a, 
catalyzed the asymmetric direct aldol reaction of 2- or 4-nitrobenzaldehyde and cyclohexanone 
to give the anti aldol product in moderate yields (70-79%), with the indicated range of ee values 
(53–90% ee for anti, Table II.2, Entries 5, 6, 16 and 17). Although longer reaction times were 
required in comparison with cyclic ketones, satisfactory results were obtained. As it was 
expected, in contrast with the o-NO2 substituent group, the p-NO2 substituent group gave higher 
yields as well as higher ee values. [Choline][S-MeCysCO2], 3b, and [Emim][S-MeCysCO2], 3c, 
showed a moderate performance in the case of acetone and 2 or 4-nitrobenzaldehyde (40% of 
yield and 66% of ee for 3b and 77% yield with 68% ee in the case of 3c) as model substrates. 
 
Table II.2 Asymmetric aldol reaction using acetone or cyclohexanone with 2 or 4-
nitrobenzaldehyde as model compounds and chiral RTILs based on S-protected-L-cysteine as 
organocatalysts. 
 
Entry Ketone/Benzaldehyde
[a]
 Catalyst
[b] 
Yield [%]
[c] 
dr (anti: syn)
 [d]
 ee%
[e] 
1 Acetone/2-Nitro L-PRO 85 -- 89 
2
 
Acetone/4-Nitro L-PRO 90 -- 91 
3
 
4 
Acetone/2-Nitro 
Acetone/4-Nitro 
L-CYS 
L-CYS 
no reaction 
no reaction 
-- 
-- 
-- 
-- 
5 Acetone/2-Nitro 2a 70 -- 53 
6 Acetone/4-Nitro 2a 79 -- 70 
7 Acetone/2-Nitro 2b 42 -- 37 
8 
    9 
10 
11 
Acetone/2-Nitro 
Acetone/2-Nitro 
Acetone/4-Nitro 
Acetone/2-Nitro 
3a 
3b 
3c 
5a 
no reaction 
40 
77 
no reaction 
-- 
-- 
-- 
-- 
-- 
66 
68 
-- 
12 Cyclohexanone/2-Nitro L-PRO 63 94:6 76 
   13 Cyclohexanone/4-Nitro L-PRO 68 98:2 84 
14 Cyclohexanone/2-Nitro L-CYS no reaction -- -- 
15 Cyclohexanone/4-Nitro L-CYS no reaction -- -- 
16
 
Cyclohexanone/2-Nitro  2a 63 89:11 88 
17 
18 
19 
20 
Cyclohexanone/4-Nitro 
Cyclohexanone/2-Nitro 
Cyclohexanone/2-Nitro 
Cyclohexanone/2-Nitro 
2a 
2b 
3c 
5a 
73 
no reaction 
no reaction 
21 
89:11 
-- 
-- 
91:9 
90 
-- 
-- 
n.d.
[f]
 
[a]
 Reaction conditions: acetone (2mmol) or cyclohexanone (1 mmol) in water (0.5ml) and 2 or 4-nitrobenzaldehyde (0.5 or 1 
mmol) at room temperature, 24 h when acetone was used, 48 h when cyclohexanone. 
[b]
 Legend of Catalysts (20 mol% in 
the case of acetone examples and 10 mol% in the case of cyclohexanone examples) for : L-PRO- L-proline, , 2a) [S-
MeCysNH3][NTf2], 2b) [S-MeCysNH3][AOT], 3a) [P6,6,6,14][S-MeCysCO2], 3b) [Choline][S-MeCysCO2], 3c) [Emim][S-
MeCysCO2], 5a) [S-carboxyMeCysNH3][NTf2]. 
[c]
 Isolated yield. 
[d]
 Anti:syn diastereomers were determined from 400.13Hz 
1
H NMR spectroscopy. 
[e]
 Enantiomeric excesses determined by 
1
H NMR after use of chiral agent (Mosher´s acid 
derivatives) and chiral HPLC analysis (AD-H column i-PrOH/hexane = 20:80; 0.5 mL.min
-1
; 20 °C; λ = 254 nm). 
[f]
 n.d.: not 
determined. 
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With the optimal reaction condition at hand, we further studied the generality of the asymmetric 
direct aldol reaction of various substituted benzaldehydes in the presence of a catalyst: L-
proline and 2a as shown in Table II.3. It is important to note that changing the position of the 
substituent groups in benzaldehydes leads to different results. Thus, [S-MeCysNH3][NTf2], 2a, 
in the case of 4-hydroxy-3-nitrobenzaldehyde, proved to be a better chiral catalyst than common 
L-proline (Table II.3, Entries 5, 6; 76% yield, 95% ee). This can be explained by the fact that 
electron-withdrawing groups enhance the electrophilicity of carbonyl carbons in aldehydes, 
which facilitates the reaction, while electron-donating groups reduce the electrophilicity. When 
2-hydroxy-3-metoxy-5-nitrobenzaldehyde was used, similar results were obtained (Table II.3, 
Entries 10 and 11). 
 
For all the cases using L-cysteine as organocatalyst no aldol product was observed. In the same 
line, other CILs based on S-methyl-L-cysteine have been tested without any efficiency to aldol 
reactions. Additionally, for this model reaction it was proved that the cysteine-based 
organocatalyst can be recovered and reused. 
 
Table II.3 Studies on asymmetric aldol reactions with different aromatic benzaldehydes. 
Entry
[a]
 Catalyst
[b] 
Ketone Substituted benzaldehyde
 
Yield 
[%]
[c] 
dr (anti: 
syn)
 [d]
 
ee%
[e] 
1 1 Acetone Benzaldehyde 68 -- 84 
2 2a Acetone Benzaldehyde 73 -- 90 
3 1 Cyclohexanone Benzaldehyde 69 98:2 82 
4 2a Cyclohexanone Benzaldehyde 70 90:10 85 
5 L-PRO Acetone 4-hydroxy-3-nitro 67 -- 92 
6 2a Acetone 4-hydroxy-3-nitro 76 -- 95 
7 L-PRO Acetone 2-hydroxy-5-nitro 70 -- 95 
8 2a Acetone 2-hydroxy-5-nitro 58 -- 96 
9 L-PRO Acetone 2-hydroxy-3-metoxy-5-nitro 41 -- 94 
10 2a Acetone 2-hydroxy-3-metoxy-5-nitro 76 -- 93 
[a]
 Reagents and conditions: ketone (1mmol), benzaldehyde or substituted benzaldehyde (0.5mmol), room temperature, 24h.
 
[b]
 Legend of Catalysts (10 mol% loading) for: L-PRO- L-proline, 1) S-MeCys, 2a) [S-MeCysNH3][NTf2]. 
[c]
 Isolated yield. 
[d]
 Anti:syn diastereomers were determined from 400Hz 
1
H NMR spectroscopy. 
[e]
 Enantiomeric excesses determined by 
1
H 
NMR after use of chiral agent (Mosher´s acid derivatives) and chiral HPLC analysis (AD-H column i-PrOH/hexane = 20:80; 
0.5 mL.min
-1
; 20 °C; λ = 254 nm). 
 
II.8. Synthesis of novel CILs based on other L-cysteine derivatives 
 
Due to the possibilities of applying amino acids (AA) as either cations or anions, because of 
their unique molecule structure and their close association with chirality and biomolecules, 
other L-cysteine derivatives were used for the development of novel CILs. In this context, 
additionally, four novel CILs were synthesized from L-cysteine ethyl ester hydrochloride and S-
carboxymethyl-L-cysteine. Using a similar methodology as for the S-methyl-L-cysteine 
described before, it was possible to obtain the L-cysteine derivative scaffold as cation combined 
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with bis(trifluoromethanesulfonyl)imide ([NTf2]) and docusate ([AOT]) as presented in Figure 
II.9. All four compounds were developed as RTILs with moderate to high yields (44-98%). 
Additionally, a complete characterization by 
1
H, 
13
C and 
19
F (in the case of NTf2 anion) NMR 
and elemental analysis (C, N, H), was performed in order to check their structure, purity and 
chemical stability. A chemical shift of the protons from protonated cysteine derivatives was 
observed (protons were more shielded). The proper cation: anion (1:1) proportion could be 
confirmed by 
1
H NMR in the case of AOT anion. In relation with the water insoluble counter-
ions chosen, all CILs were also water immiscible. 
 
 
 
Figure II.9- Synthesis of CILs based on L-cysteine ethyl ester hydrochloride and S-carboxymethyl-
L-cysteine. 
 
After some main characterization of the prepared compounds, their further possible application 
as chiral organocatalysts for asymmetric aldol reaction was studied. In contrast to S-methyl-L-
cysteine based CILs, these additionally synthesized CILs using other cysteine scaffolds didn´t 
allowed to obtain good results. In all performed cases using the same conditions previously 
tested, no reaction occurred. This limitation in the case of L-cysteine ethyl ester is related with 
the tio-free group which throught dimmerization could form disulfides bound. L-cysteine with a 
not protected tio group causes problems with stability. Thus, this particular cysteine derivative 
may be used in acidic conditions but not in basic solutions. 
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II.9. Conclusions 
 
Novel CILs based on S-methyl-L-cysteine as a cation or anion combined with appropriate 
counter-ions were developed. The optimized synthetic routes were appropriated in order to 
obtain the desired CILs in good yields and purities. No crystallization and glass transition 
temperatures were detected in the case of CILs, in contrast with initial S-methyl-L-cysteine. 
 
With the use of cysteine derivative as a cation or anion and it‟s combination with appropriate 
counter-ions, it was possible to adjust thermal (Tg) and physical (optical rotation, density and 
solubilty profile in water and common organic solvents) properties of final CILs.  
 
CILs [Choline][S-Me(Cys)CO2] and [Emim][S-Me(Cys)CO2] are the most promising examples 
as chiral shift reagents for enantiomeric resolution. The strong cation-anion interaction 
attributed to the H-bonding formation between OH group from choline or H-2 acidic proton 
from imidazolium ring, with the carboxylate group from cysteine anion, can justify the 
significant variation of their optical rotation as well as their effective use for chiral 
discrimination of racemic Mosher salt. 
 
These novel CILs can open perspectives on their use for asymmetric catalytic reactions as chiral 
organocatalysts or chiral ligands and also for different chiral recognition processes in analytical 
chemistry or biological applications. 
 
II.10. Experimental Part 
 
General: Commercially available reagents S-methyl-L-cysteine (MW= 135.187 g.mol
-1
, CAS 
No.187-84-4), L-cysteine ethyl ester hydrochloride (MW= 185.67 g.mol
-1
, CAS No.868-59-7), 
S-carboxymethyl-L-cysteine (MW= 179.19 g.mol
-1
, CAS No.638-23-3), 2-methoxy-2-
(trifluoromethyl) phenylacetic acid-Mosher‟s acid (MW= 234.17 g.mol
-1
, CAS No.17257-71-5), 
ionic liquids and solvents were purchased from Alfa Aestar, Aldrich, Solchemar and were used 
without further purification. 
1
H and 
13
C NMR spectra were recorded at 25 ºC on a Bruker 
AMX400 spectrometer with TMS as internal standard. Chemical shifts are reported downfield 
in parts per million (ppm). DSC analysis is carried out using a TA Instruments Q-series TM 
Q200 DSC with a refrigerated cooling system. The samples for elemental analysis were 
performed by Laboratório de Análises at REQUIMTE, Departamento de Química at Faculdade 
de Ciências e Tecnologia (Monte da Caparica), using Thermo Finnigan-CE Instruments 
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equipment, model Elementar Analyser 1112 series. Optical rotations were recorded on a Perkin 
Elmer 241MC. Density measurements were performed with the use of pycnometer at room 
temperature (25 ºC). 
II.10.1. Synthesis of (S)-1-carboxy-2-(methylthio)ethanaminium 
bis((trifluoromethyl)sulfonyl)amide (2a) 
 
S-methyl-L-cysteine (0.5 g; 3.69 mmol) was 
dissolved in water and 1 M solution of HCl in H2O 
(1:1 eq., 3.7 ml) was added slowly in order to 
protonate the amine group. The reaction mixture was 
stirred at room temperature for 1 hour. After the 
protonation was finished the solvent was evaporated 
and the crude was redissolved in acetonitrile and isopropylic alcohol and Li[NTf2] was added to 
perform the ion exchange (0.92 g; 3.21 mmol). The reaction was stirred for 24 hours at room 
temperature. Acetone was added in order to remove the inorganic salts by precipitation. The 
solution was evaporated and dried in vacuo for 24 hours. The desired product was obtained as a 
viscous orange liquid (1.1 g, 74%). Tg=-74.63 
o
C; [α]D= 3.0±2º (c= 1 mg.mL
-1
 in acetonitrile); 
1
H NMR (400.13 MHz, CD3CN) δ 4.30 (t, 
3
JH2-H3,H3´=8Hz, 1H, H2), 4.08 (s, 3H, -NH3), 3.47 (m, 
2H, H3, H3´), 2.40 (s, 3H, H4). 
13
C NMR (100.61 MHz, CD3CN) δ 172.94 (C1), 122.55 (Ca), 
56.13 (C2), 34.41 (C3), 14.68 (C4). 
19
F NMR (376 MHz, (CD3)2SO) δ -79.23. Elemental analysis 
(%) calcd for C6H10F6N2O6S3 (MW=416.34 g.mol
-1
): C 17.31, H 2.42, N 6.73, S 23.10; found: C 
17.23, H 2.43, N 6.76, S 22.97. 
 
II.10.2. Synthesis of (S)-1-carboxy-2-(methylthio)ethanaminium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (2b) 
 
S-methyl-L-cysteine (0.5 
g; 3.69 mmol) was 
dissolved in water and 1 
M solution of HCl in 
H2O (1:1 eq., 3.7 ml) 
was added slowly in 
order to protonate the amine group. The reaction mixture was stirred at room temperature for 1 
hour. After the protonation was finished the solvent was evaporated and the crude was 
redissolved in acetonitrile and isopropylic alcohol and Na[AOT] was added to perform the ion 
 Development of novel ionic liquids based on biological molecules 
46 
exchange (1.54g; 3.46 mmol). The reaction was stirred for 24 hours at room temperature. 
Acetone was added in order to remove the inorganic salts by precipitation. The solution was 
evaporated and dried in vacuo for 24 hours. The desired product was obtained as a viscous 
brown liquid (1.8 g, 87%). [α]D= 6.0±2º (c= 1 mg.mL
-1
 in acetonitrile); 
1
H NMR (400.13 MHz, 
(CD3)2CO ) δ 5.25 (t, 
3
JH2-H3,H3´=8Hz, 1H, H2), 4.54 (t, 
3
J Hg-Hh= 3.2Hz, 1H, Hg), 4.01 (m, 4H, 
Hf), 3.32 (m, 2H, H3, H3´), 3.15 (m, 2H, Hh), 2.25 (s, 3H, H4), 1.60 (m, 2H, Hd), 1.41 – 1.15 (m, 
16H, Hb, Hc, He), 0.92 (m, 12H, Ha). 
13
C NMR (100.61 MHz, (CD3)2CO) δ 171.32 (C1), 169.21 
(-C=O), 168.75(-C=O), 67.34 (Cf), 66.80 (Cf´), 62.25 (Cg), 52.47 (C2), 39.14 (C3, Cd), 34.05 
(Cc), 30.45 (Cc), 30.07 (Ch), 23.57(Ce), 22.74(Cb), 15.31 (C4), 13.88 (Ca), 10.80 (Ca). Elemental 
analysis (%) calcd for C24H47NO9S2 (MW=557.76 g.mol
-1
): C 51.68, H 8.49, N 2.51, S 11.50; 
found: C 51.42, H 8.44, N 2.50, S 11.46. 
 
II.10.3. Synthesis of trihexyl(tetradecyl)phosphonium (S)-2-amino-3-
(methylthio)propanoate (3a) 
 
 S-methyl-L-
cysteine (0.5 g; 
3.69 mmol) was 
dissolved in 
ethanol and 0.5M 
solution of NaOH 
in EtOH (1:1 eq., 
7.4 ml) was added 
slowly in order to 
deprotonate the 
carboxylic acid 
group. The reaction mixture was stirred at room temperature for 1 hour. After the deprotonation 
was finished the solvent was evaporated and the crude was redissolved in acetone and 
[P6,6,6,14]Cl was added to perform the ion exchange (2.25 g; 4.33 mmol). The reaction was stirred 
for 24 hours at room temperature. Dichloromethane was added in order to remove the inorganic 
salts by precipitation. The solution was evaporated and dried in vacuo for 24 hours. The desired 
product was obtained as a viscous brown liquid (2.4 g, 92%). Tg=-73.06 
o
C, [α]D= 6.0±2º (c= 1 
mg.mL
-1
 in acetonitrile); 
1
H NMR (400.13 MHz, CDCl3) δ 6.09 (s, 1H, -OH), 5.30 (s, 3H, -
NH3), 4.32 (m, 1H, H2), 3.64 (m, 2H, H3), 2.40 (s, 3H, H4), 2.32 (m, 8H, Hf), 1.27 (m, 16H, Hb, 
e), 1.26-1.20 (m, 32H, Hc,), 0.83 (m, 12H, Ha).
 13
C NMR (100.61 MHz, CDCl3) δ 172.50 (C1), 
56.49 (C2), 31.81 (C3), 31.01 (Cc), 30.65 (Cc), 30.46 (Cc, Cd), 26.00 (C4), 22.58 (Cf), 22.24 (Cb), 
Development of novel ionic liquids based on biological molecules 
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21.89 (Ce), 14.00 (C4)
,
 13.82 (Ca).
 
Elemental analysis (%) calcd for C36H76NO2PS (MW= 618.03 
g.mol
-1
): C 69.96, H 12.39, N 2.27, S 5.19; found: C 69.61, H 12.33, N 2.26, S 5.17.
 
II.10.4. Synthesis of 2-hydroxy-N,N,N-trimethylethanaminium (S)-2-amino-
3-(methylthio)propanoate (3b) 
 
S-methyl-L-cysteine (0.5 g; 3.69 mmol) 
was dissolved in ethanol and 0.5M solution 
of NaOH in EtOH (1:1 eq., 7.4 ml) was 
added slowly in order to deprotonate the 
carboxylic acid group. The reaction mixture 
was stirred at room temperature for 1 hour. 
After the deprotonation was finished the solvent was evaporated and the crude was redissolved 
in methanol and [Choline]Cl was added to perform the ion exchange (0.44 g; 3.18 mmol). The 
reaction was stirred for 24 hours at room temperature. Acetone was added in order to remove 
the inorganic salts by precipitation. The solution was evaporated and dried in vacuo for 24 
hours. The desired product was obtained as a viscous brown liquid (1.1 g, 74%). Tg=-56.11 
o
C; 
[α]D= 12.0±2º (c= 1 mg.mL
-1
 in acetonitrile); 
1
H NMR (400.13 MHz, CD3OD) δ 4.88 (s, 1H, -
OH), 4.02 (m, 2H, Hb), 3.53 (t, 
3
JH2-H3,H3´=8Hz, 1H, H2), 3.44 (m, 2H, Ha), 3.24 (s, 9H, Hc), 
2.96-2.92 (dd, 
3
JH3-H3´= 4Hz, 2H, H3, H3´), 2.12 (s, 3H, H4). 
13
C NMR (100.61 MHz, CD3OD) δ 
179.30 (C1), 68.04 (Ca), 56.05 (C2), 54.91 (Cb), 53.71 (Cc), 40.64 (C3), 14.37 (C4). Elemental 
analysis (%) calcd for C9H22N2O3S (MW= 238.35g.mol
-1
): C 45.35, H 9.30, N 11.75, S 13.45; 
found: C 45.12, H 9.26, N 11.70, S 13.45. 
 
II.10.5. Synthesis of 1-ethyl-3-methyl-1H-imidazol-3-ium (S)-2-amino-3-
(methylthio)propanoate (3c) 
 
S-methyl-L-cysteine (0.5 g; 3.69 mmol) 
was dissolved in ethanol and 0.5M solution 
of NaOH in EtOH (1:1 eq., 7.4 ml) was 
added slowly in order to deprotonate the 
carboxylic acid group. The reaction mixture 
was stirred at room temperature for 1 hour. 
After the deprotonation was finished the solvent was evaporated and the crude was redissolved 
in methanol and [Emim]Br was added to perform the ion exchange (0.61 g; 3.18 mmol). The 
reaction was stirred for 24 hours at room temperature. Dichloromethane was added in order to 
remove the inorganic salts by precipitation. The solution was evaporated and dried in vacuo for 
24 hours. The desired product was obtained as a viscous yellow liquid (0.62 g, 69%). Tg=-
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107.12 
o
C; [α]D= 14.0±2º (c= 1 mg.mL
-1
 in acetonitrile); 
1
H NMR (400.13 MHz, CD3OD) δ 
7.69-7.61 (d, 
3
JHd-Hd´= 12 Hz, 2H, Hd, d´), 4.96 (s, 3H, Hg), 4.29 (q, 
3
JHe-Hf= 7.3 Hz, 2H, He), 3.76 
(m, 2H, H3), 3.33 (m, 1H, H2), 2.16 (t,
 3
JHf-He= 7.3 Hz, 3H, Hf). 
13
C NMR (100.61 MHz, 
CD3OD) δ 179.30 (C1), 123.89 (Cb), 122.27 (Cd), 48.42 (C2), 45.03 (Ce), 35.51 (C3), 34.05 (Cg), 
14.60 (C4, Cf). Elemental analysis (%) calcd for C10H19N3O2S (MW= 245.34 g.mol
-1
): C 48.95, 
H 7.81, N 17.13, S 13.07; found: C 48.95, H 7.79, N 17.05, S 13.05. 
II.10.6. (S)-1-ethoxy-3-mercapto-1-oxopropan-2-aminium 
bis((trifluoromethyl)sulfonyl)amide (4a) 
 
 L-cysteine ethyl ester hydrochloride (0.5 g; 2.69 
mmol) was dissolved in methanol and 1.2 eq. of 
Li[NTf2] was added to perform the ion exchange 
(0.93 g; 3.23 mmol). The reaction was stirred for 24 
hours at room temperature Acetone was added in 
order to remove the inorganic salts by precipitation. 
The solution was evaporated and dried in vacuo for 24 hours. The desired product was obtained 
as a viscous yellow liquid (0.51 g, 44%). 
1
H NMR (400.13 MHz, DMSO) δ 7.00 (s, 3H, -NH3), 
4.70 (t, 
3
JH2-H3=6Hz, 1H, H2), 4.16 (m, 2H, -CH2), 3.15 (m, 2H, H3, H3´), 1.30 (t, 
3
JCH3-CH2=6Hz, 
3H, -CH3). 
13
C NMR (100.61 MHz DMSO) δ 169.03 (C1), 122.23 (Ca), 62.50 (-CH2), 56.05 
(C2), 32.26 (C3), 15.34 (-CH3).
 19
F NMR (376 MHz, DMSO) δ -79.23. Elemental analysis (%) 
calcd for C7H12F6N2O6S3 (MW= 430.37 g.mol
-1
): C 19.54, H 2.81, N 6.51, S 22.35; found: C 
19.44, H 2.80, N 6.48, S 22.25. 
 
II.10.7. (S)-1-ethoxy-3-mercapto-1-oxopropan-2-aminium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (4b) 
 
L-cysteine ethyl ester 
hydrochloride (0.5 g; 2.69 
mmol) was dissolved in 
methanol and 1.2 eq. of 
Na[AOT] was added to 
perform the ion exchange 
(1.32 g; 2.96 mmol). The reaction was stirred for 24 hours at room temperature. Acetone was 
added in order to remove the inorganic salts by precipitation. The solution was evaporated and 
dried in vacuo for 24 hours. The desired product was obtained as a viscous white liquid (1.49 g, 
97%). 
1
H NMR (400.13 MHz, (CD3)2CO) δ 5.25 (t, 
3
JH2-H3,H3´=6Hz, 1H, H2), 4.54 (t, 
3
J Hg-Hh= 
3.2Hz, 1H, Hg), 4.16 (m, 2H, -CH2), 4.01 (m, 4H, Hf), 3.32 (m, 2H, H3), 3.15 (m, 2H, Hh), 2.07 
Development of novel ionic liquids based on biological molecules 
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(m, 2H, Hd), 1.41 – 1.15 (m, 19H, Hb, Hc, He, -CH3), 0.92 (m, 12H, Ha). 
13
C NMR (100.61 MHz, 
(CD3)2CO) δ 171.32 (C1), 169.21 (-C=O), 168.75 (-C=O), 67.34 (Cf), 67.02 (Cf´), 63.70 (-CH2), 
62.25 (Cg), 52.47 (C2), 39.14 (C3, Cd), 35.51 (Cc), 30.45 (Cc), 30.07 (Ch), 23.57 (Ce), 22.74(Cb), 
14.60 (-CH3), 13.88 (Ca), 10.80 (Ca). Elemental analysis (%) calcd for C25H49NO9S2 (MW= 
571.79 g.mol
-1
): C 52.51, H 8.64, N 2.45, S 11.22; found: C 52.24, H 8.58, N 2.45, S 11.17. 
 
II.10.8. (S)-1-carboxy-2-((carboxymethyl)thio)ethanaminium 
bis((trifluoromethyl)sulfonyl)amide (5a) 
 
S-carboxymethyl-L-cysteine (0.5 g; 2.79 
mmol) was dissolved in methanol and 1 
M solution of HCl in MeOH (1:1 eq., 
2.79 ml) was added slowly in order to 
protonate the primary amine group. The 
reaction mixture was stirred at room 
temperature for 1 hour. After the protonation was finished Li[NTf2] was added to perform the 
ion exchange (0.96 g; 3.35 mmol). The reaction was stirred for 24 hours at room temperature. 
Acetone was added in order to remove the inorganic salts by precipitation. The solution was 
evaporated and dried in vacuo for 24 hours. The desired product was obtained as a viscous 
yellow liquid (0.81 g, 63%). 
1
H NMR (400.13 MHz, CD3OD) δ 4.17 (m, 1H, H2), 3.47 (s, 2H, 
H4), 3.30 (m, 1H, H3), 3.08 (m, 1H, H3´). 
13
C NMR (100.61 MHz, CD3OD) δ 172.89 (C5), 
122.79 (C1), 119.61 (Ca), 53.56 (C2), 34.44 (C4), 33.96 (C3). 
19
F NMR (376 MHz, (CD3)2SO) δ -
79.23. Elemental analysis (%) calcd for C7H10F6N2O8S3 (MW= 460.35 g.mol
-1
): C 18.26, H 
2.19, N 6.09, S 20.90; found: C 18.16, H 2.18, N 6.06, S 21.00. 
 
II.10.9. (S)-1-carboxy-2-((carboxymethyl)thio)ethanaminium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (5b) 
 
S-carboxymethyl-L-
cysteine (1 g; 5.58 mmol) 
was dissolved in methanol 
and 1.2 eq. of Na[AOT] 
was added to perform the 
ion exchange (2.97 g; 
6.69 mmol). The reaction was stirred for 24 hours at room temperature. Acetone was added in 
order to remove the inorganic salts by precipitation. The solution was evaporated and dried in 
vacuo for 24 hours. The desired product was obtained as a viscous white liquid (2.74 g, 98%). 
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1
H NMR (400.13 MHz, (CD3)2CO) δ 4.30 (m, 1H, H2), 4.10-4.01 (m, 5H, Hg, Hf), 3.77 (s, 2H, 
H4), 3.53 (m, 1H, H3), 3.36-3.13 (m, 3H, H3´, Hh), 1.49 (m, 2H, Hd), 1.41 – 1.15 (m, 16H, Hb, 
Hc, He), 0.93 (m, 12H, Ha). 
13
C NMR (100.61 MHz, (CD3)2CO) δ 171.39 (C5), 171.22 (-C=O), 
168.85 (C1), 168.38 (-C=O), 67.34 (Cf), 67.02 (Cf´), 61.87(Cg), 51.82 (C2), 40.04 (C4), 39.14 
(Cd), 35.51 (Cc), 30.45 (Cc), 30.07 (Ch), 29.18 (C3), 23.57 (Ce), 22.74(Cb), 13.04 (Ca), 9.98 (Ca). 
. Elemental analysis (%) calcd for C25H47NO11S2 (MW= 601.77 g.mol
-1
): C 49.90, H 7.87, N 
2.33, S 10.66; found: C 49.80, H 7.83, N 2.32, S 10.64. 
 
II.10.10. 19F NMR Experiment- enantiomeric resolution 
 
Racemic Mosher‟s sodium salt was prepared from Mosher‟s acid by reacting 
with an equivalent of sodium hydroxide in water and the salt was dried 
under vacuum before 
19
F NMR measurement. The racemic Mosher‟s sodium 
salt (8.38 mg, 0.03 mmol) and 77-159 mg (0.32 mmol) of chiral ionic 
compounds were dissolved in 0.5 ml of d-DMSO. The mixture was 
dissolved in ultrasonificator bath for 10 minutes at 35 ºC before recording 
19
F NMR spectra. 
 
II.10.11. General procedure for asymmetric aldol reaction 
 
Asymmetric aldol reaction between aromatic aldehydes and acetone/cyclohexanone was carried 
out in neat ketone reaction system (acetone) and water or DMSO (cyclohexanone). The 
suspension of chiral catalyst based on cysteine scaffold (10-20 mol%) and ketone (100 µl, 2 
mmol) was stirred for 30 minutes at RT. After that time aromatic aldehyde (0.0756 g, 1mmol) 
was added and the resulting mixture was allowed to stirr at RT for 24-48 hours as indicated in 
Tables II.2 and II.3. In the next step, the solvent was evaporated in vacuo and the crude was 
redissolved in DCM, in order to be filtered through a silica gel pad (1 g) and washed with 
diethyl ether (Et2O). The solvent was removed under vacuum to afford the desired aldol product 
as colourless solid. Relative and absolute configurations of the products and enantiomeric 
excess values were determined by comparison with the known 
1
 H NMR. 
 
Procedure for Catalyst Recovery: 
The reaction mixture was stirred at RT as specified in Tables II.2 and II.3. After the excess 
solvent was evaporated, Et2O was added to the crude and vigorous stirred for 5 minutes. Later, 
an extraction using Et2O (4x2ml) was performed. Then the organic layer was concentrated in 
vacuo to afford the aldol product. The catalyst phase remaining, according to the immiscibility 
Development of novel ionic liquids based on biological molecules 
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of the catalyst in Et2O, was redissolved in acetone in order to be recovered and was dried under 
vacuum. 
 
4-hydroxy-4-(2-nitrophenyl)butan-2-one: 93 mg, yield: 89%. 
 1
H 
NMR (400.13 MHz, CDCl3) δ 7.95 (d, 
3
JH3´-H4´ = 8 Hz, 1H, H3´), 7.90 
(d, 
3
JH6´-H5´ = 8 Hz, 1H, H6´), 7.65 (t, 
3
JH5´-H6´, H4´= 8 Hz, 1H, H5´), 7.43 
(t, 
3
JH4´-H5´, H3´= 8 Hz, 1H, H4´), 5.68 (d, 
3
JH4-H3 = 8 Hz, 1H, H4), 3.13 
(dd, 
3
JH3-H3, H4 = 8 Hz, 1H, H3), 2.79 (dd, 
3
JH3-H3, H4 = 8 Hz, 1H, H3), 
2.23 (s, 3H, H1). 
13
C NMR (100.61 MHz, CDCl3) δ 208.20 (C2), 147.24 (C6´), 138.28 (C5´), 
133.91 (C2´), 128.27 (C3´), 124.26 (C4´), 65.53 (C4), 51.18 (C3), 30.00 (C1). 
 
4-hydroxy-4-(4-nitrophenyl)butan-2-one:
 
95 mg, yield: 91%. 
 1
H NMR 
(400.13 MHz, CDCl3) δ 8.38 (d, 
3
JH5´-H6 ,́ H3´-H2´= 8 Hz, 2H, H5´, H3´), 7.51 
(d, 
3
JH6´-H5 ,́ H2´-H3´= 8 Hz, 2H, H6´, H2´), 5.29 (d, 
3
JH4-H3 = 8 Hz, 1H, H4), 
3.48 (t, 
3
JH3-H3, H4 = 8 Hz, 1H, H3), 2.13 (s, 3H, H1). 
13
C NMR (100.61 
MHz, CDCl3) δ 190.47 (C2), 150.93 (C1´), 139.89 (C4´), 128.72 (C6´), 
128.43 (C2´), 125.27 (C3´), 124.26 (C5´), 65.71 (C4), 50.18 (C3), 30.81 
(C1). 
 
2-(hydroxy(2-nitrophenyl)methyl)cyclohexanone: 78 mg, yield: 
63%. 
 1
H NMR (400.13 MHz, CDCl3) δ 8.14 (dd, 
3
JH3´-H4´= 8 Hz, 
4
J 
H3´-H5´= 11 Hz, 1H, H3´), 7.96 (dd, 
3
JH6´-H5´= 8 Hz, 
4
J H6´-H4´= 11 Hz, 
1H, H6´), 7.79 (m, 2H, H5´,H4´), 5.43 (d, 
3
JH*-H2= 8 Hz, 1H, H
*
), 3.47 
(t, 
3
JH2-H*, H3 = 8 Hz, 1H, H2), 2.43 - 2.34 (m, 2H, H6), 2.20 - 2.08 
(m, 1H, H3), 1.70 – 1.51 (m, 4H, H4, H5), 1.25 – 1.13 (m, 1H, H3). 
13
C NMR (100.61 MHz, 
CDCl3) δ 209.45 (C1), 147.08 (C6´), 140.46 (C5´), 133.22 (C2´), 131.53 (C3´), 126.95 (C1´), 
121.46 (C4´), 71.56 (C*), 57.48 (C2), 39.34 (C6), 29.20 (C5), 23.12 (C4), 20.53 (C3). 
 
2-(-hydroxy(4-nitrophenyl)methyl)cyclohexanone: 90 mg, 
yield: 73%. 
 1
H NMR (400.13 MHz, CDCl3) δ 8.07 (d, 
3
JH5´-
H6 ,́ H3´-H2´= 8 Hz, 2H, H5´, H3´), 7.48 (d, 
3
JH6´-H5 ,́ H2´-H3´= 8 Hz, 
2H, H6´, H2´), 4.93 (d, 
3
JH*-H2= 8 Hz, 1H, H
*
), 3.45 (t, 
3
JH2-H3, 
H4*= 8 Hz, 1H, H2), 2.82 - 2.44 (m, 2H, H6), 2.34 - 2.15 (m, 
1H, H3), 1.90 – 1.71 (m, 4H, H4, H5), 1.55 – 1.38 (m, 1H, H3). 
13
C NMR (100.61 MHz, CDCl3) 
δ 207.02 (C1), 151.08 (C1´), 146.46 (C4´), 127.39 (C6´), 127.13 (C2´), 123.95 (C3´), 123.46 (C5´), 
76.56 (C*), 57.38 (C2), 40.04 (C6), 29.20 (C5), 25.12 (C4), 22.13 (C3). 
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4-hydroxy-4-(4-hydroxy-3-nitrophenyl)butan-2-one: 77 mg, 
yield: 76%. 
 1
H NMR (400.13 MHz, CDCl3) δ 8.63 (s, 1H, H2´), 
8.13 (d, 
3
JH6´-H5´= 8 Hz, 1H, H6´), 7.30 (d, 
3
JH5´-H6´= 8 Hz, 1H, H5´), 
3.47 (t, 
3
JH4-H3, = 8 Hz, 1H, H4), 3.15 (dd, 
3
JH3-H3, H4 = 8 Hz, 1H, 
H3), 2.89 (dd, 
3
JH3-H3, H4 = 8 Hz, 1H, H3), 2.20 (s, 3H, H1). 
13
C 
NMR (100.61 MHz, CDCl3) δ 188.52 (C2), 159.22 (C4´), 136.30 
(C3´), 133.55 (C6´), 129.26 (C1´), 128.53 (C2´), 121.24 (C5´), 68.88 (C4), 53.27 (C3), 29.66 (C1). 
 
4-hydroxy-4-(2-hydroxy-5-nitrophenyl)butan-2-one: 71 mg, 
yield: 70%. 
 1
H NMR (400.13 MHz, CDCl3) δ 8.59 (s, 1H, H6´), 
8.43 (d, 
3
JH4´-H3´= 8 Hz, 1H, H4´), 7.15 (d, 
3
JH3´-H4´= 8 Hz, 1H, H3´), 
3.74 (t, 
3
JH4-H3, = 8 Hz, 1H, H4), 3.12 (dd, 
3
JH3-H3, H4 = 8 Hz, 1H, H3), 
2.78 (dd, 
3
JH3-H3, H4 = 8 Hz, 1H, H3), 2.25 (s, 3H, H1). 
13
C NMR 
(100.61 MHz, CDCl3) δ 195.58 (C2), 166.13 (C2´), 140.63 (C5´), 
131.68 (C1´), 129.78 (C4´), 119.42 (C6´), 119.00 (C3´), 65.84 (C4), 30.92 (C3), 29.68 (C1). 
 
4-hydroxy-4-(2-hydroxy-3-methoxy-5-nitrophenyl)butan-2-
one: 74 mg, yield: 76%. 
 1
H NMR (400.13 MHz, CDCl3) δ 8.20 
(s, 1H, H6´), 7.90 (s, 1H, H4´), 4.00 (s, 3H, H7´), 3.45 (t, 
3
JH4-H3, = 
8 Hz, 1H, H4), 3.07 (dd, 
3
JH3-H3, H4 = 8 Hz, 1H, H3), 2.88 (dd, 
3
JH3-
H3, H4 = 8 Hz, 1H, H3), 1.39 (s, 3H, H1). 
13
C NMR (100.61 MHz, 
CDCl3) δ 195.45 (C2), 156.73 (C3´), 148.90 (C2´), 140.29 (C5´), 
120.34 (C1´), 118.72 (C6´), 111.24 (C4´), 56.69 (C4), 56.11 (C7´), 49.69 (C3), 30.02 (C1). 
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III. L-proline based ionic liquids  
III.1. Background 
 
Proline (Pro) is an abundant chiral scaffold as well as inexpensive secondary, cyclic pyrrolidine-
based amino acid. This characteristic provides the increase in pKa values of its amine compared 
to primary amino acids. Proline is a bifunctional amino acid available in both enantiomeric forms 
(Figure III.1). Concerning the amino and carboxylic acid group, they can both react as an acid or 
base and also facilitate the further chemical transformations. Those diverse reasons contribute to 
proline´s role in catalysis as universal asymmetric catalyst.  
 
 
Figure III.1 - Zwitterionic structure of both proline enantiomers: L-proline (left) and D-proline 
(right). 
 
Proline was firstly studied for catalysis in the Hajos-Parrish-Eder-Sauer-Wiechert reaction. In 
the 1970‟s, L-proline-catalyzed intramolecular aldol cyclizations in the synthesis of optically 
pure starting materials for the CD rings of steroids (C-one of three cyclohexane rings, D- 
cyclopentane ring )
128
 were investigated. The skeleton of steroids consists in three fused 
cyclohexane rings and one cyclopentane ring. To each of the four rings was given an alphabet 
letter; the cyclohexane rings are A-C and the cyclopentane ring at the right edge is D. 
 
Hajos and Parrish isolated the hydrindane dione from proline-catalyzed intramolecular aldol 
cyclization. The studies resulted in high yields and enantiomeric excesses as presented in 
Scheme III.1. 
   
 
Scheme III.1 - Hajos- Parrish- Eder- Sauer- Wiechert Reaction. 
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Taking into accout the versatile properties of this stable, non-toxic and powerful catalyst, it 
would seem daring to expect anything less than the discovery of novel proline-based ionic 
liquids. Therefore, in this chapter, the synthesis, characterization and application of a new class 
of chiral salts derived from commercially available L-proline are proposed. 
 
III.2. Synthesis and characterization 
 
Different structures of chiral salts developed from L-proline, including six using the amino acid 
unit as a cation and other six using it as an anion are shown in Figure III.2. 
 
 
Figure III.2- Structures of chiral salts developed from L-proline. 
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According to synthesis of CILs derived from L-proline scaffold, similar approaches to those in 
the case of L-cysteine presented in chapter II have been used. The protonation of the secondary 
amine (NH) from L-proline was performed using hydrochloride acid in methanol solution. This 
correspondent chloride anion was then exchanged to more appropriate organic anions such as 
bis(trifluoromethanesulfonyl)imide ([NTf2]), 7a, docusate ([AOT]), 7b, p-toluenosufonate 
([TsO]), 7c, and saccharinate ([SAC]), 7d, in order to obtain room temperature CILs (Scheme 
III.2). Additionaly, two enantiomers from camphorsulfonic acid sodium salt, in the form of 
anions (R)-CSA, 7e, and (S)-CSA, 7f, were combined with the L-proline cation as examples of 
novel chiral salts containing chirality on both ionic units. 
 
  
 
Scheme III.2 - General strategy for the synthesis of CILs based on L-proline as cationic unit. 
 
The method selected to synthesize the proline- based salts with the amino acid as anion was the 
neutralization method. Ion exchange resin method developed by Ohno and coworkers is being 
effectively used as alternative anion exchange processes and it has been extended to other 
reactions
129
. This strategy led to overcome many limitation related with the conventional 
method (anion metathesis), such as contamination of halides salts, limited variety of 
commercially available metal salt and adequate combination of amino acids to counter ions. 
 
In this work, Amberlite resin (in the OH form) has been used in order to exchange halides 
(bromide or chloride) to the hydroxide form and then this basic solution was neutralized by the 
addition of an adequate acid solution, as described in Scheme III.3. The direct acid-base 
reaction allows the preparation of desired proline salt combined with organic cations such as 
trihexyltetradecylphosphonium ([P6,6,6,14]), 8a, 1-ethyl-3-methylimidazolium ([Emim]), 8b, 1-(2-
methoxyethyl)-3-methylimidazolium ([C3Omim]), 8c, 1-(2-hydroxyethyl)-3-methylimidazolium 
([C2OHmim]), 8d, and 1-(2-hydroxyethyl)-2,3-dimethylimidazolium([C2OHDmim]), 8e. In the 
case of choline ([Choline]) cation, a direct acid- base reaction was performed due to the 
commercial available choline hydroxide in methanol solution (40% w/w), 8f. 
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After optimizing the synthetic approach, CILs based on L-proline were obtained in moderate to 
high yields (66-99%) as well as high purities (confirmed by 
1
H NMR spectroscopy and 
elemental analysis). 
 
 
 
Scheme III.3 - Synthesis of L-proline based salts using ion exchange resins method. 
 
All novel CILs based on L-proline were completely characterized by 
1
H and 
13
C NMR 
spectroscopy, Fourier transform infrared (FTIR) spectroscopy, elemental analysis (C, N, H) and 
differential scanning calorimetry (DSC) analysis, in order to check their structure, purity and 
chemical stability. In the 
1
H- and 
13
C-NMR spectra, no peaks attributable to impurities were 
found. NMR studies also elucidate about the expected cation/anion correlations by a 
quantitative integration of their characteristic 
1
H resonance peaks. Figure II.3 shows the 
1
H 
NMR spectrum of trihexyl(tetradecyl)phosphonium (S)-pyrrolidine-2-carboxylate, 8a, with the 
correct cation /anion proportion 1:1.08 (value included in the 10% error) and 99% of purity. 
Figure II.4 presents (S)-2-carboxypyrrolidin-1-ium 1,4-bis((2-ethylhexyl)oxy)-1,4-dioxobutane-
2-sulfonate, 7b, where L-proline was used as a cation combined with the biocompatible 
docusate anion (cation /anion proportion 1:1.03 and 97% of purity). 
 
It is important to emphasize that 
1
H NMR spectra of the synthesized compounds based on L-
proline as the cationic unit, show the dubbling of the peak belonging to the chiral proline carbon 
atom. This phenomenon is presented for (S)-2-carboxypyrrolidin-1-ium 3-oxo-3H-
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benzo[d]isothiazol-2-ide 1,1-dioxide, 7d, in Figure III.5. The corresponding triplet of H2 
appeared at the same time at 4.65-4.62 ppm and 4.47-4.44 with the same coupling constant of 
4Hz. It can be concluded that the chiral carbon is influenced by the protonation of the close 
amino group and for that reason this dubbling occurs. 
 
Figure III.3 - 
1
H NMR spectrum of trihexyl(tetradecyl)phosphonium (S)-pyrrolidine-2-carboxylate 
(8a) performed in CDCl3 (Synthesis was carried out using ion exchange resin method). 
 
 
Figure III.4 - 
1
H NMR spectrum of (S)-2-carboxypyrrolidin-1-ium 1,4-bis((2-ethylhexyl)oxy)-1,4-
dioxobutane-2-sulfonate (7b) performed in DMSO (Synthesis was carried out using anion metal 
exchange method). 
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Figure III.5 - Dubbling of peak from chiral carbon observed for [ProNH2][SAC] (7d) in 
1
H NMR. 
The NMR description of the proton: 4.65-4.62 ppm (t, 
3
JH2-H3=4Hz, 1H) and 4.47-4.44 ppm (t, 
3
JH2-
H3=4Hz, 1H). 
 
Most of novel salts derived from L-proline were obtained as coloured viscous Room 
Temperature Ionic Liquids (RTILs), except in the case of [ProNH2][(R)-CSA], 7e, and 
[ProNH2][(S)-CSA], 7f, which were developed as white crystalline solids. The colour of CILs 
changed due to the use of L-proline as a cation or anion and the selected counter-ions between 
yellow, orange and brown viscous liquids as presented in Figure III.6. The cation/anion 
interaction can justify the colour variation when comparing with the initial white powder L-
proline form. 
 
 
 
Figure III.6- RTILs derived from L-proline [P6,6,6,14][ProCO2] (left), [Emim][ProCO2] (middle) and 
[C3Omim][ProCO2] (right). 
 
III.3. Physical properties of novel L-proline based salts 
 
Table III.1 summarizes all prepared CILs based on L-proline and some of their physical 
properties such as optical rotation (αD) and density (ρ) values. Our optimized synthetic 
procedure allowed us to obtain pure compounds in high yields (75 to 99%). 
 
Development of novel ionic liquids based on biological molecules 
 
L
-p
ro
li
n
e 
b
as
ed
 i
o
n
ic
 l
iq
u
id
s 
61 
L
-p
ro
li
n
e 
b
as
ed
 i
o
n
ic
 l
iq
u
id
s 
61 
Table III.1 Some properties of new synthesized salts based on L-proline scaffold. 
CIL
 
 
 
Yield [%]
[a] 
 
Purity
[b] 
 
Density
[c]
 
[g cm
-3
] 
 
αD
[d] 
[cm
2
 g
-1
] 
L-Pro 6 --- --- --- -41.3±2° 
[ProNH2] [NTf2] 7a 90 ˃99 1.63 -12.7±2° 
[ProNH2] [AOT] 7b 97 99 1.32 -12.0±2° 
[ProNH2] [TsO] 7c 66 98 0.93 -4.0±2° 
[ProNH2] [SAC] 7d 98 98 0.98 -4.5±2° 
[ProNH2] [(-)CSA] 7e 99 99 --- -44.0±2° 
[ProNH2] [(+)CSA] 7f 95 98 --- +66.0±2° 
[P6,6,6,14] [ProCO2] 8a 97 98 0.93 -17.3±2° 
[Emim] [ProCO2] 8b ˃99 98 1.19 -8.8±2° 
[C3Omim] [ProCO2] 8c 98 99 1.24 -5.3±2° 
[C2OHmim] [ProCO2] 8d 80 99 1.25 -6.7±2° 
[C2OHDmim] [ProCO2] 8e 75 99 1.28 -19.0±2° 
[Choline] [ProCO2] 8f 99 ˃99 0.97 -12.7±2° 
[a] 
Isolated yields. 
[b] 
Purity obtained from 
1
H NMR spectroscopy.
 [c] 
Density was measured by pycnometer at 25 ºC.
 [d] 
Optical rotation values measured in MeOH (1 mg.mL
-1
) by polarimetry at 20 ºC recorded on a Perkin Elmer 241MC. 
 
The optical rotation values were measure in methanol solution for all CILs and the initial L-
proline protonated form (1 mg.mL
-1
) by polarimetry at 20 ºC. For most of the CILs, the optical 
rotations oscillated between -2.0 to -12.7° (with ±2° error). Higher optical rotations values were 
observed for CILs 8a and 8e. In general, salts derived from L-proline as chiral anion resulted in 
higher optical rotation values, but still significantly lower when compared with the initial L-
proline (-41.3±2°). This difference can be explained by a stronger influence of organic cations 
combined with L-proline moiety as anion. Another relevant observation, all proline salts 
combined with methylimidazolium cations showed lower optical rotations (8b, 8c and 8d with 
values between -5.3 to -8.8º) except 8e (-19.0º) comparing with phosphonium and ammonium 
cations. The presence of H-2 acidic proton from methylimidazolium cation can interact strongly 
with proline anion comparing with [C2OHDmim] cation where the acidic proton is replaced by 
methyl group. Compounds 7e and 7f were developed with the idea of introducing chirality on 
both cation and anion units, showed the highest optical rotation values -44.0±2° for D and 
+66.0±2° for L enantiomers respectively (lit. -21.0º for D-camphorsulfonic acid and +19.9º for 
L-camphorsulfonic acid, c=2 in H2O). 
 
Density measurements were performed by the use of pycnometer at 25 ºC. The higher density 
values were obtained for CILs 7a, 7b and 8e, because of the presence of NTf2 or AOT anion 
and the imidazolium cation, respectively. In the presence of ammonium or phosphonium 
cations, expected density values lower than 1 g.cm
-3
 were also observed. Obviously the ILs 
densities decrease with the increase of substituents chain lengths. This fact can be attributed to 
the increased number of interstices between ions caused by the more bulky cations, which 
 Development of novel ionic liquids based on biological molecules 
62 
 
cannot pack closely with the anion. In fact, the density of many substances is compared to the 
density of water. These new CILs with significant difference in density value could be applied 
for biphasic systems using water (The denser ILs can be found on the bottom while the densest 
ILs are upper from water phase). 
 
The same solubility behaviour studies and results, as previously described in chapter II, were 
performed for all L-proline based salts. The CILs were miscible with water, methanol, acetone, 
and other more polar organic solvents and immiscible with diethyl ether and other apolar 
organic solvents. The combination of proline derivative with more hydrophobic counter-ions 
can strongly influence the final water solubility profile, as already mentioned in the case of 
cysteine based ILs. Overall, it is possible to improve the neutral proline solubility by a simple 
combination with the appropriate counter-ions. This fact can be appropriate for the applications 
of L-proline as organocatalyst in asymmetric synthesis using alternative solvent mixtures. 
 
III.4. Thermal properties of novel L-proline based salts 
 
It is known that ILs are defined as organic salts with low melting points. Many of them have 
been broadly applied as liquid materials such as electrolytes, phase-transfer reagents, 
surfactants, fungicides and biocides
5
. 
 
Commercial L-proline, 6, as a crystalline solid with higher melting temperature (Tm=228 ºC, 
decomposes), can be transformed in amorphous salts by simple change in the counter-ions 
types. It is important to emphasize that melting points obtained as proline based salts were 
lower than the ones from the comercial available compound (from 198 ºC to 154 ºC in the case 
of (-) CSA and 196-200 ºC to 155-160 ºC for (+) CSA), according to the special cation-anion 
combination. The melting point of the salt decreases according with weaker coulombic 
interactions and efficient distribution of charge on the cation.  
 
The thermal properties of twelve ILs were investigated, in particular their characteristic glass 
transition temperature (Tg) values, using a differential scanning calorimetry (DSC) analysis by 
heating/cooling rate of 10 ºC.min
-1
.  
 
Table III.2 summarizes the physical state, melting temperature (Tm) and glass transition 
temperature (Tg) for the series of selected salts. The DSC analysis showed that for most of the 
novel compounds, cooling from the liquid state caused glass formation at low temperatures 
except in the case of [ProNH2][SAC], 7d, [ProNH2][D-CSA], 7e, and [ProNH2][L-CSA], 7f. 
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Similar values of glass transition temperatures were detected for most proline salts (-61.88 ºC to 
-83.00 ºC), except in the case of [C2OHmim][ProCO2], 8d, [C2OHDmim][ProCO2], 8e, and 
[ProNH2][SAC], 7d. As expected for [Emim] and [C3Omim] cations, low glass transition 
temperatures were recorded in the typical region between -77.57 and -83.00. Figures III.7 and 
III.8 present the DSC curves of [ProNH2][NTf2], 7a, where proline moiety was used as the 
cationic unit and [Emim][ProCO2], 8b, with the proline as anion in a cooling and heating cycle. 
 
Decomposition temperatures (Tdec) were analysed by TGA analysis for some of the synthesized 
compounds. As expected, these studies indicated that the selection of the organic cation 
influences the thermal stability of CILs based on L-proline. [P6,6,6,14][ProCO2] presented higher 
thermal stability than those based on imidazolium cations. All proline based salts showed 
significantly higher decomposition temperatures (258 to 299ºC) than original L-proline (238.60 
ºC). 
 
Table III.2 Thermal Properties (Tm, Tdec and Tg) of ILs based on L-proline. 
CIL
 
 
Physical state Tg [ºC]
[a] 
(Tm) 
Tdec [ºC]
[b]
 
L-Pro 6 white powder (228 dec.) 238.60 
[ProNH2] [NTf2] 7a yellow liquid -77.67 287.10 
[ProNH2] [AOT] 7b yellow liquid -61.88 258.40 
[ProNH2] [TsO] 7c yellow liquid -25.07 273.90 
[ProNH2] [SAC] 7d white liquid -- 
[c]
 299.50 
[ProNH2] [(-)CSA] 7e white solid 
 
--
[c] 
(154)
[d]
 
292.90 
[ProNH2] [(+)CSA] 7f white solid 
 
-- 
[c]
 
(160)
[d]
 
292.30 
[P6,6,6,14] [ProCO2] 8a orange liquid -74.40 290.10 
[Emim] [ProCO2] 8b orange liquid -77.57 247.80 
[C3Omim] [ProCO2] 8c orange liquid -83.00 256.30 
[C2OHmim] [ProCO2] 8d yellow liquid -52.60 270.40 
[C2OHDmim] [ProCO2] 8e yellow liquid -40.30 277.50 
[Choline] [ProCO2] 8f brown liquid -79.85 
[e]
 
[a]
 Glass transition temperature (Tg) was determined by DSC measurements at a heating/cooling rate of 10 ºC.min
-1
 for all 
salts. 
[b] 
Decomposition temperature (Tdec) was determined by TGA studies.
 [c] 
Not observed by DSC studies.
 [d] 
Melting 
temperature was determined on Electrothermal Melting Point Apparatus.
 [e] 
Not determined. 
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Figure III.7- DSC curve of [ProNH2][NTf2] (7a) in a heating cycle. 
 
 
 
 
Figure III.8- DSC curve of [Emim][ProCO2] 8b in a heating cycle. 
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III.5. Rheology studies of novel L-proline based salts 
 
The behavior of a fluid in a flow is very much correlated to two of its intrinsic characteristics: 
density and viscosity. The second is one of the most important physical properties of a liquid 
system. Measurements of viscosity have been performed on protein, polystyrene, pineapple 
juice, vegetable oil and dark beer among other (bio)materials 
130
. Viscosity changes upon shear 
rate, pressure, moisture, and concentration and all these changes can be described by equations. 
Viscosity decreases with increasing temperature and the relationship is normally fitted by 
Arrhenius-type relationship that is shown below: 
 
      
      Eq. III.1 
 
where η is dynamic viscosity (Pa.s); A is the pre-exponential factor (Pa.s); Ea is the exponential 
constant known as activation energy (J.mol
-1
); R is the gas constant (J.(mol/K)
-1
) and T is the 
absolute temperature (in Kelvin). The value of A can be described as the infinite-temperature 
viscosity   , which is strict in the limit of infinite temperature. Therefore, equation III.1 can be 
composed in the following form: 
 
       
      Eq. III.2 
 
Newtonian´s law of viscosity defines the relationship between the shear stress and the shear rate 
of a fluid subjected to a mechanical stress. The ratio of share stress to share rate is a constant for 
a given temperature and pressure and it is defined as the viscosity or coefficient of viscosity. 
 
In these terms, viscosity distinguishes two broad classes of fluids: Newtonian and non-
Newtonian. Newtonian fluids have a constant viscosity despite of the strain rate (Figure III.9). 
Low-molecular-weight pure liquids are examples of Newtonian fluids. Non-Newtonian fluids 
do not have a constant viscosity and they will moreover thicken or thin when strain is applied. 
ILs are much more viscous than common solvents and commonly classified as Newtonian 
fluids. 
 
In this part of work, we are interested in the study of Newtonian behaviour of some novel 
proline-based ILs, to model the changes in viscosity as a function of temperature, followed by 
the calculation of activation energy. In this context, several types of CILs derived from L-
proline including [P6,6,6,14][ProCO2], 8a, [C3Omim][ProCO2], 8c, [C2OHmim][ProCO2], 8d, and 
[C2OHDmim][ProCO2], 8e, were chosen for the viscosity studies using a rotational 
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viscosimeter. This method could potentially give us information regarding the Newtonian 
behavior of the developed ILs. In the first step, all selected chiral RTILs were tested in order to 
evaluate if they follow the Newtonian´s law. The profile of strain versus shear rate indicates that 
these CILs show a Newtonian fluid behavior. Although the viscosity changes with temperature, 
it does not change with the shear rate. So, at a given temperature, the viscosity of a Newtonian 
fluid remains constant regardless of which viscosimeter model, spindle or speed is used to 
measure it (Figure III.10). 
 
Figure III.9- Viscosity, the slope of each line, varies among materials. 
 
 
Figure III.10 - Studies on the Newtonian behaviour of CILs derived from L-proline. 
Development of novel ionic liquids based on biological molecules 
 
L
-p
ro
li
n
e 
b
as
ed
 i
o
n
ic
 l
iq
u
id
s 
67 
L
-p
ro
li
n
e 
b
as
ed
 i
o
n
ic
 l
iq
u
id
s 
67 
Table III.3 summarizes the viscosity values of L-proline based salts at room temperature. The 
viscosities of these CILs vary between 0.275 to 2.971 Pa.s depending on the cation species. 
[C3Omim][ProCO2], 8c, showed the lowest viscosity value (0.275 Pa.s) while 
[C2OHDmim][ProCO2] indicated us a very viscous fluid at room temperature. Comparison of 
imidazolium based ILs followed a sequence [C3Omim] < [C2OHmim] < [C2OHDmim]. As 
described in the literature, the overall contribution of the strong electrostatic terms to the 
interactions diminuishes with an increase in the side-chain length
5
. Nevertheless, the 
contribution of weaker, non-associating, dispertion forces also improves the viscosity. 
Therefore, viscosity enhances with an increase on the size of the non-polar part of the cation. 
Also, the terminal hydroxy group of the cation might contribute to strong inter-molecular 
hydrogen bonding, explaining higher viscosity values. The water content according to the 
choice of counterions was also not without significance. 
 
In the second part of the rheology studies, the relation between temperature and viscosity was 
monitored. In this context, studies related with viscosity variation as a function of temperature 
were performed. A temperature controller (temperature accuracy of ±1 ºC) was used to increase 
(heating studies) and decrease (cooling studies) the temperature of the CILs samples from 25 ºC 
(298.15 K) to 80 ºC (353.15 K) and from 80 ºC back to 25 ºC with an increment of 0.5 ºC. The 
results are shown in Figures III.11 and III.12. As expected, the viscosity decreases with the 
increase of temperature. This kind of information could be important for our future work on 
optimization of the conditions for asymmetric catalysis using proline-based salts as catalysts. 
The activation energy of viscous fluids (Ea), was obtained by fitting the viscosity temperature 
dependence in the Arrhenius equation, for all ILs tested. Results collected in the case of 
[C2OHDmim][ProCO2], 8d, are presented in Figures III.13 and III.14. Activation energies vary 
from 46 to 77 kJ.mol
-1 
at 25 until 80 ºC (with accuracies of R
2 
> 0.990 for all individual plots, 
except in case of 8c in heating process). Ea values depend on the structure of the cation and 
anion (Table III.3). 
 
In general, rheological relationships contributed for a better understanding of the fluids aimed in 
these studies, in terms of either knowing their behaviour or force them to behave according to 
the required. 
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Table III.3- Parameters of Arrhenius plots calculated for CILs derived from L-proline. 
CIL Viscosity  
(25ºC) 
[Pa.s] 
Heating Cooling 
Ea 
[kJ/mol] 
R
2
- 
squared 
value
 
Ea 
[kJ/mol] 
R
2
- 
squared 
value
 
 
[P6,6,6,14][ProCO2] 8a 0.312 47 0.992 46 0.999 
[C3Omim][ProCO2] 8c 0.275 54 0.771 57 0.999 
[C2OHmim][ProCO2] 8d 0.558 56 0.990 63 0.999 
[C2OHDmim][ProCO2] 8e 2.971 75 0.999 77 0.999 
 
 
Figure III.11 - Viscosity of proline based salts as a function of temperature at heating studies. 
 
 
 
Figure III.12 -Viscosity of proline based salts as a function of temperature at cooling studies. 
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Figure III.13 - Scheme developed for [C2OHmim][ProCO2] 8d in order to calculate the activation 
energy (Ea) and the R squared values during heating. 
 
 
 
 
Figure III.14 -Scheme developed for [C2OHmim][ProCO2] 8d in order to calculate the activation 
energy (Ea) and the R squared values during cooling. 
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III.6. Proline based CILs for asymmetric Michael Addition 
 
The purpose of this new family of CILs, after its detailed characterization, is related with the 
evaluation of their potential as catalysts in asymmetric reactions. In contrast to cysteine-based 
CILs which were tested in asymmetric aldol reactions, as presented in chapter II, proline salts 
were examinated in another important carbon-carbon bond forming reaction: asymmetric 
Michael reaction.  
 
Since the Michael addition of ketone (Michael donor) to nitroalkenes (Michael acceptor) 
catalyzed by L-proline upraised, many research groups have been concentrated on development 
of more efficient and selective catalytic systems using CILs derived from natural acids for this 
functional transformation. The advantage of using proline as a nucleophile with carbonyl groups 
or Michael acceptors to form iminium ions or enamines is related with its enhanced 
nucleophilicity comparing with other amino acids due to its secondary amine functionality and 
higher pKa value
131
.  
 
In general, the Michael donor can be catalytically activated either through enamine or enolate 
formation for the addition to a Michael acceptor (Scheme III.4, paths a and b). There is also the 
possibility for carbonyl-derived Michael acceptors to be activated via formation of an iminium 
species (Scheme III.4, path c)
132
.  
 
Scheme III.4 –Enamine-, Enolate-, and Iminium- Catalytic Michael Reaction, where 
EWG=electron withdrawing group
132
. 
 
The enamine-catalytic Michael addition of carbon nucleophiles to nitroalkenes is a useful 
synthetic method for the preparation of γ- nitrocarbonyl compounds due to its possible 
transformations, for example to pyrrolidines, aminocarbonyl compounds or aminoalkanes. 
Enamines can be formed reversibly from amines and carbonyl compounds and used as 
intermediates in a catalytic cycle (Scheme III.5). Similar to the well-studied reactions of 
preformed enamines, further reaction with an acceptor leads to the final Michael adduct. 
Interestingly, hydrolysis with in situ-generated water liberates the product and restores the 
catalyst. 
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Scheme III.5 - Enamine-Catalyzed Michael Reaction. 
 
Common strategies often include the need of strongly acidic additives to obtain a protonated 
ammonium moiety as essential H-bonding unit, which is characteristic for enamine-based 
organocatalysis
133
 . Toxic and corrosive trifluoroacetic acid or other strong acids have to be 
added to observe high diastereo- and enantioselectivities, and therefore the development of 
novel effective catalysts is still desired. This new set of CILs based on L-proline was 
specifically designed to replace trifluoroacetic acid in enamine-based organocatalysis for 
asymmetric C-C bond formation. Based on their permanent charge, these CILs could be applied 
as organocatalysts in asymmetric Michael addition of cyclohexanone to trans-nitrostyrene and 
good conversions and selectivities up to 97 % ee were obtained without additional acid. The 
model reaction was promoted by using a chiral catalyst in a range of loading between 10-90 
mol%. Ethanol or different ILs were tested as possible reaction media. Table III.4 summarizes 
the different conversions, trans-cis ratios and enantiomeric excesses of tested asymmetric 
Michael reactions. The stereoselectivities can be explained by a probable transition model 
proposed originally by Seebach and Golinski as shown in Figure III.15
134
. In this hipothesis, the 
pyrrolidine scaffold of the catalyst reacts with cyclohexanone to form a nucleophilic enamine 
and the carbonyl oxygen directs the nitro group through hydrogen bonding to organize a 
favorable TS.  
 
The partially positive nitrogen of the enamine and the partially negative nitro group should be 
situated close to each other, due to favorable electrostatic interactions. An intermolecular 
hydrogen bond between the carboxylic acid moiety and the nitro group was assumed to further 
fix the conformation. 
 
The attack of this enamine on the re-face of the nitrostyrene leads to the formation of the 
observed major enantiomer of the syn diastereomer. The formation of a cyclic intermediate 
might also help to explain why the diastereoisomeric ratios are so high. 
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Figure III.15 - Proposed ionic liquid strategy for acid replacement based on the example of the 
common organocatalyst (L)-1-[(pyrrolidin-2-yl)methyl]pyrrolidin. 
 
The initial investigation using ethanol as well as ILs as reaction media confirmed that well-
known L-proline is an effective organocatalyst for asymmetric Michael addition yielding high 
enantioselectivities between 87 to higher than 99% (Table III.4, Entries 1-6).  
 
The corresponding catalytic and enantioselective activities varied significantly with different 
ILs structures. In general, it was observed that better results could be obtained when L-proline 
moiety was used as the anionic unit. This fact confirms the importance of keeping the amine 
group not protonated (not modificated). At the same time, ionic and highly polar nature of the 
imidazolium cation may also contribute in the TS. Interestingly, Wang and his group tested the 
asymmetric version of Michael addition of cyclohexanone with chalcone using 
[Emim][ProCO2] in similar conditions and obtained dr: 15:85 and 69% of ee
135
. In our studies 
different imidazolium based CILs such as [Emim] 8b, [C3Omim] 8c, [C2OHmim] 8d, and 
[C2OHDmim] 8e, combined with the L-proline scaffold, allowed to obtain the desired product 
with moderate to high enantioselectivity, up to 94 % in the case of 8b (Table III.4, Entries 20 
and 21). Incorporation of a protic group in the side chain of the cation, as in 8d and 8e, led to a 
decrease in both the catalytic activity and selectivity (Table III.4, Entries 27 and 28). The use of 
biocompatible [Choline] cation 8f, combined with the proline anion resulted in a significant 
increase of stereoselectivity to 97 %, comparing with other cations tested.  
 
However, when the L-proline scaffold was used as cationic unit its catalytic ability drop 
drastically. Conversion values vary between 19 to 56% and 53-59% ee. 
 
Taking in mind that ILs have been extensively tested as alternative and recyclable solvents for 
many catalytic and non-catalytic organic transformations, [Emim][EtSO4] and [Bmim][DCA] as 
selected reaction media were also used. The replace of ethanol to these ILs provided with high 
enhanced on both the activities and selectivities in most of the cases. Particulary, it was possible 
to improve the conversion up to 100 %, ee and dr values, when docusate [AOT] and [NTf2] 
were chosen as counter-ions (from 55 % to 65 % ee for 7b, and from 58 % to 96 % ee for 7a). 
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In general, the use of [Bmim][DCA] as alternative solvent showed better results when 
comparing with [Emim][EtSO4]. 
 
The aim of this subsection is related with the the possibility to apply new developed L-proline 
based salts as asymmetric catalysts for Michael reaction. Functionalized CILs tested in this 
work showed comparable performance with previously reported chiral pyrrolidine catalysis in 
EtOH or ILs as reaction media. For example, only 30 mol% of L-proline based CILs without 
any additive was required to catalyze cyclohexanone addition to nitrostyrene in ILs with 100% 
conversion after 90 h (d.r.=91:9 and 97% ee for the syn diastereomer). 
 
After the optimization of catalytic reaction conditions, further efforts to study several 
nitroalkenes in the presence of cyclohexanone should be performed, in order to emphatisize the 
potential of these novel CILs based on L-proline for asymmetric Michael reaction. 
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Table III.4- Michael addition reaction of cyclohexanone to trans-nitrostyrene catalyzed by CILs 
based on L-proline. 
 
Entry Catalyst Loading of 
catalyst 
[mol%] 
Solvent Conversion 
[%] 
dr (syn: 
anti)
 [d] 
ee 
[%]
[e]
 
1
[a]
 L-PRO 6 10 EtOH 98 95:5 94 
2
[a]
 L-PRO 6  30 EtOH 100 93:7 94 
3
[b]
 L-PRO 6  30 EtOH 100 90:10 >99 
4
[b]
 L-PRO 6  30 [Emim][EtSO4] 100 90:10 87 
5
[b]
 L-PRO 6  30 [Bmim][DCA] 100 93:7 96 
6
[c]
 L-PRO 6 60 EtOH 100 91:9 96 
7
[c]
 [ProNH2] [Cl] 7 30 EtOH 50 85:15 53 
8
[c]
 [ProNH2] [TsO] 7c 30 EtOH 50 75:25 n.d.
[f] 
9
[b]
 [ProNH2] [AOT] 7b 30 EtOH 19 73:27 55 
10
[c]
 [ProNH2] [AOT] 7b 30 [Emim][EtSO4] 92 78:22 n.d.
[f] 
11
[c]
 [ProNH2] [AOT] 7b 30 [Bmim][DCA] 100 90:10 65 
12
[c]
 [ProNH2] [AOT] 7b 60 EtOH 50 82:18 59 
13
[c]
 [ProNH2] [NTf2] 7a 30 EtOH 34 80:20 58 
14
[c]
 [ProNH2] [NTf2] 7a 30 [Emim][EtSO4] 92 64:36 n.d.
[f] 
15
[c]
 [ProNH2] [NTf2] 7a 30 [Bmim][DCA] 100 91:9 96 
16
[c]
 [ProNH2] [(+)CSA] 7f 30 EtOH 56 67:33 n.d.
[f] 
17
[c]
 [Na] [ProCO2] 8 30 EtOH 100 78:22 73 
18
[c]
 [P6,6,6,14] [ProCO2] 8a 30 EtOH 100 83:17 69 
19
[c]
 [Emim] [ProCO2] 8b 30 EtOH 100 86:14 78 
20
[c]
 [Emim] [ProCO2] 8b 30 [Emim][EtSO4] 100 94:6 94 
21
[c]
 [Emim] [ProCO2] 8b 30 [Bmim][DCA] 100 92:8 94 
22
[c]
 [Emim] [ProCO2] 8b 60 EtOH 100 69:31 81 
23
[a]
 [C3Omim] [ProCO2] 8c 30 EtOH 100 72:28 74 
24
[c]
 [C3Omim] [ProCO2] 8c 60 [Emim][EtSO4] 100 74:26 76 
25
[c]
 [C3Omim] [ProCO2] 8c 90 [Emim][EtSO4] 100 75:25 83 
26
[c]
 [C3Omim] [ProCO2] 8c 30 EtOH 100 75:25 93 
27
[c]
 [C2OHmim] [ProCO2] 8d 30 EtOH 100 70:30 62 
28
[c]
 [C2OHDmim][ProCO2] 8e 30 EtOH 100 65:35 55 
29
[c]
 [Choline] [ProCO2] 8f 30 [Emim][EtSO4] 100 91:9 95 
30
[c]
 [Choline] [ProCO2] 8f 30 [Bmim][DCA] 100 91:9 97 
[a]
 Reaction time: 48 h. 
[b]
 Reaction time: 66 h. 
[c]
 Reaction time: 90 h. 
[d]
 The trans-cis ratios were determined from 400.13 
MHz 
1
H NMR spectroscopy. 
[e]
 Determined by HPLC using Phenomenex Lux 5 um 250x10 cellulose column, flow 
1ml.min
-1
, 25 ºC column oven, hexane: i-PrOH 90:10, λ=230nm. 
[f]
 Not determined. 
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III.6.1. Extraction of Michael adduct with supercritical carbon dioxide 
(scCO2) 
 
In the previous subchapter, studies on the optimization of asymmetric Michael addition using L-
proline based CILs as organocatalysts were presented. Despite the high activities and 
selectivities, some limitations were observed during the isolation process of the chiral product. 
Following the purification methods reported in the literature, extractions with different organic 
solvents as n-hexane, diethyl ether (Et2O) or methyl tert-butyl ether (MTBE) were tested. In non 
of those cases was possible to separate efficiently the desired Michael product from the CILs 
because of the good solubility of novel CILs in a large range of solvents. 
1
H NMR spectroscopy 
studies confirmed that some of the collected samples after simple extraction with organic 
solvents were still contaminated with CILs.Therefore, further purification of the resulting 
residue by flash column chromatography using ethyl acetate/hexane (1:2) allowed a pure 
isolation of the chiral products. Additionally, the reuse of chiral catalyst and IL reaction media 
was not possible using organic solvent extraction method. In this context the possibility to use 
supercritical carbon dioxide (scCO2) as a more sustainable and efficient extraction and recycle 
methodology can be relevant.  
 
Supercritical carbon dioxide (scCO2) is a fluid state of carbon dioxide where it is held at or 
above its critical temperature and critical pressure as shown in Figure III.17
136
. According to its 
role in chemical extraction, in addition to its low toxicity and environmental impact, scCO2 is 
becoming a significant commercial and industrial green solvent
137,138
. The quite low temperature 
of the process and the stability of CO2 also allow most compounds to be extracted with little 
damage or denaturing. In addition, the solubility of many extracted compounds in CO2 differs 
with pressure, permitting selective extractions
136
. 
 
Figure III.16 - Carbon dioxide pressure-temperature phase diagram
132
. 
 
As long as ILs are not soluble in scCO2, there is a possibility to extract our Michael product 
from the reaction mixture. Therefore, advanced methods for separation and purification of 
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Michael adduct from ILs, by using scCO2 as a co-solvent have been performed in collaboration 
with Prof. M. N. Ponte and co-workers (PhD student Małgorzata Zakrzewska). The scCO2 
extraction was carried out in the apparatus described in Scheme III.5. The model reaction was 
carried out using cyclohexanone and nitrostyrene, [Emim][ProCO2] as asymmetric catalyst and 
[Emim][EtSO4] as solvent. 
 
 
Scheme III.6 - General scheme of the extraction of chiral Michael product using scCO2. 
 
Some preliminary optimization of the conditions for extraction with scCO2 has been studied. 
Using 
1
H NMR spectroscopy, it was concluded that the initial tests failed due to the presentce of 
small amout of ILs impurities (8-16%). During the extraction experiments, different parameters 
such as extraction time, pressure, temperature, amount of scCO2 and speed of bubbling were 
changed in order not only to separate the 2-((R)-nitro-1-phenyl)cyclohexanone from the reaction 
mixture, but also to obtain the products with high yields. It was proved by 
1
H NMR that the 
spectrum of the final product is pure and no peaks of ILs were detected as presented in Figure 
III.17. Nevertheless, further improvements of final Michael adduct yields and the reusability of 
the catalyst to perform more cycles are in progress in our laboratory in collaboration with Prof. 
M. N. Ponte group. 
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Figure III.17 - 
1
H NMR spectra of Michael adduct extrated with scCO2 (pure product up, mixture 
of product and catalyst down). 
 
III.7. Other efforts related with synthesis attempts 
 
Among those twelve CILs derived from L-proline successfully synthesized, characterized and 
applied for asymmetric organocatalysis, there were other attempts to develop new CILs based 
on L-proline scaffold as the cation combined with different anions, such as ascorbic [vitC] and 
dicyanamide [DCA] (Figure III.18). Studies on the protonation of L-proline amino group using 
acids stronger than hydrochloridic acid, as mesylic and weaker, as glucolic acids, were also 
performed. All these efforts related with the synthesis resulted in failures. To understand and 
explain the reason of the methodology failure, more attention should be payed to the section of 
protic ILs. They are formed simply by proton transfer from pure Brønsted acid to pure Brønsted 
base. The presence of a variable proton activity is its special characteristic that makes them 
more conductive than in the aprotic cases. In fact, by taking advantage of these features, some 
of the most conductive liquids ever known have been obtained
139
.  
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Figure III.18 - Structures of counter-ions tried for synthesis of L-proline based salts. 
 
According to the information available in the literature, is understandably possible to develop 
salts based on L-proline as the anion because there isn´t a pKa problem. The amino group stays 
unchanged while the carboxylic acid group gets deprotonated. Nevertheless, in the case of ILs 
derived from L-proline used as cation, the protonation of amino group must be achieved in 
order to check protic ionic liquids based on L-proline scaffold. In some cases the conter-ions 
were not strong enough to keep the positive charge on -NH2 group of L-proline. Low pKa values 
in comparison with those from L-proline (pKa=10.96 for α-amino group) proved that a stronger 
acid is needed to obtain a stable salt and those anions used weren´t enough acidic. 
 
Due to the fact that sulfonates are good anionic scaffolds to maintain the positive charge on the 
cation, studies on the protonation of L-proline by mesylic acid were performed. All our attempts 
to use this protonation method failed. Tests on the optimization of conditions for the synthesis 
were carried out. Different parameters have been changed during the studies such as time (1-24 
hours), substrates proportion and the molarity of the fresh prepared solution of mesylic acid 
(methanesulfonic acid) in methanol variating from 0.05-1M CH3SO3H/MeOH. 
1
H NMR spectra 
proved that the final compound was either a mixture of both forms, the neutral and the ionic 
(unfinished protonation), or a big excess of acid (the presence of a mixture of mesylate anion 
and the acid form). Unfortunatelly, non of our attempts allow the desired proportion of L-
proline mesylate, 7g, to be obtained. 
 
Another approach was foccused in the protonation of amino acid moiety with gluconic acid, 7h, 
which also failed. The 
1
H NMR studies showed that the protonation wasn´t completed because 
of the weakness of the gluconic acid. Furthermore, it was also difficult to distinguish the peaks 
from both cation and anion because they overlaped on the NMR spectrum. Neverless, both of 
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these compounds 7g and 7h should be possible to obtain with a more precise control of the 
addition step.  
 
According to the design of proline-camphorsusfonates (7e and 7f), the proposal of proline 
ascorbate, 8g, as another possible example of proline salt with chirality on both cation and anion 
was studied. In contrast to 7e and 7f, not good results were obtained. Our first attempt was to 
protonate the NH group of L-proline in order to create proline hydrochloride, followed by a 
simple ion exchange reaction using sodium ascorbate. Due to the poor solubility of sodium 
ascorbate in many common solvents, including methanol, water was selected as reaction media 
but no reaction occurred. In the case of [Pro][DCA], 8h, after finishing the protonation of L-
proline, the isolated proline hydrochloride reacted with sodium dicyanamide Na[DCA] in anion 
exchange reaction using methanol as solvent. Problems associated with purification of the final 
salt limited its characterization and future application.  
 
III.8. Conclusions 
 
A series of novel CILs have been prepared using L-proline, a naturally-derived and inexpensive 
material, as cation or anion. As expected according with counter ion type is possible to tune the 
physical, chemical and thermal properties of different CILs based on L-proline. The class of 
Amino Acids (AAs) again confirmed to be a good model to study the relation between ion 
structure and properties and significant in the designing of novel task-specific ILs. It was 
demonstrated that by using the simple ion exchange reaction and the alternative ion exchange 
resin method, it was possible to obtain the required CILs in good yields and purities. Properties 
like optical rotation, glass transition and decomposition temperatures (Tg, Tdec), density and 
viscosity of some bioinspired ionic liquids (Bio-ILs) were studied. In most of the cases glass 
transition temperatures were detected in contrast with initial crystalline L-proline. The 
objectives of the rheology studies were related with the Newtonian behaviour of the liquids, the 
relation between viscosity and activation energy (Ea) and reliable indicator of the viscosity – 
temperature stability of CILs from the comparison of the Ea and the experimental data. It was 
proved that Ea depends on the structure, the combination cation anion of the prepared salt and 
varies between 46 kJ.mol
-1
 and 77 kJ.mol
-1 
at 25 – 80 ºC with accuracies of R
2 
> 0.990 for 
individual plots. 
 
L-proline based salts showed potential to be used as organocatalyst for asymmetric Michael 
reaction. Cyclohexanone could react with trans-nitrostyrene to afford Michael adducts with 
100% of conversion and moderate to good enantioselectivities (53–94% ee), particular in the 
 Development of novel ionic liquids based on biological molecules 
80 
 
presente of [Emim][ProCO2], 8b, [C3Omim][ProCO2], 8c, [C2OHmim][ProCO2], 8d, and 
[Choline][ProCO2], 8f. The precise design and selection of the cation (e.g., imidazole, choline) 
and anion scaffold of amino acid might lead to enhance levels of activity and selectivity. In 
addition, recovery of the product out of the CILs and ILs using scCO2 was studied 
experimentally. The extracted product was found to contain no detectible amount of ILs. 
 
While the Bio-ILs developed are potential candidates as environmentally-benign and low-
toxicity ILs, further research on their preparation method and toxicology should be addressed. 
III.9. Experimental Part 
 
General: Commercially available reagents L-proline (MW= 115.13 g.mol
-1
, CAS No. 147-85-
3), ionic liquids and solvents were purchased from Alfa Aestar, Aldrich, Solchemar and were 
used without further purification. The basic anion-exchange resin Amberlite IRA-400-OH (ion-
exchange capacity 1.4 eq.mL
-1
) was purchased from Supelco. 
 1
H and 
13
C NMR spectra were 
recorded at 25 [ºC] on a Bruker AMX400 spectrometer with TMS as internal standard. 
Chemical shifts are reported downfield in ppm. IR spectra were performed by Perkin Elmer 
model Spectrum 1000 using NaCl plates for neat liquids. DSC analysis was carried out using a 
TA Instruments Q-seriesTM Q200 DSC with a refrigerated cooling system. The samples for 
elemental analysis were performed by Laboratório de Análises at REQUIMTE, Departamento 
de Química Faculdade de Ciências e Tecnologia (Monte da Caparica) using Thermo Finnigan-
CE Instruments equipment, model Elemental Analyser 1112 series. Density measurements were 
performed with the use of pycnometer at room temperature (25 ºC). Optical rotations were 
recorded on a Perkin Elmer 241MC. The melting point (mp) was determined by Electrothermal 
Melting Point Apparatus. The decomposition temperatures were measured with the 
Simultaneous Thermal Analyser STA 449 F3 Jupiter, using a nitrogen atmosphere (mass 
changed in % or mg). Rheology studies were performed at Instituto Jean Piaget in Almada, 
Portugal by using a Rheometer (RS-300, Haake, Germany). Measurements were carried out 
using a controlled-stress rheometer fitted with a coneplate sensor C20/2 ºTi. The torque 
amplitude was imposed by using a logarithmic ramp of shear stress, which was increased in 30 
min intervals from 0.01 to 1000 Pa to decrease the initial acceleration and the effects due to 
instrument inertia. The temperatures of the samples were maintained at (20±0.5) ºC by means of 
a circulating water bath (DC30, Haake, Germany), and they were measured with a 
thermocouple attached to the stationary element. The temperature dependence of the viscosity 
was also studied. The ILs were heated from 20 to 70 ºC (0.5 ºC.min
-1
), using a constant shear 
stress of 5 Pa. All the measurements were performed at least twice. 
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III.9.1. Synthesis of (S)-proline hydrochloride - cationic approach (7) 
 
In the first step (S)-proline 1 (1 g; 8.69 mmol) was dissolved in 15 ml of 
methanol and 1M solution of HCl in MeOH (1:1 eq., 8.69 ml) was added 
slowly in order to protonate the amine group. The reaction mixture was 
stirred at room temperature for 24 hours. The solution was evaporated and 
dried in vacuo for ~5 hours. The (S)-proline hydrochloride 2 was obtained 
as a viscous yellow liquid (1.31 g, 100%). 
1
H NMR (400.13 MHz, D2O) δ 
4.27 (t, 
3
J H2-H3= 8Hz, 1H), 3.32 – 3.20 (m, 2H, H5, H5´), 2.32-2.27 (m, 1H, H3), 2.06-2.00 (m, 1H, 
H3´), 1.95 – 1.86 (m, 2H, H4, H4´).
13
C NMR (100.61 MHz, D2O) δ 172.12 (C6), 59.69 (C2), 46.20 
(C5), 28.31 (C4), 23.37 (C3). 
 
III.9.2. Synthesis of (S)-2-carboxypyrrolidin-1-ium 
bis((trifluoromethyl)sulfonyl)amide (7a) 
 
After the protonation was finished, the isolated L-proline 
hydrochloride (0.4 g; 2.64 mmol) was dissolved in 5ml of 
methanol and Li[NTf2] was added to perform the ion 
exchange (0.79 g; 2.77 mmol). The reaction was stirred for 
24 hours at room temperature. Acetone was added in order to 
remove the inorganic salts by precipitation. The solution was 
evaporated and dried in vacuo for 8 hours. The desired product was obtained as a viscous 
yellow liquid (0.94 g, 90%). Tg= -77.67 
o
C; [α]D= -12.7±2º (c= 1 mg.mL
-1
 in MeOH); 
1
H NMR 
(400.13 MHz, D2O) δ 4.27 (t, 
3
J H2-H3= 8Hz, 1H), 3.38 – 3.25 (m, 2H, H5, H5´), 2.38-2.278 (m, 
1H, H3), 2.13-2.02 (m, 1H, H3´), 1.99 – 1.92 (m, 2H, H4, H4´).
13
C NMR (100.61 MHz, D2O) δ 
172.12 (C6), 120.79 (Ca) 59.69 (C2), 46.20 (C5), 28.31 (C4), 23.37 (C3). 
19
F NMR (376 MHz, 
DMSO) δ -79.19. FTIR (NaCl) ʋ = 3414, 2362, 2345, 2067, 1638, 1350, 1199, 1133, 1056, 793, 
766, 743, 666 cm
-1
. Elemental analysis (%) calcd for C7H10F6N2O6S2 (MW= 396.28g.mol
-1
): C 
21.22, H 2.54, N 7.07, S 15.48; found: C 21.12, H 2.52, N 7.04, S 15.4. 
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III.9.3. Synthesis of (S)-2-carboxypyrrolidin-1-ium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (7b) 
 
The protonated L-proline (0.5 g; 
3.30 mmol) was dissolved in 5ml 
of methanol and sodium docusate 
Na[AOT] was added to perform the 
ion exchange (1.76 g; 1.96 mmol). 
The reaction was stirred for 24 
hours at room temperature. Then the solvent was evaporated and the crude was redissolved in 
acetone in order to remove the inorganic salts by precipitation. The solution was evaporated and 
dried in vacuo for 8 hours. The desired product was obtained as a viscous yellow liquid (1.73 g, 
97%). Tg= -61.88 
o
C; [α]D= -12.0±2º (c= 1 mg.mL
-1
 in MeOH); 
1
H NMR (400.13 MHz, DMSO) 
δ 4.26 (t, 
3
JH2-H3 = 8Hz, 1H, H2), 3.92 – 3.87 (m, 4H, Hf), 3.62 (dd, 
2
J Hh-Hh´= 4 Hz, 
3
J Hh´-Hg= 8 
Hz, 1H, Hh), 3.23 – 3.19 (m, 1H, H5), 2.89 (m, 1H, Hg), 2.80 (dd, 
2
J Hh´-Hh= 4 Hz, 
3
J Hh´-Hg= 8 Hz, 
1H, Hh´), 2.25 (m, 1H. H3), 2.03 – 1.82 (m, 3H, H3´, H4), 1.49 (m, 2H, Hd), 1.41 – 1.15 (m, 16H, 
Hb, Hc, He), 0.84 (m, 12H, Ha). 
13
C NMR (100.61 MHz, DMSO) δ 171.49 (C6), 170.99 (-C=O), 
168.81 (-C=O), 66.65 (Cf), 66.58 (Cf´), 61.88 (Cg), 59.42 (C2), 49.05 (C5), 45.92 (Cd), 30.20 
(C3), 30.02 (Cc), 28.80 (Cc), 28.36 (Ch), 23.62 (Ce), 23.47 (Cb), 22.86 (C4), 14.35 (Ca), 11.24 
(Ca). FTIR (NaCl) ʋ = 3450, 2960, 2932, 2874, 2861, 2362, 2343, 1736, 1638, 1508, 1460, 
1414, 1390, 1356, 1243, 1091, 1041, 855, 768, 730, 666 cm
-1
. Elemental analysis (%) calcd for 
C25H47NO9S (MW= 537.71g.mol
-1
): C 55.84, H 8.81, N 2.60; found: C 55.57, H 8.87, N 2.57. 
 
III.9.4. Synthesis of (S)-2-carboxypyrrolidin-1-ium 4-
methylbenzenesulfonate (7c) 
 
The protonated L-proline (0.30 g; 1.98 mmol) was dissolved in 5ml of methanol and p-
toluenosulfonic sodium salt Na[TsO] was added to 
perform the ion exchange (0.39 g; 2.0 mmol). The 
reaction was stirred for 24 hours at room 
temperature. Then the solvent was evaporated and 
the crude was redissolved in acetone in order to 
remove the inorganic salts by precipitation. The solution was evaporated and dried in vacuo for 
8 hours. The desired product was obtained as a viscous yellow gel (0.38 g, 66%). Tg= -25.07 
o
C; 
[α]D= -4.0±2º (c= 1 mg.mL
-1
 in MeOH); 
1
H NMR (400.13 MHz, CDCl3) δ 7.70 (d, 
3
J = 7.5 Hz, 
2H, Hb), 7.16 (d, 
3
J = 7.5 Hz, 2H, Hc), 4.48 (t, 
3
JH2-H3 =8Hz, 1H, H2), 3.43 (m, 2H, H5), 3.33 (m, 
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1H, H3), 2.34 (s, 3H. He), 2.08 (m, 1H, H3´) 1.90 (m, 2H, H4). 
13
C NMR (100.61 MHz, CDCl3) δ 
171.17 (C6), 141.01 (Ca), 140.83 (Cd), 129.07 (Cc), 125.84 (Cb), 59.76 (C2), 46.52 (C5), 28.48 
(C3), 23.51 (C4), 21.35 (Ce). FTIR (NaCl) ʋ = 3430, 2361, 2343, 2092, 1736, 1639, 1458, 1181, 
1126, 1036, 1012, 819, 750, 689, 666 cm
-1
. Elemental analysis (%) calcd for C12H17NO5S 
(MW= 287.33g.mol
-1
): C 50.16, H 5.96, N 4.87, S 11.16; found: C 50.01, H 5.98, N 4.85, S: 
11.12. 
 
III.9.5. Synthesis of (S)-2-carboxypyrrolidin-1-ium 3-oxo-3H-
benzo[d]isothiazol-2-ide 1,1-dioxide (7d) 
 
The protonated L-proline (0.5 g; 3.30 mmol) was 
dissolved in 5ml of methanol and 5ml water and 
sodium saccarin Na[SAC] was added to perform 
the ion exchange (0.82 g; 3.96 mmol). The 
reaction was stirred for 24 hours at room 
temperature. Then the solvent was evaporated and the crude was redissolved in acetone in order 
to remove the inorganic salts by precipitation. The solution was evaporated and dried in vacuo 
for 8 hours. The desired product was obtained as a viscous yellow gel (0.96 g, 98%). [α]D= -
4.5±2º (c= 1 mg.mL
-1
 in MeOH); 
1
H NMR (400.13 MHz, CDCl3) δ 7.74 (m, 4H, Ha, Hb, Hc, 
Hd), 4.65-4.62 (t, 
3
JH2-H3=8Hz, 1H), 4.47-4.44 (t, 
3
JH2-H3=8Hz, 1H, H2), 3.61- 3.46 (m, 2H, H5, 
H5´), 2.51 – 2.30 (m, 1H, H3), 2.24 – 2.13 (m, 1H, H3´), 2.10 – 1.96 (m, 2H, H4, H4´). 
13
C NMR 
(100.61 MHz, CDCl3) δ 169.86 (-C=O), 167.82 (C6), 142.36 (Ce), 133.09 (Cc), 131.54 (Cf, Cb), 
124.13 (Ca), 120.43 (Cd), 59.30 (C2), 46.30 (C5), 29.00 (C4), 24.24 (C3). FTIR (NaCl) ʋ = 3430, 
2960, 1720, 1630, 1335, 1258, 1148, 1120, 1053, 951, 758, 681 cm
-1
. Elemental analysis (%) 
calcd for C12H14N2O5S (MW= 298.31g.mol
-1
): C 48.31; H 4.73; N 9.39; S 10.75; found: C 
48.25, H4. 57, N 9.35, S: 10.80. 
 
III.9.6. Synthesis of (S)-2-carboxypyrrolidin-1-ium ((1R, 4R)-7,7-dimethyl-2-
oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate (7e) 
 
First, the (1R)-(-)-10-camphorsulfonic acid was 
transformed in a sodium salt. Then the acid (0.5 g, 2.12 
mmol) was dissolved in 15 ml of ethanol and 0.5 M 
solution of NaOH in EtOH (1 eq., 4.31ml) was added 
dropwise. The mixture was stirred overnight at room 
temperature. The final salt was isolated and used for ion 
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exchange in the second step with [ProNH2]Cl. The protonated L-proline (0.34 g; 2.24 mmol) 
was dissolved in 5 ml of methanol and camphorsulfonic acid sodium salt Na[CSA] was added 
to perform the ion exchange (0.57 g; 2.24 mmol). The reaction was stirred for 24 hours at room 
temperature Then the solvent was evaporated and the crude was redissolved in acetone in order 
to remove the inorganic salts by precipitation. The solution was evaporated and dried in vacuo 
for 8 hours. The desired product was obtained as a white solid (0.78 g, 99%); Tm= 154 [
o
C]; 
[α]D= -44.0±2º (c= 1 mg.mL
-1
 in MeOH); 
1
H NMR (400.13 MHz, D2O) δ 4.27 (t, 
3
JH2-H3=8Hz, 
1H, H2), 3.34-3.29 (m, 2H, H5), 3.17 (d, 
2
JHj-Hj´=16Hz, 1H, Hj), 2.75(d, 
2
JHj´-Hj=16Hz, 1H, Hj´), 
2.30 (m, 3H, H3,H4), 2.03-1.84 (m, 6H, H3´,Hb, He, Hk), 1.52 (m, 1H, Hc), 1.33 (m, 1H, Hc´), 
0.91 (s, 3H, Hh), 0.71 (s, 3H, Hi). 
13
C NMR (100.61 MHz, D2O) δ 210.0 (Cf), 172.19 (C6), 59.73 
(C2), 58.43 (Ca), 48.15 (Cj), 47.09 (C5), 46.18 (Ce), 42.54 (Cg), 28.35 (Cc), 26.15 (C4), 24.51 
(C3), 3.22 (Cb), 18.67 (Ch, Ci). Elemental analysis (%) calcd for C15H25NO6S (MW= 
347.43g.mol
-1
): C 51.86, H 7.25, N 4.03, S 9.23; found: C 51.70, H 7.22, N 3.99, S 9.18. 
 
III.9.7. Synthesis of (S)-2-carboxypyrrolidin-1-ium ((1S, 4R)-7,7-dimethyl-2-
oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate (7f) 
 
 First, the (1S)-(+)-10-camphorsulfonic acid was 
transformed in a sodium salt. Then the acid (0.5 g, 2.12 
mmol) was dissolved in 15ml of ethanol and 0.5M 
solution of NaOH in EtOH (1 eq., 4.31ml) was added 
dropwise. The mixture was stirred overnight at room 
temperature. The final salt was isolated and used for ion 
exchange in the second step with [ProNH2]Cl. The protonated L-proline (0.3 g; 2.24 mmol) was 
dissolved in 5ml of methanol and camphorsulfonic acid sodium salt Na[CSA] was added to 
perform the ion exchange (0.57 g; 2.24 mmol). The reaction was stirred for 24 hours at room 
temperature. Then the solvent was evaporated and the crude was redissolved in acetone in order 
to remove the inorganic salts by precipitation. The solution was evaporated and dried in vacuo 
for 8 hours. The desired product was obtained as a white solid (0.74 g, 95%); Tm= 155-160 [
o
C]; 
[α]D= +66.0±2º (c= 1 mg.mL
-1
 in MeOH); 
1
H NMR (400.13 MHz, D2O) δ 4.27 (t, 
3
JH2-H3=8Hz, 
1H, H2), 3.34-3.29 (m, 2H, H5), 3.17 (d, 
2
JHj-Hj´=16 Hz, 1H, Hj), 2.75(d, 
2
JHj´-Hj=16Hz, 1H, Hj´), 
2.30 (m, 3H, H3,H4), 2.03-1.84 (m, 6H, H3´,Hb, He, Hk), 1.52 (m, 1H, Hc), 1.33 (m, 1H, Hc´), 
0.91 (s, 3H, Hh), 0.71 (s, 3H, Hi). 
13
C NMR (100.61 MHz, D2O) δ 210.0 (Cf), 172.19 (C6), 59.73 
(C2), 58.43 (Ca), 48.15 (Cj), 47.09 (C5), 46.18 (Ce), 42.54 (Cg), 28.35 (Cc), 26.15 (C4), 24.51 
(C3), 3.22 (Cb), 18.67 (Ch, Ci). Elemental analysis (%) calcd for C15H25NO6S (MW= 347.43g 
.mol
-1
): C 51.86, H 7.25, N 4.03, S 9.23; found: C 51.80, H 7.25, N 4.00, S 9.19. 
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III.9.8. Synthesis of trihexyl(tetradecyl)phosphonium (S)-pyrrolidine-2-
carboxylate (8a) 
 
 For the preparation of trihexyl(tetradecyl)phosphonium (S)-pyrrolidine-2-carboxylate a column 
ion exchange method 
was used. The 
phosphonium chloride 
[P6,6,6,14]Cl (2.26 g; 4.34 
mmol) which was first 
transformed into 
hydroxide by the use of 
an ionic exchange 
column (Amberlite IRA-
400 OH) in methanol and 
then this basic solution was neutralized by reacting with the (S)-proline (0.5 g; 4.34 mmol) in 
methanol solution. The mixture was stirred at room temperature for 24 hours. After the 
indicated time the established water was evaporated and dried in vacuo for 8 hours. The final 
product was obtained as a viscous yellow liquid (2.52 g, 97%). Tg=-74.40 
o
C; [α]D= -17.3±2º 
(c= 1 mg.mL
-1
 in MeOH). 
1
H NMR (400.13 MHz, CDCl3) δ 3.56 (t, 
3
JH2-H3= 8Hz, 1H, H2), 3.07 
(m, 1H, H5), 2.82 (m, 1H, H5´),), 2.32 (m, 8H, Hf), 2.03 (m, 1H, H3), 1.66 (m, 1H, H3´), 1.45 (m, 
2H, H4), 1.27 (m, 16H, Hb, e), 1.26-1.20 (m, 32H, Hc,), 0.83 (m, 12H, Ha).
 13
C NMR (100.61 
MHz, CDCl3) δ 178.50 (C6), 62.49 (C2), 47.06 (C5), 31.79 (Cc), 30.99 (C3), 30.45 (Cc, Cd), 26.00 
(C4), 22.52 (Cf), 22.22 (Cb), 21.77 (Ce), 13.82 (Ca). FTIR (NaCl) ʋ = 3400, 2956, 2927, 2856, 
2361, 1586, 1458, 1414, 1310, 1268, 1214, 1173, 1112, 1044, 986, 917, 862, 820, 721, 667 cm
-
1
. Elemental analysis (%) calcd for C37H76NO2P (MW= 597.98 g.mol
-1
): C 74.32; H 12.81; N 
2.34; found: C 73.97, H 12.87, N 2.30. 
 
III.9.9. Synthesis of 1-ethyl-3-methyl-1H-imidazol-3-ium (S)-pyrrolidine-2-
carboxylate (8b) 
 
For the preparation of 1-ethyl-3-methyl-1H-
imidazol-3-ium pyrrolidine-2-carboxylate a 
column ion exchange method was used. The 1-
ethyl-3-methyl-1H-imidazol-3-ium bromide 
chloride [Emim]Br (0.83 g; 4.34 mmol) which 
was first transformed into hydroxide by the use of 
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an ionic exchange column (Amberlite IRA-400 OH) in methanol and then this basic solution 
was neutralized by reacting with the (S)-proline (0.5 g; 4.34 mmol) in methanol solution. The 
mixture was stirred at room temperature for 24 hours. After the indicated time the established 
water was evaporated and dried in vacuo for 8 hours. The final product was obtained as a 
viscous yellow liquid (1.08 g, 100%). Tg=-77.57 
o
C; [α]D= -8.8±2º (c= 1 mg.mL
-1
 in MeOH). 
1
H 
NMR (400.13 MHz, CDCl3) δ 7.28 (m, 3H, Hb, d, d´), 4.36 (q, 
3
JHe-Hf =10Hz, 2H, He), 4.05 (s, 3H, 
Hg), 3.60 (t, 
3
JH2-H3=8Hz, 1H, H2), 3.12 (m, 1H, H5), 2.83 (m, 1H, H5´), 2.13 (m, 1H, H3), 1.88 
(m, 1H, H3´), 1.66 (m, 2H, H4), 1.66 (m, 2H, H4), 1.56 (t, 
3
JHf-He= 4 ppm Hz, 3H, Hf).
 13
C NMR 
(100.61 MHz, CDCl3) δ 179.63 (C6), 122.69 (Cb), 120.73 (Cd), 62.62 (C2), 47.04 (C5), 44.99 
(Ce), 36.26 (Cg), 31.45 (C3), 26.17 (C4), 15.44 (Cf). FTIR (NaCl) ʋ = 3400, 3154, 3108, 2973, 
2876, 2361, 2343, 1578, 1390, 1171, 1092, 1032, 959, 917, 856, 766, 702, 667, 649, 623 cm
-1
. 
Elemental analysis (%) calcd for C11H19N3O2 (MW= 225.29 g.mol
-1
): C 58.64; H 8.50; N 18.65; 
found: C 58.40, H 8.53, N 18.57. 
 
III.9.10. Synthesis of 1-(2-methoxyethyl)-3-methyl-1H-imidazol-3-ium (S)- 
pyrrolidine-2-carboxylate (8c) 
 
For the preparation of 1-(2-methoxyethyl)-
3-methyl-1H-imidazol-3-ium (S)-
pyrrolidine-2-carboxylate a column ion 
exchange method was used. The 1-(2-
methoxyethyl)-3-methyl-1H-imidazol-3-
ium chloride [C3Omim]Cl (0.77 g; 4.34 mmol) which was first transformed into hydroxide by 
the use of an ionic exchange column (Amberlite IRA-400 OH) in methanol and then this basic 
solution was neutralized by reacting with the (L)-proline (0.5 g; 4.34 mmol) in methanol 
solution. The mixture was stirred at room temperature for 24 hours. After the indicated time the 
established water was evaporated and dried in vacuo for 8 hours. The final product was obtained 
as a viscous yellow liquid (0.83 g, 99%). Tg=-83 
o
C; [α]D= -5.3±2º (c= 1 mg.mL
-1
 in MeOH). 
1
H 
NMR (400.13 MHz, CDCl3) δ 7.34 (m, 1H, Hb), 7.12 (m, 2H, Hd, d´), 4.56 (t, 
3
J He-Hf= 4 Hz, 2H, 
He), 4.01 (s, 3H, Hh), 3.75 (t,
 3
J Hf-He= 4 Hz, 2H, Hf), 3.56 (t, 
3
JH2-H3=4 Hz, 1H, H2), 3.33 (s, 3H, 
Hg), 3.15 (m, 1H, H5), 2.80 (m, 1H, H5´), 2.11 (m, 1H, H3), 1.84-1.65 (m, 3H, H3´,H4). 
13
C NMR 
(100.61 MHz, CDCl3) δ 179.91 (C6), 122.84 (Cb), 121.90 (Cd), 70.62 (Cf), 62.68 (C2), 58.91 
(Cg), 49.65 (C5), 47.08 (Ce), 36.24 (Ch), 31.49 (C3), 26.21 (C4). FTIR (NaCl) ʋ = 3402, 2359, 
2341, 2136, 1622, 1574, 1428, 1353, 1311, 1171, 1118, 1081, 1035, 1013, 833, 750, 666, 623 
cm
-1
. Elemental analysis (%) calcd for C12H21N3O3 (MW= 255.31 g.mol
-1
): C 56.45; H 8.29; N 
16.46; found: C 56.18, H 8.32, N 16.38. 
Development of novel ionic liquids based on biological molecules 
 
L
-p
ro
li
n
e 
b
as
ed
 i
o
n
ic
 l
iq
u
id
s 
87 
L
-p
ro
li
n
e 
b
as
ed
 i
o
n
ic
 l
iq
u
id
s 
87 
III.9.11. Synthesis of 1-(2-hydroxyethyl)-3-methyl-1H-imidazol-3-ium (S)-
pyrrolidine-2-carboxylate (8d) 
 
For the preparation of 1-(2-hydroxyethyl)-3-
methyl-1H-imidazol-3-ium (S)-pyrrolidine-2-
carboxylate a column ion exchange method was 
used. The 1-(2-hydroxyethyl)-3-methyl-1H-
imidazol-3-ium chloride [C2OHmim]Cl (0.71 g; 
4.34 mmol) which was first transformed into 
hydroxide by the use of an ionic exchange column (Amberlite IRA-400 OH) in methanol and 
then this basic solution was neutralized by reacting with the (L)-proline (0.5 g; 4.34 mmol) in 
methanol solution. The mixture was stirred at room temperature for 24 hours. After the 
indicated time the established water was evaporated and dried in vacuo for 8 hours. The final 
product was obtained as a viscous yellow liquid (0.94 g, 80%). Tg=-52.06 
o
C; [α]D= -6.7±2º (c= 
1 mg.mL
-1
 in MeOH). 
1
H NMR (400.13 MHz, D2O) δ 7.37 (m, 3H, Hb, d, d´), 4.20 (t, 
3
J He-Hf= 4 
Hz, 2H, He), 4.01 (s, 3H, Hg), 3.79 (t,
 3
J Hf-He= 4 Hz, 2H, Hf), 3.45 (t, 
3
JH2-H3= 4 Hz, 1H, H2), 
3.33 (s, 3H, Hg), 3.15 (m, 1H, H5), 2.73 (m, 1H, H5´), 2.11 (m, 1H, H3), 1.84-1.65 (m, 3H, 
H3 ,́H4). 
13
C NMR (100.61 MHz, D2O) δ 180.85 (C6), 136.28 (Cb), 123.52 (Cd), 61.42 (C2), 
59.70 (Cf), 51.46 (C5), 45.94 (Ce), 35.61 (Cg), 30.37 (C3), 24.81 (C4). FTIR (NaCl) ʋ = 3410, 
2361, 2342, 2142, 1630, 1578, 1420, 1168, 1073, 947, 872, 751, 667, 622 cm
-1
. Elemental 
analysis (%) calcd for C11H19N3O3 (MW= 241.29 g.mol
-1
): C 54.76; H 7.94; N 17.41; found: C 
54.50, H 7.91, N 17.31. 
 
III.9.12. Synthesis of 1-(2-hydroxyethyl)-2,3-dimethyl-1H-imidazol-3-ium 
(S)-pyrrolidine-2-carboxylate (8e) 
 
For the preparation of 1-(2-hydroxyethyl)-2,3-
dimethyl-1H-imidazol-3-ium (S)-pyrrolidine-2-
carboxylate a column ion exchange method was 
used. The 1-(2-hydroxyethyl)-2,3-dimethyl-1H-
imidazol-3-ium chloride [C2OHDmim]Cl (0.76 
g; 4.34 mmol) which was first transformed into 
hydroxide by the use of an ionic exchange column (Amberlite IRA-400 OH) in methanol and 
then this basic solution was neutralized by reacting with the (L)-proline (0.5 g; 4.34 mmol) in 
methanol solution. The mixture was stirred at room temperature for 24 hours. After the 
indicated time the established water was evaporated and dried in vacuo for 8 hours. The final 
product was obtained as a viscous yellow liquid (0.82 g, 75%). Tg=-40.30 
o
C; [α]D= -19.0± 2º 
(c= 1 mg.mL
-1
 in MeOH). 
1
H NMR (400.13 MHz, D2O) δ 7.24 (m, 3H, Hb, d, d´), 4.20 (t, 
3
J He-Hf= 
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4 Hz, 2H, He), 4.01 (s, 3H, Hg), 3.79 (t,
 3
J Hf-He= 4 Hz, 2H, Hf), 3.45 (t, 
3
JH2-H3= 4 Hz, 1H, H2), 
3.33 (s, 3H, Hg), 3.15 (m, 1H, H5), 2.73 (m, 1H, H5´), 2.45 (s, 3H, Hh), 2.11 (m, 1H, H3), 1.84-
1.65 (m, 3H, H3 ,́H4). 
13
C NMR (100.61 MHz, D2O) δ 180.85 (C6), 136.28 (Cb), 123.52 (Cd), 
61.42 (C2), 59.70 (Cf), 51.46 (C5), 45.94 (Ce), 35.61 (Cg), 30.37 (C3), 24.81 (C4), 8.97 (Ch). 
FTIR (NaCl) ʋ = 3390, 2360, 2339, 2142, 1630, 1588, 1416, 1169, 1076, 872, 771, 666 cm
-
1
.Elemental analysis (%) calcd for C13H25N3O3 (MW= 271.36 g.mol
-1
): C 57.54; H 9.29; N 
15.49; found: C 57.27, H 9.26, N 15.48. 
 
III.9.13. Synthesis of 2-hydroxy-N,N,N-trimethylethanaminium (S)-
pyrrolidine-2-carboxylate (8f) 
 
For the synthesis of 2-hydroxy-N,N,N-
trimethylethanaminium (S)-pyrrolidine-2-
carboxylate a simple acid base reaction was 
performed. Primary the choline hydroxide in MeOH 
45% (0.25 g; 2.06mmol) was diluted with additional 
10ml of methanol and next added drop wise to the 
solution of (L)-proline in 20 ml methanol. The mixture was stirred at room temperature for 24 
hours. After the indicated time the established water was evaporated and dried in vacuo for 8 
hours. The final product was obtained as a viscous brown liquid (0.65 g, 100%). Tg=-79.85 
o
C; 
[α]D= -12.7±2º (c= 1 mg.mL
-1
 in MeOH). 
1
H NMR (400.13 MHz, DMSO) δ 5.26 (m, -OH), 
3.84 (m, 2H, Hb), 3.43 (m, 2H, Ha), 3.47 (m, 1H, H2), 3.12 (s, 9H, Hc), 2.88 (m, 2H, H5), 2.11 
(m, 1H, H3), 1.84-1.65 (m, 3H, H3´,H4). 
13
C NMR (100.61 MHz, DMSO) δ 182.41(C6), 67.49 
(Ca), 61.48 (C2), 55.56 (Cb), 53.85 (Cc), 45.94(C5), 30.64 (C3), 24.99 (C4). FTIR (NaCl) ʋ = 
3401, 2360, 2341, 2134, 1633, 1574, 1488, 1417, 1352, 1204, 1134, 1086, 1052, 957, 865, 750, 
667 cm
-1
. Elemental analysis (%) calcd for C11H26N2O3 (MW=234.34 g.mol
-1
): C 56.38; H 
11.18; N 11.95; found: C 56.12, H 11.12, N 11.92.  
 
III.9.14. General procedure for the Michael reaction of cyclohexanone and 
β–nitrostyrene 
 
To a suspension of catalyst (10-30 mol%) and cyclohexanone 
(210 µl, 2 mmol) in 1ml of solvent (EtOH, Emim EtSO4 or 
Bmim DCA) trans-β-nitrostyrene (0.149 g, 1.0 mmol) was 
added. The resulting mixture was allowed to stir at room 
temperature, for 48-90 hours, then evaporated in vacuo and the 
resulting residue was purified by extraction with Et2O and 
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flash column chromatography using ethyl acetate/hexane (1:2) giving the desired product. If 
necessary the product was additionaly purified by filtration using neutral aluminium and Et2O as 
washing solvent. Relative and absolute configurations of the products were determined by 
comparison with the known 
1
 H NMR and chiral HPLC analysis. The enantiomeric excess was 
determined by chiral HPLC analysis on a Phenomenex Lux 5 um 250x10 cellulose column, 
flow 1ml.min
-1
, 25 
o
C column oven, hexane: i-PrOH 90:10, λ=230 nm. t major = 13.7 min and t 
minor = 15.0 min. 
 
(S)-2-(R)-2-nitro-1-phenylethyl)cyclohexanone: colourless solid; mp 128-130 ºC; conversion 
100%; dr (syn/anti): 93:7, % ee. 
1
H NMR (400 MHz, CDCl3) δ 7.36 – 7.26 (m, 3H, Hc, Hd), 
7.17 (d, 
4
JHb-Hb = 8 Hz, 2H, Hb), 4.94 (dd, 
2
JH2´-H2´ = 4 Hz, 
3
JH2´-H1´ = 8 Hz, 1H, H2´), 4.64 (dd, 
2
JH2´-H2´ = 4 Hz, 
3
JH2´-H1´ = 8 Hz, 1H, H2´), 4.19 (dt, 
3
JH1´-H2´ = 8 Hz, 
3
JH1´-H2 = 10 Hz, 1H, H1´), 
3.76 (ddd, 3JH2-H1´ = 8 Hz, 
3
JH1´-H3 = 8 Hz, 
3
JH1´-H4 = 10 Hz, 1H, H2), 2.74 - 2.67 (m, 2H, H6), 
2.51 - 2.36 (m, 1H, H3), 1.81–1.59 (m, 4H, H4, H5), 1.30–1.20 (m, 1H, H3). 
13
C NMR (101 
MHz, CDCl3) δ 211.88 (C1), 137.73 (Ca), 128.90 (Cc), 128.14 (Cc), 127.74 (Cd), 78.86 (C2´), 
52.51 (C2), 43.91 (C6), 42.71 (C1´), 33.18 (C5), 28.49 (C3), 25.00 (C4). 
 
III.9.15. General procedure for extraction using scCO2 
 
The scCO2 extraction was carried out in the apparatus schematically presented in Scheme III.5. 
The core of the apparatus is a 3.5 mL high-pressure cell, with two sapphire windows allowing 
visualization of the internal volume. In order to perform the extraction, the cell is charged with a 
desired amount of the reaction mixture (0.9 mL), placed inside a constant temperature (40 °C) 
water bath and pressurized with CO2 until the desired pressure (250 bar) is brought into the cell. 
Supercritical extraction starts by careful opening the venting valves and allowing the extract to 
be collected in a cold trap filled with ethanol and cooled with ice. The drop of pressure is 
continuously compensated with the introduction of fresh CO2. The total quantity of CO2 passed 
through the system is measured by a gas flow meter placed at the exit of an ethanol trap. The 
extraction is considered finished when 0.55 mol of CO2 passes through the system. After a 
careful depressurisation of the system, some additional solvent (ethanol) is injected through the 
expansion lines to ensure that all the solute is recovered in the trap. 
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IV. Studies of Cyclodextrins and Ionic Liquids 
 
Cyclodextrins (CDs), mainly β-CD is difficult to dissolve in water and in many common 
solvents and the search of more appropiate solvents is a key step to expand its application. 
Nowadays, up to 40% of new chemical entities developed by the pharmaceutical industry are 
poorly soluble or lipophilic compounds
140
. The solubility issues difficult the delivery of these 
new drugs as well as affects the delivery of many existing drugs. Thus, the dissolution 
characteristics of poorly soluble drugs could be enhanced by several methods. 
 
In last decades, ILs have emerged as a possible environmentally benign alternative to common 
organic solvents, mainly related with their peculiar properties. Understanding the interaction 
between IL and CD is important to analytical chemistry and material synthesis. The main goal 
of this chapter is related with the development of novel chiral biological compounds based on 
the interaction of biocompatible ILs and CDs. In this context, dissolution and interaction studies 
of α-, β- and γ-CDs with several ILs were investigated. Novel biomaterials based on simple 
combination of ILs and CDs can be applied for host-guest and drug delivery processes. Novel 
biocompatible materials based on the combination of ILs and CDs can be explored for relevant 
chiral discrimination or separation processes. 
 
IV.1. Studies on dissolution of beta-cyclodextrins in Ionic Liquids  
 
In order to develop novel chiral biological molecules the effect of several ILs as solvents on β-
CD has been first studied. The dissolution of β-CD in different classes of RTILs based on 
methylimidazolium, ammonium, pyridinium, sulfonium, guanidinium and phosphonium cations 
combined with halogenate (chloride or bromide), dicyanamide, acetate, tetrafluoroborate, 
saccharine and ethylsulfate anions were tested (Figure IV.1). Table IV.1 summarizes the 
dissolution performance of different examples of RTILs. The maximum percentage of β-CD 
dissolved in ILs was verified by 
1
H NMR spectra of the mixture comparing the well known 
peaks of β-CD with some characteristic ILs peaks. 
1
H NMR spectrum of dissolution of β-CD in 
[Emim][EtSO4] is presented in Figure IV.2. The same experimental protocol was repeated for 
all of the β-CD and ILs mixtures.  
 
All dissolution experiments are presented in Table IV.1. It was possible to change the solubility 
behavior of β-CD scaffold due to the choice of the counter-ion. In general, the family of cations 
that showed the best dissolution with [DCA] as the anion was the sulfonium and the 
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phosphonium, followed by the imidazolium and at last the ammonium family. Regarding the 
selection of the cation, different results were observed while using BF4 as the anion. The highest 
percentage of β-CD dissolved into IL was obtained for the family of imidazolium combined 
with BF4 in sequence [Bmim] > [C2OHmim] > [C3Omim] > [Omim] > [C10mim], respectively. 
The increase of alkyl chain connected to the imidazolium ring resulted in the decrease of β-CD 
solubility profile. The influence of anion was also not irrelevant. Changing the anion from BF4 
to [DCA], when [Bmim] was used as the cation, resulted in lower percentage of β-CD dissolved 
(from 99.3% to 76.8%). According to the biocompatibility and dissolution performance of the 
different ILs tested, it was possible to classify the chiral biological materials based on β-CDs 
and ILs as good candidates or not so good for future applications. The best candidates for 
applications are in particular based on sulfonium and imidazolium cations combined with 
dicyanamide and ethylsulfate anions ([Emim][EtSO4] or [C5O2mim][Cl]). It is important to 
emphasize that all the β-CD- ILs mixtures were obtained either as gels or viscous liquids as 
shown in Figure IV.3.  
 
 
 
Figure IV.1 - Structure of β-CDs and ILs selected for dissolution studies. 
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Table IV.1 - Results of the dissolution studies of β-CD in ILs. 
Family of ILs ILs Mass of β-CD per mass 
of IL [mg CD/mg IL]  
[%] of β-CD dissolved 
in ILs  
 
 
 
 
 
 
 
IMIDAZOLIUM 
 
 
 
 
 
[Emim][EtSO4]  100.6/206  99.3  
[Bmim][BF4]
 
50.6/204 99.3 
[Bmim][DCA] 151.5/202 76.8 
[Omim][Cl] 100.3/205 100  
[Omim][DCA]  50.1/209 92.4 
[Omim][BF4] 50.2/208 5.8 
[C10mim][SAC]
 
 100.4/217 97  
[C10mim][DCA] 50.1/202 89.2 
[C10mim][BF4] 50.0/216 3 
[C2OHmim][BF4] 50.2/200 95.5 
[C2OHmim][DCA] 100.4/202 68.5 
[C3Omim][BF4] 50.2/216 80.1 
[C5O2mim][Cl] 150.3/205 100  
 [Aliquat][DCA] 100.9/302 62.2  
AMMONIUM [Aliquat][SAC]
 
 100.5/212 33.4 
 [Aliquat][Cl] 50.2/304 22 
PHOSPHONIUM [P6,6,6,14][DCA]
 
 100.7/301 100  
 [P6,6,6,14][Cl] 50.0/302 12.4 
SULFONIUM [(C2OH) 2C6S][DCA] 50.6/219 100  
 [(C2OH) 2C6S][Br] 101.1/205 64.1 
GUANIDINIUM [DMG][Cl]
 
 101.7/200 83.5 
 [DMG][SAC] 100.2/215 79 
PYRIDINIUM [Epy][EtSO4] 150.5/202 88  
Solubility was checked by visual observation and then proofed by 
1
H NMR analysis. 
 
 
 
 
Figure IV.2 - 
1
H NMR spectrum of the mixture β–CD dissolved in [Emim][EtSO4]. 
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Figure IV.3 - Novel chiral materials based on β–CD and ILs. (A)- gel, (B)- yellow liquid, (C)- 
transparent liquid. 
 
IV.2. Recovery of beta-cyclodextrin and Ionic Liquids 
 
It was also proved that recovering of pure β-CD as well as the original ILs is possible by simple 
addition of acetone to the mixture (Figure IV.4). The recycled β-CD and ILs were recovered 
without any decomposition and not a significant lost as indicated in Table IV.2. Their stability 
and purity was checked by 
1
H NMR spectra presented in Figures IV.5, IV.6 and IV.7. 
 
Using this approach is possible to create chiral materials as gels or viscous liquids based on the 
simple combination of biocompatible task specific ILs and CDs and then recover the original 
components if required. These chiral liquid materials based CDs can be useful for asymmetric 
catalysis or chiral separation processes.  
 
 
Figure IV.4 - Recovery strategy of β-CD and IL. 
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Table IV.2 - Amounts of β-CD and ILs used for recycling studies. 
IL Mass of IL 
before 
recovery[mg] 
Mass of β-CD before 
recovery [mg] 
Mass of IL after 
recovery[mg] 
Mass of β-CD 
after recovery 
[mg] 
[Bmim][DCA] A 805.7 601.2 624.7 (78%) 395.5 (66%) 
[C5O2mim][Cl] B 800.5 600.0 600.3 (75%) 394.6 (66%) 
[Emim][EtSO4] C 801.9 603.9 509.3 (64%) 353.1 (59%) 
 
 
 
 
Figure IV.5 - 
1
H NMR spectrum of the mixture β–CD dissolved in [Bmim][DCA] before recovery. 
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FiguereIV.6 - 
1
H NMR spectrum of the pure β–CD after recovery. 
 
 
 
 
 
Figure IV.7 - 
1
H NMR spectrum of the pure [Bmim][DCA] after recovery. 
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IV.3. Application of beta-cyclodextrin-IL gels for the studies on 
improvement of water solubility of fatty acids and steroids 
 
Saturated fatty acids such as: capric acid (decanoic acid), lauric acid (dodecanoic acid), ester 
lauryl gallate (dodecyl gallate) and steroids: squalene and Provitamin D2 (Ergosterol) are 
examples of compounds poorly soluble in water (Figure IV.8). These fatty acids and steroids 
have certain significant applications in different areas (eg. pharmaceutical, food, cosmetics, 
lubricant and chemical). Because ergosterol is present in cell membranes of fungi, yet absent in 
those of animals, it is a useful target for antifungal drugs
141
. In animals, squalene is the 
biochemical precursor to the whole family of steroids. Squalene anti-tumor activity in animal 
experiments and epidemiological proof based on olive oil consumption also suggest reduction 
of cancer risk by squalene
142
. Lauryl gallate is a food additive and used under the E number 
E312 as an antioxidant and preservative compound. To overcome solubility problems of 
unpolar or weakly polar substances, the addition of a solubiliser to the solvent is necessary. In 
this context, β-CD- [Emim][EtSO4] gel was added to the water as additive. The results 
presented in Table IV.3 clearly show that the use of β-CD- [Emim][EtSO4] mixture facilitates 
the water solubility of fatty acids and steroids. It was possible to improve the values for capric 
and lauric acid up to 5 and 22%. At the same time, practically water-insoluble squalene and 
provitamin D2 proved to be totally soluble in water with additive after two additions of the 
steroids (80.10
-5 
g) and only after the last addition was visible a precipitate in both cases as 
presented in Figure IV.9. 
 
Figure IV.8 - Fatty acids and steroids chosen for the studies on improvment of their water 
solubility. 
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Figure IV.9 - (A) squalene (left) and provit.D2 (right) in water with additive after 2 additions of 
steroids, (B) squalene (left) and provit. D2 (right) in water with additive after the last addition. 
 
Table IV.3 - Results of water solubility of fatty acids and steroids using β-CD-[Emim][EtSO4] gel as 
additive. 
Fatty acid, steroid Water solubility [g.ml
-1
.10
-5
], 
(lit.) 
Amount solubilized in water 
with additive [g.ml
-1
.10
-5
]
[a] 
Capric acid 15 80 
Lauric acid 6 130 
Lauryl gallate 0 40 
Squalene 0 600 
Provitamin D2 0 155 
[a]
 Amount of fatty acid or steroid dissolved in water after the β-CD- [Emim][EtSO4] gel (50µl) was used as additive. The 
results were concluded by visual observation. 
 
IV.4. Dissolution of alfa- and gamma-cyclodextrins in Ionic Liquids 
 
In this part of the work, we are interested in the complexation and dissolution of α- and γ-CD 
with different ILs. In this context, the possibility to combine task specific ILs with CDs by 
simple dissolution process can be relevant in order to expand the range of their applications as a 
chiral media for asymmetric catalysis and chiral recognition. For these experiments, different 
RTILs were selected as indicated in Figure IV.10. The mixtures of α– and γ-CDs (100-150 mg) 
and ILs (200-300 mg) were stirred for 24 hours at room temperature. The percentage of α- and 
γ-CDs dissolved in ILs was confirmed by 
1
H NMR spectra of the mixture by comparing the 
well known peaks of α- and γ-CDs with the ILs peaks. All dissolution studies are presented in 
Table IV.4. 
 
According the selection of the counter-ion, it was possible to change the solubility behavior of 
α- and γ-CDs scaffolds. The highest percentage of α-CD dissolved into IL was obtained for the 
family of imidazolium cations, in particular [C5O2mim][Cl], [Emim][EtSO4] (Table IV.4, 
Entries 4 and 5). These results indicated us that the alkyl chain of imidazolium ring can interact 
inside of α-CD cavity as inclusion complex (This possible inclusion structure was confirmed by 
1
H NMR). In the case of ammonium IL combined with dicyanamide (Table IV.4, Entry 2) 
moderate dissolution results were obtain. It is important to note, that when the aliquat cation 
was substituted by the hydrophobic phosphonium cation, the solubility of α-CD dropped 
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dramatically (Table IV.4, Entry1). The cavity size can explain the solubility profile differences 
between ammonium and phosphonium salts. In general, γ-CD showed less miscibility with the 
chosen ILs. Furthermore, a diverse behaviour was observed when [Aliquat][DCA] was 
examinated, while the small α-CD scaffold showed moderate solubility of 77.8 %, in the case of 
bigger γ-CD only 3.6 % dissolution was obtained. This fact indicates that depending of the size 
of the CD moiety different interactions with ILs can occur. The 
1
H NMR spectra revealed that 
chemical shift data of all protons in α- and γ-CD molecules move to higher field in the presence 
of ILs. 
Table IV.4 - Results of the dissolution studies of γ-CD in ILs. 
Entry ILs Mass of α-CD 
per mass of 
IL [mg 
CD/mg IL] 
[%] of α-CD 
dissolved in 
ILs 
 
Mass of γ-CD 
per mass of 
IL [mg 
CD/mg IL] 
[%] of γ-CD 
dissolved 
in ILs 
 
1 [P6,6,6,14] [DCA] 101.5/212 2.1 104.9/200 2.5 
2 [Aliquat] [DCA] 101.4/209 77.8 100.0/205 3.6 
3 [Bmim] [DCA]  150.3/211 48.1 151.2/206 31.2 
4 [C5O2MIM] [Cl] 151.0/206 100 151.4/204 66.5 
5 [Emim] [EtSO4] 150.2/207 93.5 151.2/210 81.0 
    Solubility was checked by visual observation and then proofed by 
1
H NMR analysis. 
 
 
 
Figure IV.10- Structure of α- and γ-CDs and ILs selected for dissolution studies. 
 
IV.5. Studies on solubility behaviour of alfa- and gamma-
cyclodextrins in water and serum 
 
The natural CDs have limited water solubility, meaning that complexes resulting from 
interaction of lipophiles with these CDs can be of limited solubility resulting in precipitation of 
solid cyclodextrin complexes from water and other aqueous systems. In fact, the aqueous 
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solubility of the CDs is much lower comparing with other acyclic saccharides
69
. This is thought 
to be due to relatively strong intermolecular hydrogen bonding in the crystal state. In order to 
increase its apparent water solubility α- and γ-CDs were combined with [Emim][EtSO4] and 
portions of these gels were added to water as presented in Figure IV.11and 12. The addition of 
IL resulted in dramatic improvement of their aqueous solubility. In the second part of our 
studies, the dissolution of α- and γ-CDs in serum (water with sodium chloride buffer, pH=7) 
was examinated. Table IV.5 summarizes all the water and serum solubility experiments. It was 
found that the presence of [Emim][EtSO4] involves an increase in the solubility of α- and γ-CD 
in serum. 
 
 
 
Figure IV.11 - CDs-ILs gels prepared for improvement of CDs water and serum solubility. 
 
 
  
 
 
 
 
 
 
 
 
             1
th
 addition / last addition   1
th
 addition / last addition 
Figure IV.12 - Dissolution of α-CD with IL additive (KZ AC3) and γ-CD with IL additive (KZ 
AG4) in serum (first and last addition). 
 
 
Table IV.5 - Results of α – and γ-CDs water solubility. 
CDs or gels Dissolution in water 
[g/0.5ml]
[a] 
Dissolution in serum 
[g/0.5ml]
[a]
 
α-CD 0.041 0.050 
α-CD+[Emim] [EtSO4] 0.250 (x6 times) 0.156 (x3 times) 
γ-CD 0.025 0.046 
γ-CD+[Emim] [EtSO4] 0.050 (x2 times) 0.100 (x2 times) 
  [a]
Dissolution studies were performed at 20 ºC. 
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IV.6. Interaction of alfa- and gamma-cyclodextrins with methylene blue 
and Ionic Liquids 
 
Methylene blue (MB) is a heterocyclic aromatic compound and as example of phenothiazine 
dyes with a planar structure (Figure IV.13). Phenothiazine dyes have found a wide range of 
applications such as sensitizers in solar energy conversion, active species in electrochromism 
and dye lasers, ingredients in pharmaceutical preparation, redox mediators in catalytic oxidation 
reactions and candidates for cancer therapy by intercalating in between DNA base layers
143
. 
Nevertheless, according to the dimerization of dye molecules in aqueous media such as the great 
decrease of light sensitivity, there are some limitations for these applications. Therefore, it is 
important to improve the sensitivity of dyes towards obtaining a high number of monomers. 
 
The property of CDs to form host-guest complexes can be used to control the position of 
monomer/dimer equilibrium and aggregation abbility of dye, affecting electronic absorption and 
fluorescence spectra as the photochemical and electrochemical properties of dyes. Many 
analytical methods for the study on the complex of CD with MB including electrochemical 
method and UV//Vis spectrotometry have been reported
143
. The recent methods are limited to 
parent β-CD. 
 
The purpose of this subchapter is related with the study of complexing behavior of MB with 
initial α- and γ-CDs as well as α- and γ-CD/IL systems by absorption spectroscopy analysis. In 
this context, solutions with initial MB, α- and γ-CDs and α- and γ-CDs with either 
[Bmim][DCA] or [Aliquat][DCA] were prepared (proportions: 1.0: 0.5; 1.0: 1.0; 1.0: 1.5 and 
1.0: 2:0). Figure IV.14 shows the absorption spectra of MB monomer (666 nm) and dimer (612 
nm). In the presence of α- or γ-CD, the initial maximum absorption of MB at 612 and 666 nm 
decreases (see Figure IV.14). In the case in which CDs were used in a form of gel with ILs, 
similar profile was observed. These results were in contrast to those obtained in the literature. 
Some reports show a large increase of absorption in MB monomer peak and a slight decrease in 
MB dimer peak that proved the breaking of the aggregate of the MB. The initial idea of these 
studies was to rationalize the different dissolution results obtained with these ILs for both CDs. 
Unfortunately, no clear conclusions could be taken out of the studies. The absorption method 
was not sensitive enough to elucidate us. In this context, further studies using other methods 
such as NMR and fluorescence should be performed. 
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Figure IV.14 - Absorbtion spectra of MB (1.10
-8 
mol) with different proportions of α- and γ-CD 
solutions. 
 
 
 
 
Figure IV.15 - Absorbtion spectra of MB (1.10
-8
 mol) with different proportions of α-CD 
[Bmim][DCA] solutions. 
 
 
 
 
Figure IV.13 - Methylene blue. 
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Figure IV.16 - Absorbtion spectra of MB (1.10
-8
 mol) with different proportions of γ-CD 
[Bmim][DCA] solutions. 
 
 
Figure IV.17 - Absorbtion spectra of MB (1.10
-8
 mol) with different proportions of α-CD 
[Aliquat][DCA] solutions. 
 
 
Figure IV.18 - Absorbtion spectra of MB (1.10
-8
 mol) with different proportions of γ-CD 
[Aliquat][DCA] solutions. 
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IV.7. Conclusions 
 
This chapter was focused on the possible interactions of oligosaccharides with ILs. The studies 
showed a high potencial of some ILs for the dissolution of CDs. In particular, in the case of β-
CD, it was possible to find ILs that can be used as an alternative to organic solvents (DMSO) 
with very high solubility profiles. The difference observed for α-, β-, γ-CDs dissolution in the 
same ILs makes them task specific ILs and it is a relevant point to study in more detail in the 
future. One of the explanations for this variable behavior could be the size of each CD and 
possible hydrophobic interactions present inside CDs and more hydrophobic ILs as well as 
external hydrophilic interactions of CDs with specific ILs (acidic protons or OH groups from 
imidazolium cations). 
 
Additionally, some CDs and ILs mixtures seems to be novel (bio)materials as additives to 
improve the solubility of drugs, fatty acids and steroids as well as to improve the original CDs 
solubility in aqueous and serum solutions. 
 
Observing the chirality applications of CDs, we are interested in the use of ILs- CDs systems 
for asymmetric catalysis, chiral separation as well as in pharmaceutical industry. Some 
preliminary studies using β-CD as a chiral media for asymmetric epoxidation reactions were 
performed. Moreover, preliminary synthetic approaches in order to incorporate ionic scaffolds 
in the CD structure were also tested. In particular the functionalization of β-cyclodextrin was 
developed using three synthetic steps: the synthesis of 6-O-Monotosyl-6-deoxy-β-cyclodextrin, 
followed by the synthesis of 6-Monodeoxy-6-azido-β-cyclodextrin in order to obtain the final 6-
Monodeoxy-6-amino-β-cyclodextrin. The preparation of these CDs based ILs is in progress. 
 
IV.8. Experimental Part 
 
General: Commercially available reagents α-CD (M= 972.84 g.mol
-1
, CAS No. 10016-20-3), β-
CD (M = 1134.98 g.mol
-1
, CAS No. 7585-39-9), γ-CD (M=1296.42 g.mol
-1
, CAS No. 17465-
86-0) ionic liquids and solvents were purchased from TCI Europe nv (Zwijndrecht, Belgium), 
Fluka (Buchs, Switzerland), Alfa Aestar, Aldrich, Solchemar and were used without further 
purification.
1
H NMR spectra were recorded on a Bruker AMX 400 Spectrometer. Chemical 
shifts are reported downfield in ppm from a TMS reference.  
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Absorption measurements: UV/Vis absorption spectra were recorded with a Varian-Cary 100 
Bio UV/Vis spectrophotometer. 
IV.8.1. General procedure for the dissolution of β-CD in ILs 
 
Following the general procedure for the β-CD dissolution studies for these experiments, RTILs 
were selected based on phosphonium, ammonium, methylimidazolium, pyridinium, dimethyl 
guanidinium and sulfonium cations connected with chloride, bromide, dicyanamide, acetate, 
tetrafluoroborate, sacharine and ethylsulfate as anions. To a 1 ml vial, 200-300 mg of ILs were 
added and also 50-150 mg of β-CD until saturation was observed. The samples were stirred for 
24 hours at room temperature and filtrated. The percentage of β-CD dissolved in ILs was 
confirmed using 
1
H NMR spectra of the mixture after 24 hours by comparing the well known 
peaks of β-CD with the ILs peaks. 
 
β-CD
 1
H NMR (400.13 MHz, DMSO) δ 5.53 (m, 7H, H1), 
5.44 (s, 7H, 2-OH), 4.79 (s, 7H, 3-OH), 4.45 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.61 (m, 7H, H2), 3.55-3.53 (m, 14H, 
6-OH, H6), 3.28 (m, 14H, H3, H4).
13
C NMR (100.61 MHz, 
DMSO) δ 101.99 (C1), 81.58 (C4), 73.09 (C5), 72.45 (C2), 
72.08 (C3), 59.97 (C6). 
 
 
β-CD
 
+[(C2OH) 2C6S][DCA]
 1
H NMR (400.13 MHz, DMSO) δ 
5.72 (m, 7H, H1), 5.51 (s, 7H, 2-OH), 4.80 (s, 7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.84 (m, 7H, H2), 3.62-3.46 
(m, 20H, 6-OH, H6, He, e-OH), 3.28 (m, 14H, H3, H4), 2.54 (t, 
3
JHd- He= 4 Hz, 4H, Hd), 1.74 (m, 2H, Ha)1.37-1.27 (m, 8H, Hb), 
0.85 (t, 
3
JHc-Hb=8 Hz, 3H, Hc). 
 
 
β-CD
 
+[C5O2MIM][Cl]
 1
H NMR (400.13 
MHz, DMSO) δ9.25 (s, 1H, Hb), 7.76(s, 1H, 
Hd), 7.71 (s, 1H, Hd´), 5.85 (m, 7H, H1), 5.67 
(s, 7H, 2-OH), 4.81 (s, 7H, 3-OH), 4.35 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.89 (m, 3H, Hi), 3.75 (t, 
2
JHe-He=4 Hz, 
3
JHe-Hf=8 Hz, 2H, 
He), 3.63 (m, 7H, H2), 3.60-3.51 (m, 16H, 6-OH, H6, Hf), 3.40 (s, 4H, Hg), 3.36 (m, 14H, H3, 
H4), 3.19 (s, 3H, Hh). 
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β-CD
 
+[Emim][EtSO4]
 1
H NMR (400.13 
MHz, DMSO) δ 9.09 (s, 1H, Hb), 7.76 (s, 1H, 
Hd), 7.68 (s, 1H, Hd´), 5.85 (m, 7H, H1), 5.67 
(s, 7H, 2-OH), 4.82 (s, 7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 4.16 (t, 
2
JHe-
He=4 Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (m, 3H, Hg), 3.72 (m, 2H, Hh), 3.62 (m, 7H, H2), 3.60-3.53 
(m, 14H, 6-OH, H6), 3.28 (m, 14H, H3, H4), 1.40 (t, 
3
JHi-Hh= 8 Hz, 3H, Hi), 1.09 (t, 
3
JHf-He=8 Hz, 
3H, Hf). 
 
 
β-CD
 
+[Epy][EtSO4]
 1
H NMR (400.13 MHz, DMSO) δ 
8.92 (d, 
3
JHa-Hb=8 Hz, 2H, Ha), 8.44 (d, 
3
JHb-Ha=8 Hz, 2H, 
Hb), 8.92 (d, 
3
JHa-Hb=8 Hz, 2H, Ha), 8.04 (t, 
3
JHc-Hb=8 Hz, 
1H, Hc), 5.82 (m, 7H, H1), 5.68 (s, 7H, 2-OH), 4.82 (s, 
7H, 3-OH), 4.58 (q, 
3
JHd-He=8 Hz, 2H, Hd), 3.76 (q, 
3
JHf-
Hg=8 Hz, 2H, Hf), 3.67- 3.54 (m, 7H, H2), 3.44 (m, 14H, 6-OH, H6), 3.28 (m, 14H, H3, H4), 1.53 
(t, 
3
JHe-Hd=8 Hz, 3H, He), 1.06 (t, 
3
JHg-Hf=8 Hz, 3H, Hg).  
 
 
β-CD
 
+[Bmim][DCA]
 1
H NMR (400.13 MHz, DMSO) δ 
9.08 (s, 1H, Hb), 7.74 (s, 1H, Hd), 7.68 (s, 1H, Hd´), 5.74 
(m, 7H, H1), 5.68 (s, 7H, 2-OH), 4.82 (s, 7H, 3-OH), 4.46 
(t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 4.14 (t, 
2
JHe-He´=4 
Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (, 3H, Hi), 3.62 (m, 7H, 
H2), 3.61-3.54 (m, 14H, 6-OH, H6), 3.28 (m, 14H, H3, H4), 1.75 (m, 2H, Hf), 1.25 (m, 2H, Hg), 
0.89 (t, 
3
JHh-Hf=8 Hz, 3H, Hh). 
 
 
β-CD
 
+ [Omim][Cl]
 1
H NMR (400.13 MHz, 
DMSO) δ 9.07 (s, 1H, Hb), 7.74 (s, 1H, Hd), 
7.67 (s, 1H, Hd´), 5.76 (m, 7H, H1), 5.68 (s, 
7H, 2-OH), 4.82 (s, 7H, 3-OH), 4.46 (t, 
3
JH5-
H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 4.13 (t, 
2
JHe-He´=4 Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (, 3H, Hk), 
3.62 (m, 7H, H2), 3.61-3.54 (m, 14H, 6-OH, H6), 3.38 (m, 14H, H3, H4), 1.77 (m, 2H, Hf), 1.25 
(m, 10H, Hg, Hi), 0.84 (t, 
3
JHj-Hi=8 Hz, 3H, Hj). 
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β-CD
 
+[P6,6,6,14][DCA]
 1
H 
NMR (400.13 MHz, DMSO) 
δ 5.74 (m, 7H, H1), 5.70 (s, 
7H, 2-OH), 5.17 (s, 7H, 3-
OH), 4.82 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.62 
(m, 7H, H2), 3.60-3.53 (m, 
14H, 6-OH, H6), 3.28 (m, 
14H, H3, H4), 2.49 (m, 8H, 
Hf), 1.46-1.27 (m, 16H, Hb, e), 1.26-1.20 (m, 32H, Hc,), 0.84 (m, 12H, Ha). 
 
 
β-CD
 
+ [C10mim][SAC]
 1
H NMR (400.13 
MHz, DMSO) δ 9.08 (s, 1H, Hb), 7.74 (s, 1H, 
Hd), 7.68 (s, 1H, Hd´), 7.57 (m, 4H, Hj, Hk, Hl, 
Hm), 5.74 (m, 7H, H1), 5.68 (s, 7H, 2-OH), 4.82 
(s, 7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 
Hz, 7H, H5), 4.13 (t, 
2
JHe-He´=4 Hz, 
3
JHe-Hf=8 Hz, 
2H, He), 3.82 (, 3H, Hi), 3.62 (m, 7H, H2), 3.61-3.54 (m, 14H, 6-OH, H6), 3.38 (m, 14H, H3, H4), 
1.77 (m, 2H, Hf), 1.25 (m, 14H, Hg,), 0.84 (t, 
3
JHh-Hg=8 Hz, 3H, Hh). 
 
 
β-CD
 
+[C2OHMIM][BF4]
 1
H NMR (400.13 MHz, DMSO) 
δ9.04 (s, 1H, Hb), 7.69 (s, 1H, Hd), 7.66 (s, 1H, Hd´), 5.74 (m, 
7H, H1), 5.70 (s, 7H, 2-OH), 5.17 (s, 7H, 3-OH), 4.82 (t, 
3
JH5-
H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 4.19 (t, 
2
JHe-He=4 Hz, 
3
JHe-
Hf=8 Hz, 2H, He), 3.84 (m, 3H, Hg), 3.62 (m, 7H, H2), 3.60-3.53 (m, 14H, 6-OH, H6), 3.28 (m, 
14H, H3, H4), 1.40 (t, 
3
JHf-He= 8 Hz, 3H, Hf). 
 
 
β-CD
 
+ [Omim][DCA]
 1
H NMR (400.13 MHz, 
DMSO) δ 9.07 (s, 1H, Hb), 7.74 (s, 1H, Hd), 7.67 
(s, 1H, Hd´), 5.76 (m, 7H, H1), 5.68 (s, 7H, 2-OH), 
4.82 (s, 7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-
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H6´=8 Hz, 7H, H5), 4.13 (t, 
2
JHe-He´=4 Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (, 3H, Hk), 3.62 (m, 7H, 
H2), 3.61-3.54 (m, 14H, 6-OH, H6), 3.38 (m, 14H, H3, H4), 1.77 (m, 2H, Hf), 1.25 (m, 10H, Hg, 
Hi), 0.84 (t, 
3
JHj-Hi=8 Hz, 3H, Hj). 
β-CD
 
+ [C10mim][DCA]
 1
H NMR 
(400.13 MHz, DMSO) δ 9.08 (s, 1H, Hb), 
7.74 (s, 1H, Hd), 7.68 (s, 1H, Hd´), 5.74 
(m, 7H, H1), 5.68 (s, 7H, 2-OH), 4.82 (s, 
7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-
H6´=8 Hz, 7H, H5), 4.13 (t, 
2
JHe-He´=4 Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (, 3H, Hi), 3.62 (m, 7H, H2), 
3.61-3.54 (m, 14H, 6-OH, H6), 3.38 (m, 14H, H3, H4), 1.77 (m, 2H, Hf), 1.25 (m, 14H, Hg,), 0.84 
(t, 
3
JHh-Hg=8 Hz, 3H, Hh). 
 
 
β-CD
 
+ [(C6)4DMG][Cl]
 1
H NMR (400.13 MHz, DMSO) δ 5.74 
(m, 7H, H1), 5.68 (s, 7H, 2-OH), 4.82 (s, 7H, 3-OH), 4.45 (t, 
3
JH5-
H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.63 (m, 7H, H2), 3.61-3.54 (m, 
22H, 6-OH, H6, Hg), 3.38 (m, 14H, H3, H4), 1.52-1.23 (m, 16H, 
Hh), 0.84 (m, 12H, Hi). 
 
 
 
β-CD
 
+ [Bmim][BF4] 
1
H NMR (400.13 MHz, DMSO) δ 
9.08 (s, 1H, Hb), 7.74 (s, 1H, Hd), 7.68 (s, 1H, Hd´), 5.74 (m, 
7H, H1), 5.68 (s, 7H, 2-OH), 4.82 (s, 7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 4.14 (t, 
2
JHe-He´=4 Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (, 3H, Hi), 3.62 (m, 7H, H2), 3.61-3.54 (m, 14H, 6-OH, H6), 3.28 (m, 
14H, H3, H4), 1.75 (m, 2H, Hf), 1.25 (m, 2H, Hg), 0.89 (t, 
3
JHh-Hf=8 Hz, 3H, Hh). 
 
 
β-CD
 
+[C3Omim][BF4]
 1
H NMR (400.13 MHz, DMSO) δ 
9.09 (s, 1H, Hb), 7.71(s, 1H, Hd), 7.68 (s, 1H, Hd´), 5.74 (m, 
7H, H1), 5.67 (s, 7H, 2-OH), 5.22 (s, 7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 4.16 (t, 
2
JHe-He=4 Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (m, 3H, Hh), 3.72 (m, 2H, Hf), 3.63 (m, 7H, H2), 3.60-3.53 (m, 14H, 
6-OH, H6), 3.34 (m, 14H, H3, H4), 3.15 (s, 3H, Hg). 
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β-CD
 
+ [(C6)4DMG][SAC]
 1
H NMR (400.13 MHz, 
DMSO) δ 7.57 (m, 4H, Ha, Hb, Hc, Hd), 5.74 (m, 7H, 
H1), 5.68 (s, 7H, 2-OH), 4.82 (s, 7H, 3-OH), 4.45 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.63 (m, 7H, 
H2), 3.61-3.54 (m, 22H, 6-OH, H6, Hg), 3.38 (m, 14H, 
H3, H4), 1.52-1.23 (m, 16H, Hh), 0.84 (m, 12H, Hi). 
 
 
β-CD
 
+[C2OHMIM][DCA]
 1
H NMR (400.13 MHz, DMSO) 
δ9.09 (s, 1H, Hb), 7.68 (s, 1H, Hd), 7.65 (s, 1H, Hd´), 5.75 (m, 
7H, H1), 5.70 (s, 7H, 2-OH), 5.21 (s, 7H, 3-OH), 4.80 (t, 
3
JH5-
H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 4.19 (t, 
2
JHe-He=4 Hz, 
3
JHe-
Hf=8 Hz, 2H, He), 3.84 (m, 3H, Hg), 3.62 (m, 7H, H2), 3.60-
3.53 (m, 14H, 6-OH, H6), 3.28 (m, 14H, H3, H4), 1.40 (t, 
3
JHf-He= 8 Hz, 3H, Hf). 
 
 
β-CD
 
+ [(C2OH) 2C6S][Br]
 1
H NMR (400.13 MHz, DMSO) δ 5.72 
(m, 7H, H1), 5.52 (s, 7H, 2-OH), 4.80 (s, 7H, 3-OH), 4.45 (t, 
3
JH5-H6=4 
Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.84 (m, 7H, H2), 3.62-3.37(m, 20H, 6-
OH, H6, He, e-OH), 3.28 (m, 14H, H3, H4), 2.55 (t, 
3
JHd- He= 4 Hz, 4H, 
Hd), 1.74 (m, 2H, Ha)1.37-1.27 (m, 8H, Hb), 0.85 (t, 
3
JHc-Hb=8 Hz, 3H, 
Hc). 
 
 
β-CD
 
+[Aliquat][DCA]
 1
H NMR 
(400.13MHz, DMSO) δ 5.74 (m, 7H, H1), 5.70 
(s, 7H, 2-OH), 5.17 (s, 7H, 3-OH), 4.82 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.62 (m, 
7H, H2), 3.60-3.53 (m, 14H, 6-OH, H6), 3.35 
(s, 3H, He),3.28 (m, 14H, H3, H4), 3.20 (m, 6H, 
Ha), 1.58 (m, 6H, Hb), 1.23 (m, 28H, Hc), 0.85 (m, 9H, Hd). 
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β-CD
 
+[Aliquat][SAC]
 1
H NMR (400.13 
MHz, DMSO) δ 7.57 (m, 4H, Hf, Hg, Hh, 
Hi), 5.74 (m, 7H, H1), 5.70 (s, 7H, 2-OH), 
5.17 (s, 7H, 3-OH), 4.82 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.62 (m, 7H, H2), 
3.60-3.53 (m, 14H, 6-OH, H6), 3.35 (s, 
3H, He),3.28 (m, 14H, H3, H4), 3.20 (m, 
6H, Ha), 1.58 (m, 6H, Hb), 1.23 (m, 28H, Hc), 0.85 (m, 9H, Hd). 
 
 
β-CD
 
+[Aliquat][Cl]
 1
H NMR (400.13 MHz, 
DMSO) δ5.74 (m, 7H, H1), 5.70 (s, 7H, 2-
OH), 5.17 (s, 7H, 3-OH), 4.82 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.62 (m, 7H, H2), 3.60-
3.53 (m, 14H, 6-OH, H6), 3.35 (s, 3H, He),3.28 
(m, 14H, H3, H4), 3.20 (m, 6H, Ha), 1.58 (m, 
6H, Hb), 1.23 (m, 28H, Hc), 0.85 (m, 9H, Hd). 
 
 
β-CD
 
+[P6,6,6,14][Cl]
 1
H NMR (400.13 
MHz, DMSO) δ 5.74 (m, 7H, H1), 5.70 (s, 
7H, 2-OH), 5.17 (s, 7H, 3-OH), 4.82 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 3.62 
(m, 7H, H2), 3.60-3.53 (m, 14H, 6-OH, 
H6), 3.28 (m, 14H, H3, H4), 2.49 (m, 8H, 
Hf), 1.46-1.27 (m, 16H, Hb, e), 1.26-1.20 
(m, 32H, Hc,), 0.84 (m, 12H, Ha). 
 
 
β-CD
 
+ [Omim][BF4]
 1
H NMR (400.13 MHz, 
DMSO) δ 9.09 (s, 1H, Hb), 7.74 (s, 1H, Hd), 7.67 
(s, 1H, Hd´), 5.74 (m, 7H, H1), 5.68 (s, 7H, 2-OH), 
4.82 (s, 7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-
H6´=8 Hz, 7H, H5), 4.13 (t, 
2
JHe-He´=4 Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (, 3H, Hk), 3.62 (m, 7H, 
H2), 3.61-3.54 (m, 14H, 6-OH, H6), 3.38 (m, 14H, H3, H4), 1.77 (m, 2H, Hf), 1.25 (m, 10H, Hg, 
Hi), 0.84 (t, 
3
JHj-Hi=8 Hz, 3H, Hj).  
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β-CD
 
+ [C10mim][BF4]
 1
H NMR (400.13 
MHz, DMSO) δ 9.07 (s, 1H, Hb), 7.74 (s, 1H, 
Hd), 7.67 (s, 1H, Hd´), 5.74 (m, 7H, H1), 5.68 
(s, 7H, 2-OH), 4.82 (s, 7H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 7H, H5), 4.13 (t, 
2
JHe-He´=4 Hz, 
3
JHe-Hf=8 Hz, 2H, He), 3.83 (, 3H, Hi), 
3.62 (m, 7H, H2), 3.61-3.54 (m, 14H, 6-OH, H6), 3.38 (m, 14H, H3, H4), 1.77 (m, 2H, Hf), 1.25 
(m, 14H, Hg,), 0.84 (t, 
3
JHh-Hg=8 Hz, 3H, Hh). 
 
IV.8.2. General procedure for the recovery of β-CD and ILs 
 
After 24 hours stirring the mixture of β–CD and ILs at RT, acetone was added to extract the 
cyclic oligosaccharide from the organic layer. This experiment confirmed the possibility to 
recover β-CD as well as the ILs. This addition caused a complete β–CD precipitation while the 
IL maintain soluble in the organic phase. The β–CD precipitate could be easily recovered from 
the solution. The chemical stability of the recycled β–CD and ILs were analyzed by 
1
H NMR 
and 
13
C NMR spectroscopy.  
 
IV.8.3. General procedure for the studies on improvement of water 
solubility of fatty acids and steroids 
 
For the preparation of the β- CD- [Emim][EtSO4] gel, β-CD (0.05 g, 0.04 mmol) was mixed 
with [Emim][EtSO4] (0.2 g, 0.85 mmol) and stirred for 24h at RT. To a flask with 1 ml of water, 
50 µl of β-CD with [Emim][EtSO4] additive was added and stirred to solubilize all the gel. Then 
a portion of fatty acid, steroid respectively (0.0004 g) was added and stirred for 5 minutes at 
RT. A second portion was added if after the indicated time all the amount of fatty acid or steroid 
was solubilized. The addition was repeated until the first symptom of precipitate appeared. The 
results were concluded by visual observation. 
 
IV.8.4. General procedure for the dissolution of α- and γ-CD in ILs 
 
Following the general procedure for α- and γ-CD dissolution studies, RTILs were selected based 
on phosphonium, ammonium, methylimidazolium cations connected to chloride, dicyanamide 
and ethylsulfate anions. To a 1 ml vial, 0.2-0.3g of ILs were added and also 0.1-0.15g of α- and 
γ-CD until saturation was observed. The α- and γ-CDs solubility was determined visually. The 
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samples were stirred for 24 hours at room temperature and filtrated. The percentage of α- and γ-
dissolved in ILs was confirmed using 
1
H NMR spectra of the mixture after 24 hours by 
comparing the well known peaks of α- and γ-CD with the ILs peaks. 
 
α-CD 
1
H NMR (400.13 MHz, DMSO) δ 5.51 (m, 6H, H1), 
5.43 (s, 6H, 2-OH), 4.78 (s, 6H, 3-OH), 4.49 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 6H, H5), 3.77 (m, 6H, H2), 3.62-3.55 (m, 12H, 
6-OH, H6), 3.26 (m, 12H, H3, H4).
13
C NMR (101 MHz, 
(CD3)2SO) δ 110.40 (C1), 83.51 (C4), 79.09 (C5), 74.30 
(C2), 72.08 (C3), 60.97 (C6). 
 
γ-CD 
1
H NMR (400.13 MHz, DMSO) δ 5.73 (m, 8H, H1), 
5.67 (s, 8H, 2-OH), 4.81 (s, 8H, 3-OH), 4.46 (t, 
3
JH5-H6=4 Hz, 
3
JH5-H6´=8 Hz, 8H, H5), 361 (m, 8H, H2), 3.60-3.53 (m, 16H, 
6-OH, H6), 3.31 (m, 16H, H3, H4).
13
C NMR (100.61 MHz, 
DMSO) δ 101.99 (C1), 81.58 (C4), 73.09 (C5), 72.45 (C2), 
72.08 (C3), 59.97 (C6). 
 
IV.8.5. General procedure for the studies on improvement of water 
solubility of α- and γ-CDs 
 
First, the solubilities of α- and γ-CDs in water without any additive were studied. In this 
context, to a flask with 0.5 ml of water, portions of α- or γ-CDs (0.005 g) were added. The 
addition was repeated until the first symptom of precipitate appeared. The results were 
concluded by visual observation. For the studies of solubility of α- and γ-CDs in water with 
additive, the α- or γ-CDs [Emim][EtSO4] gels were prepared. α- or γ-CDs (0.05 g, 0.04 mmol) 
was mixed with [Emim][EtSO4] (0.2 g, 0.85 mmol) and stirred for 24h at RT. To a flask with 
0.5 ml of water, portions of α- or γ-CDs with [Emim][EtSO4] (50 µl) additive were added and 
stirred to solubilize all the gel. The addition was repeated until the first symptom of precipitate 
appeared. The results were concluded by visual observation. Then, a solution of 0.9% sodium 
chloride in water (serum solution) was prepared (0.0045 g NaCl per 0.5 ml H2O). The same 
procedures were repeated for α- and γ-CDs dissolution studies in water with sodium chloride 
buffer, pH=7.  
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V. Ionic Liquids from nucleobases  
 
Nucleotides are the building blocks of all nucleic acids and on the other hand, ILs have come 
under worldwide scrutiny mostly through their use as solvents. Mainly, the room temperature 
ionic liquids (RTILs), also known as “designer solvents” have been tested as greener 
replacement of common toxic organic solvents
5
.Their flexible nature in the solubility of various 
compounds, including pharmaceuticals and biological compouds, indicated us that ILs can be 
excellent for the dissolution of nucleobases. Nevertheless, the preparation of ILs derived from 
nucleotides has not been reported so far. Having this fact in mind, this chapter presents the 
development of novel CILs based on nucleosides such as adenosine, guanosine, thymidine and 
uridine as well as nucleotide based on adenosine monophosphoric acid (AMP).  
 
V.1. Synthesis of organic salts developed from nucleosides and AMP 
nucleotide 
 
It is interesting to note that the bases of nucleic acids are biological molecules constituted by 
heteroaromatic rings like imidazole from ionic liquid structures (Figure V.1). In this context, 
nucleosides can be manipulated in order to create novel nucleoside-based ILs according with 
combination with adequate counter-ions.  
 
 
 
Figure V.1 - Comparison of nucleic acids cations with imidazolium cation. 
 
Initially, the protonation of four nucleosides, namely guanosine, adenosine, thymidine and 
uridine, using hydrochloric acid were performed as indicated in Scheme V.I. Then different 
organic acids were tested for the studies. Hydrochloric acid (1M) and mesylic acid (0.05 to 1M) 
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in methanol or water was firstly prepared for the adequate protonation of each nucleoside. 
1
H 
NMR spectra showed that the protonation with hydrochloric acid is possible for all the cases. A 
characteristic chemical shift of all the protons was observed when compared to 
1
H NMR spectra 
of the starting materials (all protons more deshielded). The protonation using mesylic acid was 
much more difficult to carry out. This procedure failed in all of the cases, probably due to 
solubility and stability problems of the nucleoside scaffolds (Scheme V.2). Different reaction 
conditions (acid concentration, type of solvents, temperature and reaction time, among others) 
were studied without positive results. It was concluded that solubility and chemical stability of 
nucleoside could be one of the limitations that made it difficult in order to obtain the correct 
proportion of nucleoside to mesylic acid. It is important to empathize that the degradation of the 
nucleoside sugar ring was observed when an excess of mesylic acid was added. Later 
experiments on the protonation of guanosine using solutions of gluconic (1: 0.9 eq) and glycolic 
(1: 1 eq.) acids in proportion to the adequate nucleoside were also performed. All this efforts 
failled as indicated in Scheme V.2. One of the reasons could be the fact that those acids are 
much weaker than mesylic and hydrochloridic, thus aren´t acidic enough to keep the positive 
charge on the nucleoside (pKa= 3.86 for gluconic and pKa= 3.83 for glycolic acids). 
 
Similar to the procedure explained for the synthesis of CILs from amino acids (see chapter II 
and III), after the successful protonation with hydrochloric acid, the second step corresponded to 
anion exchange reaction using bis(trifluoromethanesulfonyl)imide ([NTf2]), docusate ([AOT]) 
and p-toluenosulfonate ([TsO]) as selected anions. The studies showed the importance of the 
appropriate selection of counter-ions. [NTf2] anion wasn´t acidic enough to keep the positive 
charge on the nucleoside, while [TsO] anion created too acidic condition for the compound to 
be stable. After these reactions, it was possible to conclude the limited success related with the 
preparation of organic salts based on three nucleosides as cations when combined with docusate 
[AOT] as biocompatible anion (Figure V.2). It seems that larger alkylsulfonate anions can be 
appropriate for these combinations. Only in the case of adenosine the degradation of the 
nucleoside was observed. Interestingly, both guanosine and adenosine contain a primary amine 
attached directly to the heterocyclic ring, nevertheless they showed different solubility 
behaviour and pKa values as presented in Scheme V.1. Figures V.3 and V.4 present the 
1
H 
NMR spectra of [T][AOT], 11b, and [U][AOT], 12b, respectively which elucidate about the 
expected cation/anion correlations by quantitative integration of their characteristic 
1
H 
resonance peaks (1:1 for 11b and 1.07:1 for 12b). It is interesting to note that the 
1
H NMR 
spectra of nucleoside ion combined with the large docusate anion comparing with the spectra of 
chloride as anion showed a significant chemical shift. Therefore it can be concluded that 
stronger interactions occur between the docusate anion (including sulfonate structure) and 
nucleoside cation as illustrated in additional NMR studies presented in subsection V.3. 
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Scheme V.1 - Protonation of nucleosides using hydrochloridic acid. 
 
 
 
 
 
 
 
Scheme V.2 - Studies on the protonation of nucleosides using other organic acids. 
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Figure V.2 - Structures of chiral salts synthesized from nucleosides as cations docusate [AOT] as 
anion. 
 
 
 
 
Figure V.3- 
1
H NMR spectra of [T][AOT] 11b performed in dry DMSO. 
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Figure V.4 - 
1
H NMR spectra of [U][AOT] 12b performed in dry DMSO. 
 
In addition, synthesis of chiral salts based on adenosine 5´- monophosphoric acid (AMP, 
Chapter I, Figure I.11) as nucleotide structure were also performed. According to this, 
Amberlyst A-26 resin (in the OH form) has been used to exchange halides (bromide or chloride) 
to hydroxide form and then this basic solution reacted with an adequate acid solution. The 
structures of the developed salts are presented in Figure V.5. The direct acid-base reaction 
yields the desired AMP salt combined with selected organic cations such as 
trihexyltetradecylphosphonium ([P6,6,6,14]), 13a, 1-ethyl-3-methylimidazolium ([Emim]), 13b, 
and 1-(2-methoxyethyl)-3-methylimidazolium ([C3Omim]), 13c. In the case of choline 
([Choline]) cation, a direct reaction (without resin column method) was performed from 
commercial available choline hydroxide, 13d. 
1
H NMR of an example of chiral salt based on 
AMP scaffold as the anionic unit is presented in Figure V.6. 
 
Figure V.5 - Structures of the salts developed from AMP nucleotide. 
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Figure V.6- 
1
H NMR spectra of [Emim][AMP] 13b performed in dry DMSO. 
 
V.2. Characterization of salts developed from nucleosides and AMP 
 
All isolated products were completely characterized by 
1
H and 
13
C NMR, FTIR spectra and 
elemental analysis in order to check their expected structures and final purities. The desired 
chiral nucleoside-based salts ([G][AOT], 9b, [T][AOT], 11b, and AMP-based salts 
([P6,6,6,14][AMP], 13a, [Emim][AMP], 13b, [C3Omim][AMP], 13c, and [Choline][AMP], 13d, 
were obtained in high yields (76-99%) as well as high purities as indicated in Table V.I. 
Furthermore, the uridine based salt [U][AOT], 12b, was obtained in lower yield (23% of yield) 
comparing with other cases. Table V.1 summarizes some physical and thermal characteristics of 
the synthesized salts from nucleosides and AMP-nucleotide. All protonated nucleosides with 
hydrochloric acid in methanol solution were obtained as white pastes and only characterized by 
1
H and 
13
 C NMR spectroscopy. For cream-coloured pastes of chiral guanosine and thymidine-
based salts [G][AOT], 9b, and [T][AOT], 11b, no Tg values were observed. Among all, the only 
solid synthesized was based on uridine [U][AOT], 12b, with a melting point of 134 ºC. 
Particularly relevant is the successful reduction of the initial melting point of commercial 
uridine (167.2 ºC) by the appropriate selection of the organic anion. All the salts derived from 
AMP nucleotide were obtained as viscous yellow liquids. The Tg was determined at 
heating/cooling rate of 10 ºC.min
-1
 for all compounds and the values obtained were between -
24.32 and -48.19 ºC, except for [Emim][AMP], 13b, in which the Tg was not detectable.  
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Decomposition studies were performed by TGA analysis for some of the synthesized 
compounds. In some cases it is possible to observe an improvement in the thermal stability of 
the original neutral nucleosides and AMP nucleotide compounds. This observation suggests that 
the stronger cation-anion interaction can stabilize better the final salt avoiding their thermal 
stability at lower temperatures. 
 
According to the poor miscibility of AMP in most of organic solvents, the solubility behaviour 
of novel ILs derived from AMP was studied in order to show the possibility to enhance their 
miscibility.  
 
Table V.1 - Characterization of new synthesized salts based on nucleosides and AMP scaffolds. 
Salt Yield [%] Purity [%] Physical state Tg [ºC]
[a]
 
Tdec 
[ºC]
[d]
 
[G][Cl] 9a ˃99 99 white paste Tm < 250 (lit.)
 
 
[e] 
[A][Cl] 10a 99 99 white paste Tm < 234 (lit.) 
[e]
 
[T][Cl] 11a 73 99 white paste Tm < 186 (lit.) 
[e] 
[U][Cl] 12a 76 99 white paste Tm < 163 (lit.) 
[e] 
[G][AOT] 9b 76 97 cream-coloured paste --
[b] [e] 
[T][AOT] 11b ≥99 99 cream-coloured paste --
[b]
 241.60 
[U][AOT] 12b 23 97 cream-coloured solid Tm=134
 [c] [e] 
[P6,6,6,14][AMP] 13a 98 99 viscous yellow liquid -48.19 269.20 
[Emim][AMP] 13b 76 99 viscous yellow liquid --
[b]
 275.30 
[C3Omim][AMP] 13c 96 98 viscous yellow liquid -24.32 260.10 
[Choline][AMP] 13d 98 99 viscous yellow liquid -30.51 270.50 
[a]
 Glass transition temperature (Tg) was determined by DSC measurements at a heating/cooling rate of 10 ºC.min
-1
 for all 
salts.
 [b]
 Not observed by DSC studies. 
[c] 
Melting temperature was determined on Electrotermal Melting Point Apparatus. 
[d] 
Decomposition temperature (Tdec) was determined by TGA studies. 
[e] 
Not determined. 
 
V.3. NMR interaction cation-anion studies 
 
Preliminary 
1
H NMR studies were performed in the case of [T][AOT], 11b, and [Emim][AMP], 
13b, at different temperatures to determine the degree of cation-anion interactions. Figure V.7 
and Figure V.8 illustrate a comparative 
1
H NMR measurements of both of the salts derived from 
nucleic acids bases either as cation (11b) or anion (13b) at five temperatures (25, 40, 55, 70 and 
85 
o
C) in d-DMSO. In the case of 11b, two different regions of the 
1
H NMR spectra between 
3.40 to 2.80 and around 2.10 ppm were particularly selected to check the heteroaromatic 
cationic part and the aliphatic signals close to the negative charge of docusate anion, 
respectively. In the case of CH3 group attached to the pyrimidine ring of thymidine (singlet at 
3.35 ppm), a chemical shift to right was observed between 25 ºC and 85 ºC. This variation of 
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the chemical shift (at least 0.37 ppm of difference between 25 ºC to 85 ºC) can be explained by 
the possible interaction of the protons close to the nucleoside positive charge with the aliphatic 
signals near to negative charge. The CH2 peaks close to sulfonate anion (multiplet at 2.10 ppm) 
increase for higher temperature values (free rotation of the molecule). It is clear that increase of 
temperature from 25 ºC up to 85 ºC (hence decrease of viscosity), facilitates the cation-anion 
interaction close to ion charge. 
 
 
 
Figure V.7 - Comparative 
1
H-NMR study of [T][AOT] for five temperatures (25, 40, 55, 70 and 85 
ºC) and two NMR regions (3.40 to 2.80 and at 2.10 ppm) in DMSO. 
 
In the case of [Emim][AMP] 13b, region between 4.00 to 3.00 ppm was choosen to see 
behaviour of imidazolium cation as presented in Figure V.6. Also for this sample the CH3 peak 
close to the positive charge (singlet at 3.85 ppm), increase at higher temperature and a chemical 
shift to right was observed between 25 ºC and 85 ºC. This variation of the chemical shift (0.4 
ppm of difference between 25 ºC to 85 ºC) can be explained by the possible interaction of the 
protons close to the nucleoside negative charge (monophosphate anion) with the protons near 
the positive charge of imidazolium cation.  
Development of novel ionic liquids based on biological molecules 
 
 
Io
n
ic
 L
iq
u
id
s 
fr
o
m
 n
u
cl
eo
b
as
es
 
125 
 
 
Figure V.8 - Comparative 
1
H-NMR study of [Emim][AMP] for five temperatures (25, 40, 55, 70 and 
85 ºC) in DMSO. 
 
V.4. Critical micellar concentration studies 
 
In colloidal and surface chemistry, surfactants (also known as surface-active agents or 
detergents) are among the most adaptable chemicals available. Because of their unique 
functional properties, surfactants find a wide range of uses including chemistry (chemical 
kinetics or equilibria), biology (as membrane mimetics), and pharmacy
 144
. Depending on the 
type of product, these include improving the solubility (increase of bioavailability), stability of 
specific drugs in liquid preparation and extention of drug absorption. Surfactants can provoke 
direct effects on biological membranes thus altering drug transport across the membrane. 
Furthermore, they may reduce the effectiveness of antimicrobials or preservatives included in a 
specific biological formulation. Detergents are amphiphilic materials containing both apolar 
long-chain hydrocarbon ´tail´ and polar, usually ionic, ´head´groups
145
. In polar solvents, for 
example water, this property of the amphiphile leads to self-association: the surfactant 
molecules arrange themselves into organized molecular assemblies known as micelles or 
colloid-sized clusters as presented in Figure V.9. Amphiphilic molecules form micelles above a 
particular concentration which is called as critical micellar concentration (CMC)
145
. The CMC 
is an important characteristic of a surfactant. Before reaching the CMC, the surface tension 
varies strongly with the concentration of the surfactant. After reaching the CMC, the surface 
tension stays relatively constant or changes with a lower slope. The value of the CMC for a 
specific dispersant in a given medium depends on temperature, pressure, and (sometimes 
strongly) on the presence and concentration of other surface active substances and electrolytes. 
CMC has been obtained by numerous researchers using different techniques such as surface 
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tension (tensiometer), conductivity (coductimeter) or absorption studies (UV/VIS 
spectrophotometer)
 146
. For example, the value of CMC for anionic surfactant [Na][AOT] at 20 
ºC, atmospheric pressure, measured by conductivity method is 2.40 (mol.dm
-3
.10
3
). 
 
 
Figure V.9 - An idealized model for a spherical micelle of sodium dodecyl sulfate
144
. 
 
According to the surfactant nature of the biocompatible [AOT] used for the preparation of novel 
chiral salts based on nucleosides presented in this chapter, CMC measurements of 9b and 11b 
were performed firstly using Absorption Spectroscopy Method. Unfortunetly, this method failed 
due to the strong interactions between the nucleosides derived salts and the chosen colored 
probe (acridine yellow G as well as normal acridine). In the second approach, electrical 
conductivity measurements were chosen in order to measure the type of micelles of the 
surfactants with two different nucleoside counterions (guanosine and thymidine). The possible 
CMC values were obtained by plotting conductance ᴧ against the concentration of the 
surfactant. There are some indications that chiral cations derived from nucleosides may lower 
CMC values comparing with common Na[AOT]. It seems that the size of counter-ion plays an 
important role: a bigger size of the counter-ion lowers its accessibility towards the head group 
and the chance for micellization at lower concentration is better. Nevertheless, in order to prove 
this hipothesis a large range of concentrations should be used for conductivity studies or other 
method such as surface tension should be examinated. In order to measure the type of micelles, 
more detail studies should be performed using for instance Dynamic Light Scattering method 
(DLS). 
 
V.5. Fluorescence studies 
 
Nucleotides display environmentally sensitive fluorescence and therefore give strong signals 
upon a binding event which makes them a perfect probe for stopped- flow and equilibrium 
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analysis
147
. It was observed that these new chiral salts derived from AMP nucleotide are 
fluorescent at ambient temperature as the neutral AMP nucleotide. Figure V.10 shows the 
comparative fluorescence between RTIL [Emim][AMP], 13b (right) and original crystalline 
powder AMP (left) by UV light. In this context, novel RTILs [Emim][AMP], 13b and 
[C3Omim][AMP] 13c were chosen in order to evaluate their fluorescence. The studies were 
performed in aqueous solutions (10.
-6
 M), so for this reason water insoluble [P6,6,6,14][AMP], 
13a, was not selected. The emission spectrum was monitored at wavelenght λ=521 nm. The 
spectroscopic measurements showed that the starting material AMP is the least fluorescent 
material proving that the enhancement of the fluorescence of nucleotide in aqueous solution is 
possible when AMP was transformed to a chiral salt (Figure V.11). Specifically, [Emim][AMP] 
caused a 2-fold increase in the fluorescence intensity comparing with the initial nucleotide 
(increase from 1.13 to 2.23). In the case of [C3Omim][AMP] it was possible to obtain a 1.35-
fold enhancement of fluorescence intensity. This fact could be explained by possible 
interactions between the acidic imidazolium proton (2-H) with the phosphate [AMP] anion. 
 
 
 
Figure V.10 -An example of fluorenscence material- photo of [Emim][AMP](right) and the solid 
AMP nucleotide (left) under UV lamp. 
 
Figure V.11- Emission spectra of AMP nucleotide (violet) and new AMP-based chiral salts 
[Emim][AMP] in blue, and [C3Omim][AMP] in green at concentration 10.
-6
 M. 
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V.6. Conclusions 
 
In the last chapter concerning the design of novel bio-derived ionic liquid, the attention is payed 
to bases of nucleic acids. These biological compounds that lead directly to the helical structure 
of DNA and RNA showed potencial to be used as a source for design of novel pure chiral salts. 
 
After optimizing the synthetic approaches, it was possible to protonate nucleosides and also to 
combine three of them (guanosine, thymidine and uridine) with biocompatible docusate anion. 
It was concluded that protonated nucleotides may form ILs. Nevertheless, aminoacids are easier 
to protonate when comparing with nucleosides. The surfactant docusate anion was crucial in 
order to reduce the melting temperature in the case of [U][AOT] 12b, moreover because its 
large size facilitates stronger interactions with the cationic unit than chloride anion. Neverless, 
different organic anions such as mesylate ([CH3SO3]), gluconate ([HOCH2(CHOH)4CO2]), 
glycolate ([HOCH2CO2]) and bis(trifluoromethanesulfonyl)imide ([NTf2]) were not enough 
acidic to keep the positive charge on the nucleoside scaffold.  
 
Chiral salts developed from AMP nucleotide by using ion exchange resin method 
[P6,6,6,14][AMP] 13a, [Emim][AMP] 13b, [C3Omim][AMP] 13c, [Choline][AMP] 13d are the 
most promissing examples as they all were obtained as RTILs. It is important to note that this 
synthetic approach was easier to control and the sugar ring of the nucleotide was more stable in 
these basic conditions. Glass transition temperatures were detected for AMP-based CILs in 
contrast to the initial crystalline AMP nucleotide with the melting point of 178 to 185 °C. All of 
novel chiral salts derived from natural nucleosides and nucleotides were synthesized with 
moderate to high yields and purities, except in the case of [U][AOT].  
 
The attempt was to apply these new chiral salts for fluorescence enhancement of the initial 
AMP nucleotide. On the other hand, the idea was to determine the CMC in order to study their 
possibility to act as surfactants forming micelles. 
 
In our work, we illustrated the opportunity to perform chiral salts and at the same time, some 
RTILs from AMP nucleotide, thus further investigation on their preparation method, toxicology 
as well as better understanding of solubility mechanism should be attain. Different synthetic 
approaches should be examinated in order to develop other salts based on nucleic acid bases, eg. 
mixing the nucleobase with a buffer and using the ion exachange resin method. 
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From the biological, medical and pharmaceutical point of view, the possibility to prepare novel 
modified nucleosides is extremely attractive as the interest on their solubility chemistry is 
growing as well as the knowledge of its biochemical importance and applications is becoming 
better known
148
. Molecules that act like nucleosides in DNA synthesis known as nucleosides 
analogues include a range of antiviral products used to prevent viral replication in infected cells. 
These agents can be used against hepatitis B virus, hepatitis C virus, herpes simplex as well as 
cancer (chemotherapy agents). Knowledge of the often complex interactions amongst 
antiretroviral drugs and their clinical implications is important to maintain their antiretroviral 
efficiency and avoid toxicity. Some studies on the development of drugs in form of gels to 
improve their activity and solubility were performed
149
. In our work no additional media was 
needed in order to determine salts of nucleobases with a possible future application as antiviral 
drugs. Transformation of a drug from a neutral into salt form could improve the solubility, 
terapeutical activity and avoid the polymorphism as long as the derived salts are amorphous. 
Nucleobases are involved in two qualitatively diverse mutual interactions: hydrogen bonding 
and aromatic base stacking. Therefore, the correct choice of counter-ion could protect the drug, 
easy the transport and work as the drug carrier.  
 
V.7. Experimental part 
 
General: Commercially available reagents (Guanosine, MW= 283.24 g.mol
-1
, CAS No. 118-00-
3, Adenosine, MW= 267.24 g.mol
-1
, CAS No. 58-61-7, Thymidine, MW= 242.23 g.mol
-1
, CAS 
No. 50-89-5, Uridine, MW= 244.20 g.mol
-1
, CAS No. 58-96-8 and adenosine 5´- 
monophosphoric acid, MW= 346.21 g.mol
-1
, CAS No. 61-19-8), ionic liquids, solvents were 
purchased from Alfa Aestar, Aldrich, Solchemar and were used without further purification. 
The basic anion-exchange resin Amberlyst A-26 (OH-form with ion-exchange capacity 0.8 
eq.mL
-1
) was purchased from Supelco. 
 1
H and 
13
C NMR spectra were recorded at room 
temperature on a Bruker AMX400 spectrometer with TMS as internal standard. Chemical shifts 
are reported downfield in ppm. Dried DMSO was used as deutrated solvent in order to avoid 
any water cotent in the spectra of all the synthesized compounds. IR spectra were performed by 
Perkin Elmer model Spectrum 1000 using NaCl plates for neat liquids. DSC analysis was 
carried out using a TA Instruments Q-seriesTM Q200 DSC with a refrigerated cooling system. 
The decomposition temperatures were measured with the Simultaneous Thermal Analyser STA 
449 F3 Jupiter, using a nitrogen atmosphere (mass changed in % or mg). The samples for 
elemental analysis were performed by Laboratório de Análises at REQUIMTE, Departamento 
de Química Faculdade de Ciências e Tecnologia (Monte da Caparica) using Thermo Finnigan-
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CE Instruments equipment, model Elemental Analyser 1112 series. The melting point (mp) was 
determined by Electrothermal Melting Point Apparatus.  
Absorption measurments: UV/Vis absorption spectra were recorded with a Varian-Cary 100 Bio 
UV/Vis Spectrophotometer at 20 ºC. 
Emission measurments: Emission spectra were performed using Perkin Elmer LS 45 
Luminescence Spectrometer at 20 ºC. 
Conductivity measurments: CMC was determined by using Crison Conductimeter Basic 30, 
conductivity cell + Pt 1000 at 20 ºC. 
V.7.1. General procedure for protonation of nucleosides (9a), (10a), (11a), 
(12a) 
 
The general approach of the protonation was to dissolve the nucleoside (9, 10, 11, 12) in 40 ml 
of methanol and add slowly 1M solution of HCl in MeOH (1:1 eq., 1.77 ml) in order to 
protonate the amine group. The reaction mixture was stirred at room temperature for 24h. The 
solution was evaporated and dried in vacuo for ~24h. The adequate nucleoside hydrochloride 
9a, 10a, 11a, 12a was obtained as a white solid. 
 
9-(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-
dihydro-1H-purin-2-aminium chloride (9a): (0.56 g, >99 %). 
1
H NMR (400.13 MHz, 
DMSO) δ 11.71 (s, 1H, H1), 9.12 (s, 1H, H8), 7.30 (s, 3H, H2), 5.82 (d, 
3
JH1´-H2´= 4 Hz, 1H, H1´), 
5.78 (t, 
2, 3
JH2´-H2 ,́ H1´=4 Hz, 1H, H2´), 4.51 (s, 3H, H2´, H3´, H5´), 4.39 (t, 
2, 3
JH3´-H3´, H2´=4 Hz, 1H, 
H3´), 4.16 (m, 1H, H4´), 3.97 (t, 
2, 3
JH2´-H3 ,́ H2´=4 Hz, 1H, H2´), 3.72 (dd, 
2
J H5´-H5´= 4 Hz, 
3
J H5´-H4´= 
16 Hz, 1H, H5´), 3.61 (dd, 
2
J H5´-H5´= 4 Hz, 
3
J H5´-H4´= 16 Hz, 1H, H5´). 
13
C NMR (100.61 MHz, 
DMSO) 155.85 (C6), 154.25 (C2), 150.04 (C4), 135.65 (C8), 109.76 (C5), 88.75 (C1´), 85.74 
(C4´), 74.55(C2´), 69.63 (C3´), 49.04 (C5´). 
 
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 
chloride (10a): (0.63 g, 99%). 
1
H NMR (400.13 MHz, DMSO) δ 9.51 (s, 3H, H6), 8.74 (s, 1H, 
H2), 8.54 (s, 1H, H8), 5.97 (d, 
3
JH1´-H2´= 4 Hz, 1H, H1´), 4.52 (t, 
2, 3
JH2´-H2 ,́ H1´=4 Hz, 1H, H2´),4.18 
(t, 
2, 3
JH3´-H3´, H2´=4 Hz, 1H, H3´), 3.68 (d, 
3
JH4´-H3´=4 Hz, 1H, H4´), 3.61 (dd, 
2
J H5´-H5´= 4 Hz, 
3
J H5´-
H4´= 16 Hz, 1H, H5´), 3.58(dd, 
2
J H5´-H5´= 4 Hz, 
3
J H5´-H4´= 16 Hz, 1H, H5´). 
13
C NMR (100.61 
MHz, DMSO) 155.85 (C6), 151.25 (C4), 150.04 (C2), 136.33 (C8), 108.88 (C5), 87.52 (C1´), 
85.64 (C4´), 72.35(C2´), 67.63 (C3´), 48.97 (C5´). 
 
3-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methyl-2,6-
dioxo-1,2,3,6-tetrahydropyrimidin-1-ium chloride (11a): (0.21 g, 73%). 
1
H NMR (400.13 
MHz, DMSO) δ 11.25 (s, 2H, H3), 7.68 (s, 1H, H6), 6.15 (t, 
2, 3
JH1´-H2´=4 Hz, 1H, H1´), 4.22 (q, 
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3
JH4´-H3 ,́ H5´= 4 Hz, 1H, H4´), 5.01(t, 
3
JH5´-H5´, H4´= 4 Hz, 1H, H5´), 3.55 (m, 2H, H5´, H3´), 2.09 (m, 
2H, H2´), 2.05 (s, 3H, H7). 
13
C NMR (100.61 MHz, DMSO) δ 164.20 (C4), 150.93 (C2), 136.58 
(C6), 109.82 (C5), 87.71 (C1´), 84.19 (C4´), 70.90 (C3´), 61.80 (C5´), 49.06 (C2´), 12.72 (C7). 
 
3-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-1-ium chloride (12a): (0.21 g, 76%). 
1
H NMR (400.13 MHz, 
DMSO) δ 11.329 (s, 2H, H3), 7.88 (d, 
3
JH6-H5=8 Hz, 1H, H6), 5.76 (d, 
3
JH1´-H2´=4 Hz, 1H, H1´), 
5.56 (d, 
3
JH5-H6=8 Hz, 1H, H5), 4.01-3.83 (m, 3H, H3´, H4´, H2´), 3.53 (m, 2H, H5´).
 13
C NMR 
(100.61 MHz, DMSO) δ 163.59 (C4), 151.22 (C2), 141.19 (C6), 102.21 (C5), 88.14 (C1´), 85.30 
(C4´), 74.00 (C2´), 70.35 (C3´), 61.31 (C5´).
 
 
V.7.2. Synthesis of 9-(2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-
purin-2-aminium 1,4-bis((2-ethylhexyl)oxy)-1,4-dioxobutane-2-
sulfonate (9b) 
 
After the protonation was 
finished, the isolated guanosine 
hydrochloride (0.2 g; 0.63 
mmol) was dissolved in 10ml of 
methanol and Na[AOT] was 
added to perform the ion 
exchange (0.33 g; 0.75 mmol). 
The reaction was stirred for 24 h 
at room temperature. Then the solvent was evaporated and the crude was redissolved in acetone 
in order to remove the inorganic salts by precipitation. The solution was evaporated and dried in 
vacuo for 24 h. The desired product was obtained as a cream-coloured paste (0.33 g, 76%). 
1
H 
NMR (400.13 MHz, DMSO) δ 11.72 (s, 1H, H1), 9.00 (s, 1H, H8), 7.26 (s, 3H, H2), 6.17 (t, 
2, 
3
JH2´-H2 ,́ H1´=4 Hz, 1H, H2´), 5.78 (d, 
3
JH1´-H2´= 4 Hz, 1H, H1´), 5.38 (d, 
3
JH3´-H2´=4 Hz, 1H, H3´), 
4.40 (m, 1H, H4´), 3.90- 3.86 (m, 4H, Hf), 3.77 (m, 1H, H3´), 3.62 (dd, 
2
J Hh-Hh´= 4 Hz, 
3
J Hh´-Hg= 
8 Hz, 1H, Hh), 3.58 (m, 2H, H5´), 3.13 (d, 
3
JH2´-H3´=1H, H2´), 2.96 (m, 1H, Hg), 2.79 (dd, 
2
J Hh´-
Hh= 4 Hz, 
3
J Hh´-Hg= 8 Hz, 1H, Hh´,), 1.52 (m, 2H, Hd), 1.35 – 1.23 (m, 16H, Hb, Hc, He), 0.91-
0.84 (m, 12H, Ha).
 13
C NMR (100.61 MHz, DMSO) δ 171.51 (-C=O), 158.39 (C6), 153.77 (C2), 
149.47 (C4), 136.66 (C8), 117.81 (C5), 108.36 (C1´), 89.11 (C4´), 81.64 (C2´), 71.33 (C3´), 68.23 
(Cf), 65.12 (Cg), 61.87 (C5´), 38.59 (Cd), 30.20 (Cc), 30.02 (Cc), 28.80 (Ch), 23.65 (Cb), 22.86 
(Ce), 11.28 (Ca), 11.25 (Ca). FTIR (NaCl) ʋ = 3424, 2960, 2930, 2868, 2588, 2364, 1716, 1642, 
1613, 1526, 1463, 1371, 1219, 1169, 1092, 1045, 924, 818, 772, 733, 678, 573, 467, 450 cm
-1
.
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Elemental analysis (%) calcd for C30H51N5O12S (MW= 705.82 g.mol
-1
): C 51.05; H 7.28; N 
9.92; S 4.54; found: C 50.79; H 7.32; N 9.88; S 4.51.  
 
V.7.3. Synthesis of 3-(2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-5-methyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-1-ium 1,4-bis((2-ethylhexyl)oxy)-1,4-
dioxobutane-2-sulfonate (11b) 
 
The isolated protonated 
thymidine hydrochloride 
(0.21 g; 0.74 mmol) was 
dissolved in 10ml of 
methanol and Na[AOT] was 
added to perform the ion 
exchange (0.39 g; 0.89 mmol). The reaction was stirred for 24 h at room temperature. Then the 
solvent was evaporated and the crude was redissolved in acetone in order to remove the 
inorganic salts by precipitation. The solution was evaporated and dried in vacuo for 24 h. The 
desired product was obtained as a cream-coloured paste (0.49 g, ≥ 99%). 
1
H NMR (400.13 
MHz, DMSO) δ 11.27 (s, 2H, H3), 7.71 (s, 1H, H6), 6.17 (t, 
2, 3
JH1´-H2´=4 Hz, 1H, H1´), 5.24 (q, 
3
JH4´-H3 ,́ H5´= 4 Hz, 1H, H4´), 5.01(t, 
3
JH3´-H2´= 4 Hz, 1H, H3´), 4.25 (m, 1H, H5´), 3.91- 3.87 (m, 
4H, Hf), 3.77 (m, 1H, H3´), 3.66 (dd, 
2
J Hh-Hh´= 4 Hz, 
3
J Hh´-Hg= 8 Hz, 1H, Hh), 3.53 (m, 1H, H5´), 
2.96 (m, 1H, Hg), 2.82 (dd, 
2
J Hh´-Hh= 4 Hz, 
3
J Hh´-Hg= 8 Hz, 1H, Hh´,), 2.06 (m, 1H, H2´), 1.75 (s, 
3H, H7), 1.51 (m, 2H, Hd), 1.36 – 1.24 (m, 16H, Hb, Hc, He), 0.89-0.82 (m, 12H, Ha).
 13
C NMR 
(100.61 MHz, DMSO) δ 171.06 (C4, -C=O), 168.39 (-C=O), 163.75 (C2), 150.47 (C6), 136.13 
(C5), 109.36 (C1´), 87.26 (C4´), 83.74 (C2´), 70.45 (C3´), 66.23 (Cf), 66.16 (Cg), 61.42 (C5´),38.18 
(Cd), 29.74 (Cc), 29.57 (Cc), 28.80 (Cc), 28.34 (Ch), 23.20 (Cb), 23.17 (Ce), 13.92 (C7), 12.24 
(Ca), 10.78 (Ca). FTIR (NaCl) ʋ = 3862, 3450, 2959, 2929, 2865, 2362, 1732, 1657, 1463, 1391, 
1218, 1048, 853, 766, 734, 667, 585, 468 cm
-1
. Elemental analysis (%) calcd for C30H52N2O13S 
(MW= 680.80 g.mol
-1
): C 52.93; H 7.70; N 4.11; S 4.71; found: C 52.66; H 8.02; N 3.90; S 
4.47.  
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V.7.4. Synthesis of 3-(2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-1-ium 1,4-bis((2-ethylhexyl)oxy)-1,4-
dioxobutane-2-sulfonate (12b) 
 
The isolated protonated uridine 
hydrochloride (0.21 g; 0.74 
mmol) was dissolved in 10ml of 
methanol and Na[AOT] was 
added to perform the ion 
exchange (0.39 g; 0.89 mmol). 
The reaction was stirred for 24 h at room temperature. Then the solvent was evaporated and the 
crude was redissolved in acetone in order to remove the inorganic salts by precipitation. The 
solution was evaporated and dried in vacuo for 24 h. The desired product was obtained as a 
cream-coloured solid (0.11 g, 23%). Tm=134 ºC.
 1
H NMR (400.13 MHz, DMSO) δ 11.31 (s, 2H, 
H3), 7.90 (d,
3
JH6-H5=4 Hz, 1H, H6), 5.79 (d, 
3
JH1´-H2´=4 Hz, 1H, H1´), 5.66 (d, 
3
JH5-H6=4 Hz, 1H, 
H5), 5.38 (d, 
3
JH2´-H1´=4 Hz, 1H, H2´), 5.09(t, 
3
JH3´-H2´=4 Hz, 1H, H3´), 4.02 (m, 1H, H4´), 3.91- 
3.85 (m, 4H, Hf), 3.77 (m, 1H, H3´), 3.62 (dd, 
2
J Hh-Hh´= 4 Hz, 
3
J Hh´-Hg= 8 Hz, 1H, Hh), 3.34 (m, 
2H, H5´), 3.18 (d, 
3
JH2´-H3´=4 Hz, 1H, H2´), 2.91 (m, 1H, Hg), 2.82 (dd, 
2
J Hh´-Hh= 4 Hz, 
3
J Hh´-Hg= 8 
Hz, 1H, Hh´,), 1.50 (m, 2H, Hd), 1.34 – 1.24 (m, 16H, Hb, Hc, He), 0.89-0.82 (m, 12H, Ha).
 13
C 
NMR (100.61 MHz, DMSO) δ 176.28 (C4), 173.60 (-C=O), 168.33(C2), 155.97 (C6), 145.99 
(C5), 109.96 (C1´), 92.90 (C4´), 90.06 (C2´), 78.76 (C3´), 75.10 (Cf), 71.40 (Cg), 66.64 (C5´), 39.32 
(Cd), 35.90 (Cc), 34.96 (Cc), 33.56 (Cc), 28.39 (Cc), 28.34 (Ch), 27.63 (Cb), 23.20 (Ce), 19.11 
(C7), 16.00 (Ca), 15.97 (Ca). FTIR (KBr) ʋ = 3454, 3323, 3051, 2967, 2927, 2862, 2362, 1715, 
1679, 1456, 1418, 1257, 1218, 1076, 1044, 910, 853, 767, 722, 658, 581, 447, 425 cm
-1
. 
Elemental analysis (%) calcd for C29H50N2O13S (MW= 666.78 g.mol
-1
): C 52.24; H 7.56; N 
4.20; O 31.19; S 4.81; found: C 52.03; H 7.54; N 4.17; S 4. 
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V.7.5. Synthesis of trihexyl(tetradecyl)phosphonium (2R,3S,4R,5R)-5-(6-
amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate (13a) 
 
For the preparation of 
trihexyl(tetradecyl)phosphonium 
((2R,3S,4R,5R)-5-(6-amino-9H-
purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-
yl)methyl hydrogenphosphate, a 
column ion exchange method 
was used. The [P6,6,6,14]Cl (0.74 
g; 1.44  mmol) was first 
transformed into hydroxide by 
the use of an ionic exchange 
column (Amberlyst A-26 OH) in 
methanol and then this basic solution was neutralized by reacting with the AMP acid (0.5 g; 
1.44 mmol) in methanol solution. The mixture was stirred at room temperature for 24 h. After 
the indicated time, the established water was evaporated and dried in vacuo for 24 h. The final 
product was obtained as a viscous yellow liquid (1.17 g, 98%). Tg= -48.19 
o
C. 
1
H NMR (400.13 
MHz, DMSO) δ 8.50 (s, 1H, H6), 8.14 (s, 1H, H8), 7.23 (s, 2H, H2), 5.91 (d, 
3
JH1´-H2´=4 Hz, 1H, 
H1´), 4.72 (t, 
3
JH2´-H1´=8 Hz,
 2
JH2´-H2´=4 Hz, 1H, H2´), 4.27 (m, 2H, H3´,H4´), 3.81- 3.73 (m, 4H, 
H2´,H3´, H5´), 2.17 (m, 8H, Hf), 1.38 (m, 16H, Hb, e), 1.29-1.25 (m, 32H, Hc,), 0.86 (m, 12H, Ha).
 
13
C NMR (100.61 MHz, DMSO) δ 155.92 (C2), 152.50 (C6), 149.88 (C4), 139.43 (C8), 118.67 
(C3), 86.31 (C1´), 84.69 (C4´), 74.22 (C2´), 71.51 (C3´), 63.95 (C5´), 31.28 (Cc), 30.39 (Cc), 29.85 
(Cd), 29.79 (Cd), 29.64 (Cd), 28.99 (Cb), 28.94 (Cb), 28.69 (Cb), 22.08, 21.79, 20.54 (Ce), 20.50 
(Ce), 13.93 (Ca), 13.84 (Ca). FTIR (NaCl) ʋ = 3334, 2927, 2857, 1674, 1609, 1465, 1420, 1337, 
1302, 1213, 1107, 990, 925, 830, 720, 646, 584 cm
-1
. Elemental analysis (%) calcd for 
C42H81N5O7P2 (MW= 830.07 g.mol
-1
): C 60.77; H 9.84; N 8.44; found: C 60.46; H 9.88; N 8.40.  
V.7.6. Synthesis of 1-ethyl-3-methyl-1H-imidazol-3-ium (2R,3S,4R,5R)-5-(6-
amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate (13b) 
 
For the preparation of 1-ethyl-3-methyl-1H-imidazol-3-ium ((2R,3S,4R,5R)-5-(6-amino-9H-
purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate, a column ion 
exchange method was used. The [Emim]Br (0.28 g; 1.44 mmol) was first transformed into 
hydroxide by the use of an ionic exchange column (Amberlyst A-26 OH) in methanol and then 
this basic solution was neutralized by reacting with the AMP acid (0.5 g; 1.44 mmol) in 
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methanol solution. The mixture was stirred at 
room temperature for 24 h. After the indicated 
time, the established water was evaporated and 
dried in vacuo for 24 h. The final product was 
obtained as a viscous yellow liquid (0.65 g, 99 
%). 
1
H NMR (400.13 MHz, DMSO) δ 9.19 (s, 
1H, Hb), 8.50 (s, 2H, H2), 8.14 (s, 1H, H6), 7.77 (s, 1H, Hd), 7.69 (s, 1H, Hd´), 7.24 (s, 1H, 
H8),5.91 (d, 
3
JH1´-H2´=4 Hz, 1H, H1´), 4.73 (t, 
3
JH2´-H1´=8 Hz,
 2
JH2´-H2´=4 Hz, 1H, H2´), 4.26 (m, 2H, 
H3´,H4´), 4.21-4.16 (q, 
3
JHe-Hf= 8Hz, 2H, He), 4.02 (s, 1H, H4´), 3.85 (s, 3H, Hg), 3.78-3.65 (m, 
4H, H2´, H3´, H5´), 1.40 (t, , 
3
JHe-Hf= 8 Hz, 3H, Hf).
 13
C NMR (100.61 MHz, DMSO) δ 156.38 
(C2), 153.05 (C6), 150.32 (C8), 139.90 (Cb), 124.00 (Cd), 122.38 (Cd´), 119.10 (C3), 86.76 (C1´), 
74.61 (C4´), 71.95 (C2´), 64.45 (C3´), 44.56 (C5´), 39.14 (Ce), 36.13 (Cg), 15.56 (Cf). FTIR (KBr) 
ʋ = 3407, 2930, 2857, 1654, 1576, 1478, 1424, 1391, 1389, 1300, 1216, 1171, 1065, 989, 930, 
871, 816, 765, 721, 644, 474 cm
-1
. Elemental analysis (%) calcd for C16H24N7O7P (MW= 457.38 
g.mol
-1
): C 42.02; H 5.29; N 21.44; found: C 41.82; H 5.32; N 21.33. FTIR (NaCl) ʋ = 3407, 
2930, 2857, 1654, 1576, 1478, 1424, 1391, 1389, 1300, 1216, 1171, 1065, 989, 930, 871, 816, 
765, 721, 644, 474 cm
-1
. 
 
V.7.7. Synthesis of 1-(2-methoxyethyl)-3-methyl-1H-imidazol-3-ium 
(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate (13c) 
 
For the preparation of 1-(2-
methoxyethyl)-3-methyl-1H-imidazol-3-
ium ((2R,3S,4R,5R)-5-(6-amino-9H-
purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate, a column ion 
exchange method was used. The 
[C3Omim]Cl (0.26 g; 1.44 mmol) was first transformed into hydroxide by the use of an ionic 
exchange column (Amberlyst A-26 OH) in methanol and then this basic solution was 
neutralized by reacting with the AMP acid (0.5g; 1.44 mmol) in methanol solution. The mixture 
was stirred at room temperature for 24 h. After the indicated time, the established water was 
evaporated and dried in vacuo for 24 h. The final product was obtained as a viscous yellow 
liquid (0.50 g, 98 %). Tg= -24.32 ºC. 
1
H NMR (400.13 MHz, DMSO) δ 9.15 (s, 1H, Hb), 8.46 (s, 
1H, H6), 8.15 (s, 1H, H8), 7.68 (d, 
3
JHd-Hd´=12 Hz 2H, Hd, Hd´), 7.12 (s, 2H, H2), 5.92 (d, 
3
JH1´-
H2´=4 Hz, 1H, H1´), 4.68 (t, 
3
JH2´-H1´=8 Hz,
 2
JH2´-H2´=4 Hz, 1H, H2´), 4.35 (m, 2H, H3´,H4´), 4.25 (t, 
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3
JHe-Hf= 4Hz, 2H, He), 4.15-4.06 (m, 4H, H2´, H3´, H5´), 3.86 (s, 3H, Hh), 3.66 (t, 
3
JHf-He= 4Hz, 
2H, Hf), 3.25 (s, 1H, Hg). 
13
C NMR (100.61 MHz, DMSO) δ 155.95 (C2), 152.64 (C6), 149.81 
(C8), 139.34 (Cb), 123.45 (Cd), 122.61 (Cd´), 118.72 (C3), 86.45 (C1´), 84.23 (C4´), 73.98 (C2´), 
71.18 (C2´), 69.61 (C3´), 64.34 (C5´), 58.04 (Cg), 48.62 (Ce), 35.75 (Ch). FTIR (NaCl) ʋ = 3421, 
2932. 2363, 1650, 1576, 1479, 1423, 1336, 1302, 1174, 1084, 921, 821, 722, 645, 585, 481 cm
-
1
. Elemental analysis (%) calcd for C17H26N7O8P (MW= 487.40 g.mol
-1
): C 41.89; H 5.38; N 
20.12; found: C 41.71; H 5.41; N 20.05. 
 
V.7.8. Synthesis of 2-hydroxy-N,N,N-trimethylethanaminium 
(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate (13d) 
 
For the preparation of 2-hydroxy-N,N,N-
trimethylethanaminium ((2R,3S,4R,5R)-5-(6-
amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate, a direct acid base recation 
was performed. Initially, the adenosine 5´- 
monophosphoric acid AMP (0.5 g; 1.44 mmol) 
was dissolved in 25 ml H2O and a solution of choline hydroxide in MeOH 45% (0.43 ml; 1.44 
mmol) was added dropwise. The reaction mixture was stirred at room temperature overnight. 
After the indicated time, the pH was measured to confirm that the reaction was completed (pH= 
8.0) and the water was evaporated and dried in vacuo for 8h. The final product was obtained as 
a viscous yellow liquid, (0.63 g, 98%). Tg= -30.51 
o
C. 
1
H NMR (400.13 MHz, DMSO) δ 8.46 
(s, 1H, H6), 8.14 (s, 1H, H8), 7.25 (s, 2H, H2), 5.91 (d, JH1´-H2´ = 4 Hz, 1H, H1´), 5.75 (m, 1H, 
H2´), 4.67 (m, 1H, H3´), 4.19 (m, 2H, H4´, H3´), 4.04 (m, m, 1H, H2´), 3.83 (m, 4H, Hb, H5´), 3.40 
(m, 2H, Ha), 3.11 (s, 9H, Hc).
 13
C NMR (100.61 MHz, DMSO) δ 156.41 (C2), 153.08 (C6), 
150.27 (C4), 139.81 (C8), 119.17 (C3), 86.91 (C1´), 74.48 (C4´), 71.69 (C2´), 67.47 (C3´), 64.70 
(Ca), 55.62 (C5´), 53.63 (Cb), 49.05 (Cc). FTIR (NaCl) ʋ = 3387, 2933, 2365, 1659, 1609, 1481, 
1423, 1392, 1337, 1302, 1217, 1173, 1104, 1061, 991, 960, 872, 821, 767, 719, 641, 479 cm
-1
. 
Elemental analysis (%) calcd for C15H27N6O8P (MW= 450.16 g.mol
-1
): C 40.00; H 6.04; N 
18.66; found: C 39.80; H 6.05; N 18.58. 
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V.7.9. General procedure for critical micelle concentration (CMC) of 
surfactant 9b and 11b 
 
The CMC determination of synthesised compounds was performed using two methods, UV-VIS 
spectroscopy and conductivity. 
 
Absorption measurments: In the first method it was necessary to resort to a molecular probe due 
to the lack of absorption by compounds. Therefore, two probes based on the same structure but 
with slight differences were used: Acridine Yellow G in the first place and Acridine as a second 
choice. Stock solutions (100mL) of probes were prepared in distilled water and stored. The 
same procedure was followed with chiral organic salts 9b and 11b combined with [AOT] anion. 
Then, absorption solutions (25mL) were prepared at different concentrations of product from 
compounds stock-solutions and with the same probe solution volume (5mL), in distilled water. 
The absorption spectra were measured but it wasn‟t possible determine any CMC with both 
probes.  
 
Conductivity measurments: Conductivities were measured at 20ºC by using a digital 
Conductimeter Basic 30. Compounds stock solutions (100 mL) were prepared and stored. A 
series of compounds solutions (10 mL) of different concentrations were prepared by dilutions 
from stock-solutions. The conductivities were measured in duplicate and CMC was determined. 
 
V.7.10. General procedure for fluorencence studies 
 
Solutions method: Emission spectra were performed using Perkin Elmer LS 45 Luminescence 
Spectrometer at 20 ºC with a slit width of 2.0 nm, an excitation value of 255 nm and at room 
temperature. Emission solutions (10 mL) were prepared at the same concentration for each 
target compound in distilled water (10.
-6
 M). 
 
Film method: The apparatus used was the same as in the previous method. In this method, 
instead of preparing a solution with a specific concentration a compound film from a quartz cell 
emission was prepared. The spectrum was measured in the same conditions previously used. 
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VI. Ethyl Lactate 
 
The aim of this chapter was to highlight the relevant relations and interactions between CILs 
and biological molecules such as amino acids, cyclodextrins and nucleobases. The concept of 
this thesis is strongly correlated with sustainability and green chemistry. Therefore, as an 
additional final subject (in the closure) the idea of ethyl lactate will be demonstrated. 
 
VI.1. Ethyl Lactate - an alternative green solvent besides ILs 
 
Green chemistry consists in the use of chemicals and chemical processes designed to reduce or 
eliminate negative environmental impacts. Applying this concept can also lead to reducing 
waste products, substitution of toxic for non-toxic components and simultaneously improve the 
reactions efficiency. The world demand for solvents is predicted to grow in the next years and 
the industrial requirements will lead to an increased claim for new fluids and alternative 
solvents
150
. Due to the very poor environmental and toxicological profiles and the volatile 
character of the most generally used solvents, there is a need for alternatives that may replace 
the current ones
151, 152
. Within the idea of green chemistry, a number of approaches have been 
proposed in the last few years. According to the principles of green chemistry, supercritical 
fluids and ILs have been the most promising and extended ones amongst academia (Figure 
VI.1)
153
.  
 
 
 
Figure VI.1 - Twelve principles of green chemistry. 
 
 
 Development of novel ionic liquids based on biological molecules 
142 
Due to the rising energy scarcity, countries are now paying much closer attention to clean 
energy technologies and using green technology in industry. Polar organic solvents are 
commonly used in cleaning, reactions and processing in many industries. Today these solvents 
are known to be hazardous to health, volatile, toxic and flammable, with no comparable 
alternatives. These toxic attributes make polar organic solvents very hard to work with and the 
harmful effects of these volatile compounds require that expensive procedures, equipment and 
environmental, health, and safety controls to be in place at all times to ensure employee safety. 
The market for green alternatives is increasing and simple environmental changes such as 
switching to green solvents may become a large part of this global change, revolutionizing the 
processes of industries that depend on these compounds. 
 
Figure VI.2 – Green technologies in industry- Pfizer solvent selection guide for medicinal 
chemistry. 
 
In recent years, among these optional organic solvents, ethyl lactate (EL) has gathered much 
attention, a fact indicated by the growth of the number of articles published.  
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Figure VI.3 - Publications related to ethyl lactate since 1980 using all databases
154
. 
 
VI.2. Ethyl Lactate- properties and applications 
 
Ethyl lactate is a green and economically viable monobasic unit of the lactate esters scaffold, 
also known as lactic acid ethyl ester (IUPAC name: Ethyl (S)- 2-hydroxypropanoate). It is 
formed by the reversible esterification reaction of ethanol and lactic acid, which can be 
generated from biomass raw materials through fermentation (Figure VI.4). EL can be either in 
the levo (L) or dextro (D) forms and it is industrially produced as a racemic mixture. 
 
 
Figure VI.4 - Synthesis of ethyl lactate (EL) from lactic acid. 
 
EL, similar to [choline], has very convenient toxicological properties
155
, it does not demonstrate 
any potential health risks and it undergoes metabolic hydrolysis due to the estearase enzymatic 
activity to ethyl alcohol and lactic acid, with this last compound being a natural metabolite in 
humans. Its environmental profile is very adequate considering that it is completely 
biodegradable in a very short time
156
. In case of vapors release, EL is a non-ozone depleting 
fluid. Considering its high solvency power, high boiling point, low vapour pressure and low 
surface tension, EL may be successfully applied in different areas such as a cleaning solvent
157
, 
for the manufacturing of magnetic and electronic devices
158
, as well as in the pharmaceutical
104
 
and paint industries
159
. It can be also used in food industry (as food additive), in perfumery, (as 
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flavour chemicals and solvent, which can dissolve acetic acid cellulose and many resins)
104
. 
Some of its peculiar properties are presented in Table VI.1. 
 
Table VI.1 Major advantages of using Ethyl Lactate. 
100% Biodegradable Reusable- made from corn and other 
carbohydrates 
Approved by the FDA as a food additive EPA approved SNAP solvent 
No carcinogenic  
Noncorrosive 
Excellent penetration characteristics 
Easily washable with water 
High boiling point 
Low VOC 
Very low vapor pressure 
Does not pollute the air 
High dissolving power for resins, polymers 
and colors 
 
Easy to recycle and cheap 
 
It does not destroy the ozone layer 
 
Some recent tests suggest that EL can replace conventional solvents in 80% of their 
applications. Nevertheless, there are some conflicting opinions because this is a high boiling 
solvent as well as a polar protic solvent. The price of EL has decreased significantly in recent 
years according to its greater use and application, being currently 50-74€ per kg for small 
suppliers (ex. Sigma-Aldrich or Alfa Aesar) or less than 15€ per kg in major suppliers for 
industrial production. 
 
VI.3. Aplication of Ethyl Lactate in organic synthesis 
 
The use of EL as green solvent in organic synthesis is still little explored. Some recent examples 
reported in the literature demonstrated the potential use of EL in organic synthesis with 
synthetic advantages. Recently, the possibility of using a solvent system based on EL and H2O 
as a co-solvent for Suzuki- Miyaura reaction has been reported by Wan et al
160
. This reaction is 
classified as a coupling reaction where the coupling partners are boronic acids with a halide 
catalyzed by a palladium (0) complex. Through this reaction, it is possible to prepare organic 
compounds significant for pharmaceutical industry and fine chemistry. The use of EL for 
Suzuki- Miyaura reaction allowed reducing the reaction time and improved the final product 
yields. The desired product was obtained with 93% of yield in a solvent system H2O/ EL (1:1) 
while in conventional organic solvent such as DMSO, the yield didn´t exceed 70% (Table VI.2).  
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Table VI.2 – Use of EL in Suzuki-Miyaura reaction
160
. 
 
 
Entry Catalyst (mol%) Base Solvent (ml) Yield (%)
b 
1 Pd(OAc)2 (1) K2CO3 EL:H2O (2:1) 26 
2 Pd(OAc)2 (1) K2CO3 EL (3) 62 
3 Pd(OAc)2 (1) K2CO3 H2O (3) 60 
4 Pd(OAc)2 (1) K2CO3 EL:H2O (1.5:1.5) 56 
5 Pd(OAc)2 (1) K2CO3 EL:H2O (1:1) 93 
6
c 
Pd(OAc)2 (1) K2CO3 EL:H2O (1:1) 47 
7 Pd(OAc)2 (1) Na2CO3 EL:H2O (1:1) 62 
8 Pd (OAc)2 (1) Et3N EL:H2O (1:1) 53 
9 Pd(OAc)2 (1) NaHCO3 EL:H2O (1:1) 44 
10 Pd(OAc)2 (0.5) K2CO3 EL:H2O (1:1) 52 
11 Pd(OAc)2 (0.25) K2CO3 EL:H2O (1:1) 44 
12 PdCl2 (1) K2CO3 EL:H2O (1:1) 23 
13 Pd(OAc)2 (1) K2CO3 DMF:H2O (1:1) 70 
14 Pd(OAc)2 (1) K2CO3 DMSO:H2O (1:1) 57 
15 Pd(OAc)2 (1) K2CO3 Dioxane:H2O (1:1) 58 
16 Pd(OAc)2 (1) K2CO3 EA:H2O (1:1) 15 
a
 Unless specified, the general conditions: 1a (0.5 mmol), 2a (0.75 mmol) and base (2 eq) at 60 ºC for  
2h. EA-ethyl acetate. 
b
 Isolated yield based on 1a. 
c
 This reaction was performed at 45 ºC. 
 
Additionally, the synthesis of dihydropyridines plays an important role due to the biological and 
pharmacological activity of these compounds. Nevertheless, the current research has been 
looking for more sustainable synthetic approaches. Last year, the synthesis of dihydropyridines 
and polytetrahydroquinolines in a solvent system of EL and water (1:1), by irradiation with 
visible light has been demonstrated
161
. This green solvent proved to be efficient, sustainable and 
no catalyst support or promotor was required. An addition of 50% of water to EL permits a 
significant improvement in reaction yield from 75% to 92%. 
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Table VI.3 - Synthesis of dihydropyridines with visible light using L-EL
161
. 
 
Entry Solvent  Yield (%)
a 
1 Toluene 49 
2 Acetonitrile 52 
3 DMSO 67 
4 Ethanol 70 
5 Water 60 
6
 
L-EL 75 
7 100% L-EL 75 
8 85% L-EL in water 80 
9 75% L-EL in water 86 
10 50% L-EL in water 92 
11 25% L-EL in water 82 
12 10% L-EL in water 73 
13 5% L-EL in water 66 
a
 Isolated yield of the pure compound. 
 
The use of EL in water was first used for 1,3-dipolar cycloaddition reactions
162
. Again the 
mixture of EL with water led to a significant improvement in the reactivity of the reaction 
process. The effect of the solvent can be observed in detail by comparing the 30% of yield 
obtained after 18h in a conventional solvent DMF, with the 82% yield obtained after a 1h 
reaction using pure EL. The addition of water allowed to obtain yields even higher, up to 93%. 
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Table VI.4 - The use of EL in water used for 1, 3-dipolar cycloaddition reactions, optimization of 
solvent
162
. 
 
Entry Solvent  Time (h) Yield (%)
a 
1 Toluene 24 22 
2 Acetonitrile 20 16 
3 THF 14 25 
4 DMF 18 30 
5 Methanol 24 
c 
6
 
Ethanol 24 
c 
7 EL 1 82 
a
 Isolated yield. 
b
 All reactions were carried out at RT. 
c 
No reaction. 
 
VI.4. Aplication of Ethyl Lactate in asymmetric organocatalysis 
 
Taking advantage of the chirality of EL (L- and D-isomers), it is possible to apply them for 
asymmetric organocatalysis in order to introduce chirality into the system. While Chapter II 
presented the application of new synthesized CILs based on L-cysteine derivatives as catalyst 
for asymmetric aldol reaction and Chapter III the L-proline based RTILs for Michael addition, 
this final Chapter includes both of the C-C bond forming reactions, this time using conventional 
catalyst L-proline, but testing the ability of EL as solvent.  
 
The aldol condensation was first chosen as a model reaction to explore the possibility of using 
L-EL as an alternative green solvent to conventional organic solvents. The optimization of 
reaction conditions for the use of both the L-EL had been previously performed at the 
laboratory. Different reaction conditions have already been tested in particular in terms of 
temperature, amount of catalyst, reaction time, concentration and type of substrate used. As the 
model reaction acetone or cyclohexanone (ketone) and ortho- or para-nitrobenzaldehyde 
(aldehyde) were tested using L-proline as organocatalyst and DMSO or L-EL as solvent (Table 
VI.5). According to the literature, the use of water as a co-solvent in combination with organic 
solvents can increase its reactivity and the yield of the final product. In this context, additional 
studies were performed, in order to compare the EL: H2O (1:1) solvent mixture with the optimal 
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conditions using pure DMSO or EL. As shown in Table VI.5, the presence of 50% of water had 
an adverse effect on this reaction. 
Table VI.5 - Asymmetric aldol reaction using different solvents. 
Entry Ketone/Benzaldehyde
[a]
 Solvent Conversion [%]
[b] 
1 Acetone/2-Nitro DMSO 100 
2
 
Acetone/2-Nitro EL 100 
3
 
4 
Cyclohexanone/2-Nitro 
Cyclohexanone/2-Nitro 
DMSO 
EL 
85 
84 
5 Cyclohexanone/4-Nitro EL: H2O 20 
[a]
 Reaction conditions: acetone (1mmol) or cyclohexanone (2 mmol) and 2 or 4-nitrobenzaldehyde (0.5 or 1 
mmol), loading of catalyst L-proline 10 mol% at room temperature, 24 h to 48 h. 
[b]
 The conversions were 
determined from 400Hz 
1
H NMR spectroscopy. 
In order to evaluate in detail the potential use of L-EL as an alternative solvent for Michael 
reaction, the effect of different reaction conditions was tested in our laboratory, in particular the 
effect of temperature (0 ºC, 24 ºC and 50 ºC); reaction time (24, 48, and 72h); amount of 
catalyst L-proline (30 to 50 mol%); concentration (0.2 and 0.4 mmol in relation to the trans-
nitrostyrene) and the use of water (10% to 50%) or ethanol (20%, 80%) as co-solvents. The 
results are summarized in Table VI.6. All the products of the reactions were analyzed by 
1
H 
NMR in comparison with the starting materials, thus allowing to evaluate the conversion of 
final product. It was found that different temperatures could promote the reaction process using 
L- EL. It was observed that with the increase of temperature the conversion of the product 
increased after the first 24h. While for the use of conventional solvents such as ethanol at 24 ºC 
seems to be more favorable. The reaction time does not appear to be particularly relevant after 
24h of reaction. Convertions of the products didn´t vary significantly after 24h. The amount of 
L-proline as a common catalyst had an important effect on the values of final conversion 
product. The use of 50 mol % L-proline catalyst allowed conversions and ee values to be 
comparable with the conventional Michael reaction (81% conversion, 96% ee). The use of co-
solvents based on alcohols (EtOH) 20% or 80% showed no significant difference in conversions 
of the product. With the use of water as co-solvent and the other conditions optimized, it was 
found that the reaction has not progressed and no product was detected after 24 hours. Water 
has clearly a negative effect on the Michael reaction. 
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Table VI.6 - The effect of changing different conditions of Michael additon of cyclohexanone to 
trans-nitrostyrene. 
Entry Tested conditions  Solvent Conversion [%]
[e] 
1  24 EtOH 100 
2
 
Temperature [ºC] 24 L-EL 44 
3
 
4 
 4 
50 
L-EL 
L-EL 
67 
81 
5  24
[a]
 L-EL 81 
6 Reaction time [h]
 
24
[b] L-EL 67 
7  48
[a]
 L-EL 84 
8  48
[b] L-EL 71 
9          20:80[c]            L-EL: EtOH 65 
10 Co-solvent         80:20[c]            L-EL: EtOH 61 
11              1:1                L-EL: H2O 0 
12             8:2                L-EL: H2O 0 
13 Loading of catalyst 30[d] L-EL 44 
14 (mol %) 50[d] L-EL 81 
[a]
 Loading of catalyst was increased from 30 to 50 mol%. 
[b]
 Reaction was performed at 4 ºC. 
[c] 
The reaction time was 72 
[h]. 
[d]
 Conversion after 24 [h].
 [e] 
The conversions were determined from 400Hz 
1
H NMR spectroscopy. 
 
Having in hand the best reaction model, it was important to determine the enantiomeric excess 
values of the products obtained, in order to verify the effect of the chiral solvent in the reaction. 
The ee values of the final products were determined for four products. The results obtained are 
summarized in Table VI.7. The best conversions and ee values were achieved using the 
conventional system with EtOH. It seems clear that using the L-EL as an alternative solvent for 
Michael reaction is not much competitive when compared with the common solvent. 
 
Table VI.7 Michael addition reaction of cyclohexanone to trans-nitrostyrene catalyzed by L-proline 
in different solvents. 
 
Entry Solvent Temp. [ºC]
 
Loading of 
catalyst [mol%] 
Conversion [%]
[b] 
ee%
[c] 
1 EtOH 24 30 100 97 
2 L-EL 24 30 44 53 
3 EtOH 24 50 81 96 
4 L-EL 50 30 81 62 
[a]
 Reagents concentrations: trans-nitrostyrene (0.4 mmol), cyclohexanone (0.2mmol). 
[b] 
The conversions were determined 
from 400Hz 
1
H NMR spectroscopy.
 [c]
 Enantiomeric excesses determined by HPLC using Phenomenex Lux 5 um 250x10 
cellulose column, flow 1ml/min., 25 
o
C column oven, hexane: i-PrOH 90:10, λ=230nm.
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VI.5. Conclusions 
 
This additional work presented in the closure chapter, suggests that in future, L- EL can be a 
possible alternative for common organic solvents used in aldol condensation and Michael 
reaction, but some optimization steps are still required. It seems that using L-EL as a chiral 
solvent doesn´t contribute to improve the ee values. The presence of L-proline as a chiral 
catalyst is crucial. Nevertheless, to confirm this fact, studies using the racemic EL for 
organocatalysis should be made. Based on the preliminary results obtained, it would be 
appealing to develop a more complex system for organocatalysis, by combining the idea of CIL 
catalyst with chiral L-EL solvent. 
 
VI.6. Experimental Part 
 
General: Commercially available reagents L-proline (MW= 115.13 g.mol
-1
, CAS No. 147-85-
3), L-ethyl lactate (MW= 118.13 g.mol
-1
, CAS No.687-47-8) and solvents were purchased from 
Alfa Aestar, Aldrich, Solchemar and were used without further purification. 
1
H and 
13
C NMR 
spectra were recorded at 25 ºC on a Bruker AMX400 spectrometer with TMS as internal 
standard. Chemical shifts are reported downfield in parts per million (ppm). 
 
VI.6.1. General procedure for asymmetric aldol reaction 
 
Asymmetric aldol reaction between aromatic p-nitroaldehyde and cyclohexanone was carried 
out in organic solvent (0.5 ml). As the organic solvent DMSO (conventional solvent), L-ethyl 
lactate or ethyl lactate and water mixture (1:1) were chosen. The suspension of L-proline as 
chiral catalyst (30 mol%) and ketone (100 µl, 2 mmol) was stirred for 30 minutes at RT. After 
that time aromatic aldehyde (0.0756 g, 1mmol) was added and the resulting mixture was 
allowed to stirr at RT for 24-48 hours as indicated in TablesVI.5. Relative and absolute 
configurations of the products were determined by comparison with the known 
1
 H NMR as in 
chapter II. In some cases, the possibility of isolating the product by extracting the reaction 
mixture with diethyl ether or ethyl acetate was tested. In the case of the experiments with the 
addition of ethyl lactate, the addition of water allowed the product to precipitate and isolate. 
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VI.6.2. General procedure for the Michael reaction of cyclohexanone and β–
nitrostyrene 
 
To a suspension of L-proline as catalyst (30 or 50 mol%) and cyclohexanone (210 µl, 2 mmol) 
in 1ml of solvent (EtOH, L-ethyl lactate and L-ethyl lactate systems with ethanol or water as co-
solvent) trans-β-nitrostyrene (0.149 g, 1.0 mmol) was added. The resulting mixture was allowed 
to stir at 4, 25, 40 ºC, for 24-72 hours, then evaporated in vacuo and the resulting residue was 
purified by extraction with Et2O or ethyl acetate (in the case with L-ethyl lactate) or by adding 
water to allow precipitation of the final product. Relative and absolute configurations of the 
products were determined by comparison with the known 
1
 H NMR and chiral HPLC analysis. 
The enantiomeric excess was determined by chiral HPLC analysis on a Phenomenex Lux 5 um 
250x10 cellulose column, flow 1ml.min
-1
, 25 
o
C column oven, hexane: i-PrOH 90:10, λ=230 
nm. t major = 13.7 min and t minor = 15.0 min. 
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VII. Annex 
 
VII.1. NMR data for NMR assignment  
 
 
 
Figure VII.1 - 
1
H NMR data for compound (S)-1-carboxy-2-(methylthio)ethanaminium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (2b). 
 
 
 
Figure VII.2 - 
13
C NMR data for compound (S)-1-carboxy-2-(methylthio)ethanaminium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (2b). 
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Figure VII.3 - 
1
H NMR data of compound ethyl-3-methyl-1H-imidazol-3-ium (S)-2-amino-3-
(methylthio)propanoate (3c). 
 
 
 
 
 
 
Figure VII.4 - 
13
C NMR data of compound ethyl-3-methyl-1H-imidazol-3-ium (S)-2-amino-3-
(methylthio)propanoate (3c). 
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Figure VII.5 - 
1
H NMR data of aldol product 4-hydroxy-4-(2-nitrophenyl)butan-2-one. 
 
 
 
 
 
 
 
Figure VII.6 – 
13
C NMR data of aldol product 4-hydroxy-4-(2-nitrophenyl)butan-2-one. 
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Figure VII.7 - 
1
H NMR data of compound (S)-2-carboxypyrrolidin-1-ium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (7b). 
 
 
 
 
 
 
 
Figure VII.8 - 
13
C NMR data of compound (S)-2-carboxypyrrolidin-1-ium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (7b). 
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Figure VII.9 - 
1
H NMR data of compound trihexyl(tetradecyl)phosphonium (S)-pyrrolidine-2-
carboxylate (8a). 
 
 
 
 
 
 
 
 
Figure VII.10 - 
13
C NMR data of compound trihexyl(tetradecyl)phosphonium (S)-pyrrolidine-2-
carboxylate (8a). 
 Development of novel ionic liquids based on biological molecules 
160 
 
 
Figure VII.11 - 
1
H NMR data of compound 1-ethyl-3-methyl-1H-imidazol-3-ium pyrrolidine-2-
carboxylate (8b). 
 
 
 
 
 
 
Figure VII.12 - 
13
C NMR data of compound 1-ethyl-3-methyl-1H-imidazol-3-ium pyrrolidine-2-
carboxylate (8b). 
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Figure VII.13- 
1
H NMR data of compound (S)-2-[(R)-2-Nitro-1-phenylethyl]cyclohexanone 
(Michael product). 
 
 
 
 
 
 
Figure VII.14 - 
13
C NMR data of compound (S)-2-[(R)-2-Nitro-1-phenylethyl]cyclohexanone 
(Michael product). 
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Figure VII.15 - 
1
H NMR data of compound α- CD. 
 
 
 
 
Figure VII.16 - 
1
H NMR data of compound γ- CD. 
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Figure VII.17 - 
1
H NMR data of compound 3-((2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-ium 1,4-
bis((2-ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (11b). 
 
 
 
 
 
 
Figure VII.18 - 
13
C NMR data of compound 3-((2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-ium 1,4-
bis((2-ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (11b). 
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Figure VII.19 -
1
H NMR data of compound 3-((2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-ium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (12b). 
 
 
 
 
Figure VII.20 - 
13
C NMR data of compound 3-((2R,3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-ium 1,4-bis((2-
ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (12b). 
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Figure VII.21 - 
1
H NMR data of compound trihexyl(tetradecyl)phosphonium ((2R,3S,4R,5R)-5-(6-
amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate (13a). 
 
 
 
 
 
 
 
Figure VII.22 – 
13
C NMR data of compound trihexyl(tetradecyl)phosphonium ((2R,3S,4R,5R)-5-(6-
amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate (13a). 
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Figure VII.23 - 
1
H NMR data of compound 1-ethyl-3-methyl-1H-imidazol-3-ium ((2R,3S,4R,5R)-5-
(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate (13b). 
 
 
 
 
 
 
Figure VII.24 – 
13
C NMR data of compound 1-ethyl-3-methyl-1H-imidazol-3-ium ((2R,3S,4R,5R)-5-
(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate (13b). 
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Figure VII.25 - 
1
H NMR data of compound 1-(2-methoxyethyl)-3-methyl-1H-imidazol-3-ium 
((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate (13c). 
 
 
 
 
 
 
Figure VII.26 – 
13
C NMR data of compound 1-(2-methoxyethyl)-3-methyl-1H-imidazol-3-ium 
((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate (13c). 
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Figure VII.27 – 
1
H NMR data of compound 2-hydroxy-N,N,N-trimethylethanaminium 
((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate (13d). 
 
 
 
 
Figure VII.28 - 
13
C NMR data of compound 2-hydroxy-N,N,N-trimethylethanaminium 
((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate (13d). 
 
Development of novel ionic liquids based on biological molecules 
 
 
 
A
n
n
ex
 
169 
VII.2. FTIR data  
 
 
 
Figure VII.29 - FTIR data for compound (L)-2-carboxypyrrolidin-1-ium 
bis((trifluoromethyl)sulfonyl)amide (7a). 
 
 
 
 
Figure VII.30 - FTIR data for compound trihexyl(tetradecyl)phosphonium (L)-pyrrolidine-2-
carboxylate (8a). 
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Figure VII.31 - FTIR data for compound 3-((2D,3D,4L,5D)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-5-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-ium 1,4-
bis((2-ethylhexyl)oxy)-1,4-dioxobutane-2-sulfonate (11b). 
 
 
 
 
 
 
 
 
Figure VII.32 - FTIR data for compound trihexyl(tetradecyl)phosphonium ((2D,3L,4D,5D)-5-(6-
amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogenphosphate (13a). 
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VII.3. DSC curves data  
 
 
 
Figure VII.33 - DSC curve for compound (L)-1-carboxy-2-(methylthio)ethanaminium 
bis((trifluoromethyl)sulfonyl)amide (2a) in a heating cycle. 
 
 
 
 
 
 
 
Figure VII.34 - DSC curve for compound trihexyl(tetradecyl)phosphonium (S)-2-amino-3-
(methylthio)propanoate (3a) in a heating cycle. 
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Figure VII.35 - DSC curve for compound 1-ethyl-3-methyl-1H-imidazol-3-ium pyrrolidine-2-
carboxylate (8b) in a heating cycle. 
 
 
 
 
 
 
 
 
 
Figure VII.36 - DSC curve for compound (L)-2-carboxypyrrolidin-1-ium 
bis((trifluoromethyl)sulfonyl)amide (7a) in a heating cycle. 
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Figure VII.37 - DSC curve for compound 1-(2-methoxyethyl)-3-methyl-1H-imidazol-3-ium 
((2D,3L,4D,5D)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate (13c) in heating cycle. 
 
 
 
 
 
 
Figure VII.38 - DSC curve for compound 2-hydroxy-N,N,N-trimethylethanaminium 
((2D,3L,4D,5D)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
hydrogenphosphate (13d) in heating cycle. 
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